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ABSTRACT 
 
Modulation of GABA mediated inhibition is one of the most important approaches for 
the treatment of central nervous system (CNS) diseases. Precise targeting of such 
treatments depends on identification and characterisation of the different subunit 
complexes that exist. In the CNS, there are pools of neural stem cells (NSC), which 
can differentiate to become neurones, astrocytes or oligodendrocytes while 
progenitor cells have limited lineage. In addition to brain regions, where NSCs are 
now known to exist, the spinal cord area also has a neurogenic potential in the form 
of ependymal cells.  
Ependymal cells surrounding the central canal displayed typical properties of glial 
cells; lack of voltage-gated channels, and showed coupling indicative of the presence 
of gap junction. Ependymal cells showed responses to GABA as previously observed 
(Corns et al., 2013). The effects of GABA on ependymal cells were concentration 
dependant. 
Ependymal cells in our study showed atypical GABA receptors since it was not fully 
blocked by GABAA receptor antagonist; bicuculline. Hyperpolarising responses to low 
GABA were antagonised by the GABAρ receptor antagonist, (1, 2, 5, 6-
Tetrahydropyridin-4-yl) methylphosphinic acid (TPMPA). On further confirmation of 
this, Trans-4-aminocrotonic acid (TACA), a selective agonist of GABAρ1 elicited 
robust and reproducible hyperpolarising responses, similar to those observed with 
low concentrations of GABA. This provides evidence of a combination or coassembly 
of GABAA and ρ receptors in the ependymal cells or the presence of two different 
receptors.  
One potential site of modulation of GABA receptors is through diazepam binding 
inhibitor (DBI). DBI with its breakdown product, octadecaneurapeptide (ODN) acts as 
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positive and negative modulator at central benzodiazepine receptor (CBR). The 
responses to high concentrations of GABA were modulated by midazolam suggesting 
a potential involvement of CBR and another receptor, Translocator Protein (TSPO). 
On testing TSPO, N, N-Dihexyl-2-(4-fluorophenyl) indole-3-acetamide (FGIN-1-27); 
selective agonist at TSPO, increased the responses in ependymal cells to the higher 
concentration of GABA. When combining FGIN-1-27 with 1-(2-Chlorophenyl)-N-
methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide (PK-11195); a selective TSPO 
antagonist, the augmented GABA responses were not observed, suggesting that this 
effect was due to activation of TSPO. These results indicate that modulation of GABA 
receptors by midazolam occurred at both CBR and TSPO. However, the responses 
of GABA in the presence of ODN (20 µM) did not show significant changes regardless 
of the GABA concentration used. Nanomolar ODN application alone causes fast 
hyperpolarisations similar to low GABA and TACA effects. Responses to nanomolar 
ODN were significantly but not fully blocked by cyclo1-8[dleu5] OP (cDLOP), an ODN 
metabotropic receptor antagonist. ODN is somehow directly activating the GABA 
receptors that contain rho subunits since the hyperpolarising effects of ODN were 
significantly blocked by TPMPA. So there is an evidence there are atypical GABA 
receptors responsible for this action with ODN. 
Baclofen (a selective GABAB receptor agonist) also hyperpolarised ependymal cells, 
an effect antagonised by CGP 55845 (GABAB antagonist), indicating a further role for 
GABAB receptors on ependymal cells. The numbers of proliferative cells in the central 
canal region were significantly lower in baclofen treated slices compared with control. 
Activation of the 5-HT receptor caused both depolarisation and hyperpolarisation 
contribute to the proliferative capabilities of ependymal cells. Blockade of 5-HT 
receptor mediated depolarisations with cinanserin showed the presence of 5-HT2 
receptors in the spinal cord. Furthermore, hyperpolarisations with 8-OH-DPAT and 
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cisapride indicate that 5-HT 1A and 5-HT4 receptors are also present in the central 
canal area of spinal cord.  
Overall, our study has shown a complex and varied response profile of ependymal 
cells to GABA and its modulators. This could have important implications in the 
proliferative capabilities of spinal cord neural stem cells and thus functional 
consequences. The modulation of proliferation and differentiation by GABA may be 
an interesting future therapeutic target for conditions where there is over proliferation 
such as in spinal cord ependymomas or in conditions such as in multiple sclerosis 
where replacement cells may be useful to aid recovery.  
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Chapter 1  
General Introduction 
 
1.1 The spinal cord 
 
The spinal cord is the most important structure for relaying sensory and descending 
information between the body and the brain. It extends from the foramen magnum, 
continuous with the medulla to the level of the first or second lumbar vertebrae. 
The main structure of the spinal cord comprises the cellular grey matter, surrounded 
by neuronal tracts of white matter (De Leener et al., 2016). At the centre of grey 
matter, there is a central canal in which the cerebrospinal fluid flows. 
The spinal cord is contained within 3 protective layers of membrane, known as 
meninges. The innermost delicate layer is the pia mater which closely wraps the 
spinal cord and roots. The next layer is the arachnoid mater, with the space between 
the pia and the arachnoid mater called the subarachnoid space. The most outer side 
of the meninges is the tough protective layer called the dura mater.  
The grey matter of the spinal cord is organised into 10 layers called the Rexed 
laminae (Rexed, 1952). Laminae I-VI are responsible for sensory processing while 
laminae VIII and IX are considered as ventral horn, where the somatic motor 
neurones and their associated interneurons reside. The intermediate zone is found 
between the dorsal and ventral horn and incorporates the lateral horn, which contains 
the intermediolateral column (IML) and is associated with autonomic output. It can be 
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divided into laminae VII and X. Lamina X is the area of grey matter at the centre of 
spinal cord surrounding the spinal cord. 
 
1.2 Lamina X 
 
Lamina X is the area surrounding the central canal containing the grey commissures 
and the substantia gelatinosa centralis. It is also termed as area X or the central grey 
of the spinal cord. It consists of small to medium-sized multipolar, triangular and 
spindle shaped neurones. The density of nerve fibres in the lamina is relatively low 
(Rexed, 1954). The neurones found in lamina X of mice are triangular, multipolar and 
spindle shaped (Sengul and Watson, 2012).  
Studies have shown that Lamina X may be the site of spinal neural stem cells that 
are generated from the ependymal layer (Rusanescu and Mao, 2015) and this 
potential neurogenic niche is the main focus of my thesis. 
 
1.3 What is neurogenesis? 
 
Neurogenesis is often defined as a process of generating functional neurones from 
adult neural precursors which occurs during embryonic and perinatal stages (Ming 
and Song, 2005). However many researchers use this term to describe generation of 
new oligodendrocytes and astrocytes as well (Yang, H. et al., 2006). Thus, 
neurogenesis encompasses the production of not only new neurones but also 
oligodendrocytes and astrocytes from neural stem cells. There are two main steps of 
neurogenesis; i.e., proliferation and differentiation of neural stem cells. Neural stem 
cells include neuroepithelial stem cells, radial glial cells, basal progenitors, and 
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astrocytes. Neurogenesis is present not only during embryonic development but also 
occurs throughout adult life in specific regions or niches. 
The adult central nervous system was thought to have a static condition because it 
showed little cell turnover. Altman and Das (1965) then proved that there is evidence 
for the presence of newly generated dentate granule cells in animal models i.e. in the 
area of postnatal rat hippocampus. New neurones are continuously created and 
functionally integrated into existing neuronal networks in the adult brain. Active adult 
neurogenesis is mainly confined to two distinct locations: the subventricular zone 
(SVZ) of the lateral ventricles in the forebrain and the subgranular zone (SGZ) of the 
dentate gyrus (DG) in the hippocampus (Ming and Song, 2011). The peak time of 
neurogenesis in the dentate gyrus of a rat is seen postnatally during the first week of 
life with a progressive decline after postnatal day 9 (Liu, H. et al., 2003). Neurogenesis 
appear to be comparable between the rodent (Kuhn et al., 1996) and the human 
dentate gyrus (Eriksson et al., 1998). As in rodents, neurogenesis continues 
throughout life in the human dentate gyrus.  
Numerous studies have reported that neurogenesis does not normally occur in 
postnatal mouse cortex (Bauer and Patterson, 2005; Zhao and Brinton, 2005), which 
reflects an intrinsic limitation of the endogenous neural precursor potential, or a lack 
of appropriate micro-environmental signals necessary for neuronal differentiation or 
survival. Additional sites of neurogenesis which were previously known as non-
neurogenic areas occur in hypothalamus in the mouse (Kokoeva et al., 2005) and 
striatum in the non-human primates (Bedard et al., 2006) and in human (Ernst, A. et 
al., 2014). However there is evidence that new neurones are generated in the human 
brain comparable to those observed in rodents especially in the dentate gyrus of 
hippocampus (Eriksson et al., 1998).  
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1.3.1 Regulation of neurogenesis 
The cells that are critical in neurogenesis are the neural stem cells which are found 
throughout the central nervous system and are defined by common cellular 
properties: they proliferate, self-renew, and give rise to differentiated progeny. Cells 
defined by these proliferative and differentiative properties are present during the 
development of the central nervous system and persist into adulthood in certain 
locations. It is well confirmed that the multipotent neural stem cells are found in many 
regions of the adult central nervous system. The exact origin of these multipotent 
neural stem cells, whether from subventricular, ependymal or parenchymal areas, 
together with the induction signals which are essential for proliferation, migration, or 
differentiation remains controversial. Many experimental studies provide 
contradictory data regarding cell origin, type and the factors that induce neurogenesis 
(Rice et al., 2003; Horner, P. et al., 2000).  
Regulation of neurogenesis can be categorized as either intrinsic or extrinsic. Many 
intrinsic (cell autonomous such as via transcription factors) and extrinsic (cell non-
autonomous such as via secreted factors) factors that modulate neurogenesis have 
been identified (Aimone et al., 2014). Extrinsic and intrinsic mechanisms regulate 
different aspects of neurogenesis (Figure 1-1). Molecular factors and signalling 
pathways including niche factors or receptors, cytoplasmic factors, transcriptional 
factors and genetic regulators may cause neurogenesis in both adult and 
embryogenic situations. Between embryonic and adult neurogenesis, there is 
significant similarity in signalling pathways (Mash1, Notch etc.) although the origin 
and nature of extrinsic signals (growth factors, neurotrophins, and hormones) could 
be different. Neurotransmitters regulate brain development, changes in their levels 
have also been shown to influence neurogenesis in adulthood. These 
neurotransmitter systems are subject to regulation by pharmacological manipulations 
(Ming and Song, 2011).  
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Figure 1-1 Intrinsic and extrinsic factors in the neurogenesis signalling pathway  
Diagram demonstrating the intrinsic and extrinsic factors in the neurogenesis 
signalling pathway in the dentate gyrus of the hippocampus (modified from Aimone 
et al. (2014); Lledo et al. (2006)).  
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Among these neurotransmitters, gamma-aminobutyric acid or ɣ-aminobutyric acid 
(GABA), often considered an inhibitory neurotransmitter, regulates the neural stem 
cell niche at the level of both stem cells and young neurones. GABA released by 
nearby interneurones activates neural stem cells in a quiescent state (Song, J. et al., 
2012). Then GABA acts on neuroblasts and increases their survival and maturation 
(Song, I. et al., 2013). 
 
1.4 Neurogenesis in spinal cord 
 
1.4.1 The identity of the neurogenic niche 
 
The cells surrounding cells in the central canal of the spinal cord (see Figure 1-2) 
have similar features to the stem cell niches of the brain (Hamilton et al., 2009) since 
they express the same markers (Meletis et al., 2008) as neural stem cells and have 
the ability to proliferate (Horner et al., 2000). 
Due to growing evidence that neural stem cells may originate from the periventricular 
region along the entire axis of ventricular area, including the forebrain SVZ, the 
ependymal layer of the central canal has been considered as the neurogenic niche in 
the spinal cord by many researchers (Sabelström et al., 2013; Cusimano et al., 2012; 
Barnabé-Heider et al., 2010; Danilov et al., 2006). 
The ependymal cells of the spinal cord has been shown in several studies to be 
capable of undergoing division (Barnabé-Heider et al., 2010; Cizkova et al., 2009; 
Danilov et al., 2006; Johansson et al., 1999). Endothelial cells, astrocytes, ependymal 
cells, cerebral spinal fluid contacting cells, microglia, mature neurones, and progeny 
of adult neural precursors are among the major cellular components of the adult 
neurogenic niche (Marichal et al., 2012; Barnabé-Heider et al., 2010; Meletis et al., 
7 
 
2008; Adrian Jr and Walker, 1962). More recently, Alfaro Cervello (2012) suggested 
that biciliated ependymal cells are the primary neural stem cells in the spinal cord. 
Proliferation of ependymal cells is common during embryonic and early postnatal 
periods of development in most species; however, ependymal cell turnover declines 
significantly postnatally (Bruni, 1998).  
The neurogenic potential of astrocytes is regionally specified for neurogenesis. The 
astrocytes from adult hippocampus retain the potential to promote neurogenesis, 
but astrocytes from adult spinal cord do not (Barnabé-Heider et al., 2010). Barnabe-
Heider (2010) showed that there were less BrdU incorporation in astrocytes 
compared to 10 times higher BrdU incorporation in ependymal cells and astrocytes 
in the spinal cord only give rise to new cells of the same fate whereas ependymal 
cells differentiates to different cells. Most of the postnatal neurogenesis involves 
ependymal cells which then rely on the extrinsic factors such as neurotransmitters.
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Figure 1-2 Ependymal cell layer and the various types of cells  
Diagram depicting the ependymal cell layer and the various types of cells in the 
central canal region (Adapted and modified from Marichal et al. (2012)).
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1.4.2 Cell types that may be involved in neurogenesis- 
 
1.4.2.1 Ependymal cells 
Ependymal cells are epithelium cells lining the ventricular surface from the lateral 
ventricles to throughout the length of the spinal central canal. Ependymal cells are 
remnants of primitive neuroepithelium from which neural progenitor cells originate 
during pre- and perinatal development (Chenn and McConnell, 1995). In this 
developmental stage, from neuroepithelial cells, the neural stem cells differentiate 
into radial glial cells and then progress into the ependymal cells lining the ventricles 
and central canal. 
The cell types observed and their general organization are similar at cervical, thoracic, 
and lumbar levels of the spinal cord (Alfaro‐Cervello et al., 2012). The layer of 
ependymal cells in the majority of the central canal area is only a single cell thick 
however in some places it is thickened such that it contains multiple layers of 
ependymal cells.  
The ependymal cells in the cervical and thoracic regions are mainly round, but at the 
lumbar level, they are more likely to be oval-shaped. Ependymal cells around the 
lateral regions of the central canal are predominantly pseudostratified cuboidal 
ependymal cells forming the lining of the channel through which the cerebrospinal 
fluids flows (Bruni and Reddy, 1987). 
The cells in the single layer of ependymal cells are consistent in shape and 
orientation, with slight differences at the dorsal and ventral poles of the ependymal 
cells where the cells are more elongated in shape. Ependymal cells do not rest on 
basement membranes but the bases of the cells taper and then break up into fine 
branches which ramify into the underlying layer of processes derived from astrocytes. 
The cells are tightly bound together at their luminal surfaces by the usual epithelial 
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junctional complexes; with their surface covered by microvilli and they contain central 
clusters of long cilia (Bruni and Reddy, 1987; Sturrock, 1981). At luminal surfaces 
there are a variable number of cilia and microvilli, which probably have absorptive 
and secretory functions. Beating of the cilia of ependymal cells during development 
appears to set up concentration gradients of guidance molecules to direct migration 
of neuroblasts.  
Ependymal cells in spinal cord identified by Meletis et al. (2008) were not the classical 
multiciliated ependymal cell classified as E1 in brain by Mirzadeh et al. (2008) but 
three subpopulations of cells with one to three cilia. The most common cell type in 
the spinal cord epithelium had two cilia with some similarities to the E2 (characterized 
by only 2 cilia and complex basal bodies) cells described in the lateral ventricular wall 
by Alfaro‐Cervello et al. (2012) and Mirzadeh et al. (2008). Alfaro‐Cervello et al. 
(2012) also observed smaller subpopulations of cells with one, three and four cilia 
with highly polarized and had lipid droplets. Those spinal cord ependymal cells with 
two cilia had two unique large electron-dense basal bodies. The cilia of biciliated cells 
were long (7–9 μm) and had a 9+2 microtubule axoneme structure (Alfaro‐Cervello et 
al., 2012). The cell types observed in spinal cord were similar at cervical, thoracic and 
lumbar level. Regardless of numbers of cilia, all ependymal cell cilia are highly 
polarized since they have lipid droplets towards the apical membrane which may be 
important for membrane synthesis (Spassky et al., 2005).  
The nuclei of ependymal cells are large and round, located at the basal part, whereas 
the cytoplasm is at the apical region (Bruni and Reddy, 1987). Under electron 
microscopy ependymal cells have large nuclei and electron dense cytoplasm rich in 
intermediate filaments (Alfaro‐Cervello et al., 2012; Bruni and Reddy, 1987). They 
also have numerous mitochondria and Golgi apparatus in a horse-shoe shape (Alfaro‐
Cervello et al., 2012). 
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Ependymal cells are connected to neighbouring ependymal cells via a number of 
connections. Long zonulae adherens junctions running along the lateral sides of the 
ependymal cells (Alfaro‐Cervello et al., 2012) are formed of cadherins and are linked 
to the actin cytoskeleton. Cadherins are calcium-dependant transmembrane 
adhesion molecules that form the adherens junctions.  
The other type of junctional connection through which ependymal cells are connected 
is gap junctions. Gap junctions provide a reciprocal direct cytoplasmic linkage 
between adjacent cells for electrotonic and metabolic cell-to-cell communication. Gap 
junctions are formed by different connexin types which have different functional 
properties. There are 3 main types of connexin found in the ependymal cells of spinal 
cord. These are connexin 43 (Cx43) (Belliveau and Naus, 1995), connexin 45 
(Chapman et al., 2013) and connexin 50 (Rodriguez-Jimenez et al., 2015). 
Expression of these connexins has been shown to produce functionally active gap 
junctions between the cells as demonstrated during electrophysiological experiments. 
Dye-coupling of cells, which suggests the presence of gap junctions, was observed 
in many of the ependymal cells recorded in mouse spinal cord slices but the extent of 
dye coupling was lower in the dorsal and ventral poles and in these regions 
immunohistochemistry for Cx43 revealed less dense labelling in these regions 
(Marichal et al., 2012).There are increases in input resistance and voltage changes 
with application of gap junctions blockers (Corns et al., 2013) indicating that gap 
junction could be one way how ependymal cells modulate their responses to 
signalling. 
Ependymal cells in the mammalian spinal cord express many of the 
immunohistochemical markers which are associated with neural stem cells in other 
regions (Sabelström et al., 2014; Marichal et al., 2012; Hamilton et al., 2009), 
although not all markers were found in all regions. The markers are nestin, S100β, 
SOX2 and some expressed the radial glial marker 3CB2 or vimentin (Corns et al., 
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2015; Marichal et al., 2012). These ependymal cells have specific 
electrophysiological characteristics. Marichal et al. (2012) made patch clamp 
recordings of cells in the lateral domains of the ependymal layer of mice and found 
that these cells had linear voltage current relationships, low input resistance and 
hyperpolarized resting membrane potentials. From their morphological study, the 
cells on the whole belonged to ependymocytes lining substantial portions of the 
central canal. They were also able to record from the midline domains and these cells 
exhibited most of the markers of neural stem cells and were considered the radial 
ependymal cells. Their electrophysiological properties included a hyperpolarized 
resting membrane potential, high input resistance and sometimes potassium and 
calcium voltage gated currents. To determine whether the properties of these cells 
persisted into adulthood, Marichal et al. (2012) explored the results in P15-P21 and 
even some P40 rats where they found that the properties of the two cell types were 
similar in these older animals to the neonatal recordings. Furthermore, nestin and 
3CB2 (a radial glial marker) were still expressed in cells contacting the poles (midline 
domain) and a substantial number of cells on the lateral aspects were positive for 
proliferating cell nuclear antigen (PCNA). They concluded that progenitors in the 
ependymal layer of mature rat spinal cord maintain the basic properties of neonatal 
rodents. 
SOX2, a transcription factor essential for maintenance of pluripotency of 
undifferentiated stem cells and related proteins is widely expressed in ependymal 
cells around the central canal (Corns et al., 2015; Barnabé-Heider et al., 2010; 
Hamilton et al., 2009). Nestin is expressed in a subset of ependymal cells, 
predominantly found dorsal to the central canal (Alfaro‐Cervello et al., 2012; Hamilton 
et al., 2009). Nestin is an intermediate filament found in developing cells and cells 
after injury, suggesting that ependymal cells around the central canal may act as stem 
cells. Ependymal cells also expressed CD24, a glycoprotein expressed by mature 
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ependymal cell (Alfaro‐Cervello et al., 2012; Mirzadeh et al., 2008), CD133 (Alfaro‐
Cervello et al., 2012) which is observed in ependymal cell and astrocytes, and also 
expressed transcription factor FoxJ1 which acts as a marker for ciliated epithelia and 
cells of ependymal lineage (Alfaro‐Cervello et al., 2012; Meletis et al., 2008). 
Ependymal cells also express Akhirin (AKH), a soluble molecule that might enhance 
the stem cell proliferation and differentiation during development. Using Akhirin 
negative mutant mice (AKH-/-), Abdulhaleem M et al. (2015) showed that the size of 
neural tube was smaller in AKH-/- compared with positive mutant mice (AKH+/+). The 
smaller size could be due to a significant reduction of the proliferative activity in the 
spinal cord of AKH-/- during development.  
Vimentin is another neural stem marker found in central canal studies by Hamilton et 
al. (2009) and Meletis et al. (2008). Using postnatal mice at day 0, they performed 
immunohistochemistry on secondary spheres which were generated from primary 
spheres after 7 days. The central canal in the spinal cord is lined with cells that 
express Vimentin around the central canal in circular manner (Hamilton et al., 2009). 
Other neural stem/progenitor cell markers found in the central canal includes CD15, 
brain lipid binding protein (BLBP) and GFAP. They are expressed by subpopulations 
of cells lining the central canal (Hamilton et al., 2009; Meletis et al., 2008). The GFAP 
expressing astrocytes and Nestin expressing cells were found by Hamilton et al. 
(2009) at the dorsal area of central canal. In line with this finding, GFAP radial glial 
like cells located in the dorsal pole ependymal region have been proposed to have 
the ability to generate neurospheres producing astrocytes, oligodendrocytes and 
neurones (Sabourin et al., 2009). 
Looking specifically at biciliated cells of spinal cord identified by Alfaro‐Cervello et al. 
(2012), they showed that these expressed vimentin, CD24, FoxJ1, SOX2 and CD133. 
They were negative for Nestin and GFAP. This was in contrast with Sabourin et al. 
(2009) who found abundant GFAP positive cells around the central canal. Differences 
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in these studies highlight the issues regarding consistent classification of these 
different cells. 
 
1.4.2.2 Sub classification of ependymal cells 
There is some controversy about the subtypes of cells in the spinal cord ependymal 
niche, but cuboidal, tanycytic and radial classes of lumen-contacting, ciliated 
ependymal cells have been identified (Alfaro‐Cervello et al., 2012; Hamilton et al., 
2009; Meletis et al., 2008; Bruni and Reddy, 1987). Some authors differentiate 
ependymal cells and tanycytes (Mothe and Tator, 2005), others define three 
subtypes; cuboidal ependymal, radial ependymal (in dorsal and ventral poles) and 
tanycytes (radial) (Meletis et al., 2008).  
The ependymal layer in the spinal cord consists of roughly equal numbers of cuboidal 
ependymal cells and tanycytes, based on electron microscopy analysis (Meletis et 
al., 2008) but this depends on what cells are counted as tanycytes and other studies 
suggest that the cuboidal ependymal cells are the most numerous (Bruni and Reddy, 
1987). 
 
Cuboidal ependymal cells 
Alfaro‐Cervello et al. (2012) described a subpopulation of cells in lateral walls of 
central canal of spinal cord that did not have radial processes. These cells may be 
grouped as cuboidal ependymal cells because they reside mostly at lateral region of 
spinal cord. They had pseudostratified organization, electron-dense rich cytoplasm 
with intermediate filaments, horse-shoe shaped Golgi apparatus polarized towards 
lumen, numerous dark mitochondria throughout basal and apical cytoplasm, and 
apically located lipid droplets. The rough endoplasmic reticulum (RER) was small, 
with few free ribosomes. Nuclei were mostly located in the apical row of the 
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pseudostratified epithelium. The chromatin was condensed in small clumps, with 
three to four nucleoli associated with the nuclear envelope. Long zonulae adherens 
junctions with a beaded appearance comprised of electron-dense clumps alternating 
with thin, tightly apposed electron-dense membranes were observed between 
adjoining cells. Intercellular spaces and deep interdigitations were also observed on 
the apical surface of ependymal cell.  
The full function of cuboidal ependymal cells is not fully understood but beside 
potential proliferative capabilities, they might have other important functions such as 
propulsion of CSF flow (Sabelström et al., 2013). Using whole mounts of the central 
canal and placing fluorescent microbeads on the central canal surface, the cilia of 
these cells have been shown to move back and forth, which would allow movement 
of fluid (Alfaro-Cervello et al., 2012). The cells may also be important in providing a 
barrier to prevent harmful substances from entering the spinal cord from the CSF. 
This is a role known to occur in other regions (Del Bigio, 2010), along with potential 
metabolic regulation since the ependymal cells express glucose transporters that may 
allow them to take up glucose from the CSF to regulate the levels. Ependymal cells 
can be infected by various viruses such as measles, mumps and Herpes simplex type 
1 (Del Bigio, 2010) and may almost act as a first line of defence in the response to 
infection, although it is not clear how this may occur.     
 
Tanycytes and radial ependymal cells 
Tanycytes have a basal process, which can contact blood vessels or neurones 
suggesting interactions between ependymal cells and the surrounding niche (Meletis 
et al., 2008). Researchers also used immunoelectron microscopic analysis of CreER-
immunoreactive cells in FoxJ1-CreER mice and reported that these cells have a 
single cilium. Tanycytes have been observed along the length of the spinal cord at an 
average frequency of 1-3 cells per 0.5 μm section, and the numbers were higher in 
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lumbar and sacral regions than in cervical and thoracic levels (Bruni and Reddy, 
1987). 
The least numerous ependymal cell subtype is the radial ependymal cell, which 
resides in the dorsal and ventral poles of the central canal and extends long 
processes aligned with the dorsoventral axis (Lacroix et al., 2014; Meletis et al., 
2008). Hamilton et al. (2009) described a subpopulation of tanycyte and radial 
ependymal cells that are the same based on their long, basally projecting fibres and 
expression of Nestin. In the mouse spinal cord, ependymal cells are derived from 
Nkx6.1 expressing ventral neuroepithelial cells (Fu et al., 2003) while the mouse 
forebrain ependymal cells are derived from radial glia and appear to be post mitotic 
(Spassky et al., 2005). From the ependymoglial cells, the cells persist at the dorsal 
and ventral midlines, maintaining long filament-rich fibres which persist from embryo 
time day. Ependymal cells do not fully differentiate until late in postnatal development 
in rodents or during the third trimester in humans, when they possess multiple motile 
cilia and significant adherens junctional proteins at their apical surface (Spassky et 
al., 2005). The dorsal fibres can still be traced along the dorsal grey matter by which 
at postnatal day 5, their trajectory within the dorsal column is obscured by white 
matter (Sturrock, 1981). The cells in most dorsal and ventral tips of spinal cord central 
canal showed a very long radial expansion containing intermediate filaments running 
towards pial surface of spinal cord and there are groups of cells which also had 
dorsally located radial processes but did not reach pial surface identified by Alfaro‐
Cervello et al. (2012). The processes also identified by others in both rat (Rafols and 
Goshgarian, 1985) and mouse (Seitz et al., 1981). 
Dorsal GFAP positive cells identified by (Sabourin et al., 2009) have a radial 
morphology and some expressed BLBP (radial glial marker). These cells have been 
classified as tanycytes by others (Bruni and Reddy, 1987; Rafols and Goshgarian, 
1985; Seitz et al., 1981). A subpopulation of tanycyte ependymal cells express the 
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neural precursor marker Nestin and extend long process from the dorsal and ventral 
poles of the central canal (Hamilton et al., 2009). 
In human study by Cawsey et al. (2015), Nestin-positive cells with tanycyte 
morphology were identified in the ventral and dorsal regions of the central canal of 
spinal cord and they suggested that these cells act as neural progenitor cells. 
 
1.4.2.3 Cerebrospinal fluid contacting cells  
Cerebrospinal fluid contacting cells (CSFcC) are also commonly found in the central 
canal region and distributed around the area among neurones. CSFcCs are found in 
the subependymal layer surrounding the central canal. The cell size is smaller than 
nearby interneurones (Barber et al., 1982). The prominent feature of CSFcCs is the 
process that extends from the cell body and through the ependymal layer to contact 
the cerebrospinal fluid in the central canal (Vigh et al., 1977). It has been proposed 
that CSFcCs could connect the internal cerebral spinal fluid (CSF) with the external 
CSF surrounding the entire spinal cord (Vígh et al., 2004) and they could become 
excited through changes in CSF flow either through pH changes or neurotransmitter 
release. The primary function of these cells may therefore be to regulate the local 
environment of central canal. 
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1.4.3 Evidence that the ependymal cells are the neural stem cells 
of the spinal cord 
 
Ependymal cells are considered unique according to the following properties, which I 
will describe in detail in the following sections: 
1. Self-renewal capacity 
2. Ability to increase in number in injured tissue 
3. They are multilineage progenitors 
 
1.4.3.1 Self-renewal capacity 
An important characteristic of ependymal cells in spinal cord area is the self-renewal 
capability in normal tissues. Some of the first evidence looking at this capacity was 
carried out in neurospheres grown from ependymal cells in culture which showed that 
ependymal cells in the spinal cord are capable of neurogenesis (Shihabuddin et al., 
1997).  They reported that the majority of cells expressed vimentin, which is a marker 
of immature proliferating cells but some did differentiate into neurones, astrocytes 
and oligodendrocytes. Then in 2000, Horner et al. (2000) studied this in vivo, using 
5′-Bromo-2-deoxyuridine (BrdU) as a marker of dividing cells since it is incorporated 
into cells during the S-phase, and showed that, not only did cells proliferate but that 
they colocalised with markers of immature glial cells or to a lesser extent, mature 
astrocyte or oligodendrocytes. In a study using transgenic FoxJ1-CreER mice where 
all cells with motile cilia or flagella are labelled with β-gal (which labels the ependymal 
cells) or nestin-CreER mice which labels progenitor cells and BrdU labelling of 
dividing cells, it was shown that 19% of the ependymal cells were labelled  in the adult 
spinal cord (Meletis et al., 2008). They showed that in the intact spinal cord, 
ependymal cell proliferation occurs at a slow rate and just enables self-renewal of 
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these cells. In comparison, in the lateral ventricles, the ependymal cells were 
unlabelled with tritiated thymidine and BrdU without injury suggestive that in normal 
conditions, ependymal cells of lateral ventricle are not dividing cells (Spassky et al., 
2005). 
Bone morphogenetic proteins (BMP) are multifunctional growth factors (Navarro 
Quiroz et al., 2018) that are present in neural stem cells in brain neurogenic niches 
and have been shown to play important roles in generation of astrocytes over 
oligodendrocytes during development (Bonaguidi et al., 2005). In adult brain, BMP2 
and 4 may inhibit neurogenesis and Lim et al. (2000) found out that ependymal cells 
in the SVZ expressed Noggin; an antagonist to BMP, which may block BMP signalling 
in neural stem cells. In spinal cord, the expression of various BMPs and noggin in 
ependymal cells indicates that these cells are involved in neurogenesis and that BMP 
modulates this ability (Miyagi et al., 2012).    
 
1.4.3.2 Ability to increase in cell number in injured tissue 
Much evidence shows that ependymal cells in the spinal cord are capable of 
increasing their number in response to injury (Lacroix et al., 2014; Barnabé-Heider et 
al., 2010; Cizkova et al., 2009; Meletis et al., 2008; Danilov et al., 2006; Johansson 
et al., 1999). Cell fate mapping studies using the FoxJ1 promoter to label the 
ependymal cell in the spinal cords revealed that ependymal cells migrate to the lesion 
site following injury and give rise to cells other than spinal cord ependymal cells such 
as astrocytes and oligodendrocytes (Li, X. et al., 2016; Barnabé-Heider et al., 2010; 
Meletis et al., 2008).  
Using transgenic FoxJ1-CreER mice where all cells with motile cilia or flagella are 
labelled with β-gal (which labels the ependymal cells) or nestin-CreER mice which 
labels progenitor cells, Meletis et al. (2008) showed that in the intact spinal cord, 
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ependymal cell proliferation occurs at a slow rate and just enables self-renewal of 
these cells. They then introduced transverse spinal injury at the dorsal funiculus of 
the spinal cord in mid thoracic level. Their findings showed that there were higher 
SOX9 immunoreactive cells compared to non-injured segments after 4 weeks. FoxJ1 
+ve ependymal cells migrated to the injury site with evidence of increased numbers 
of recombined cells and there were patches of new and old ependymal cells. Even in 
dissociated spinal cord cell cultures, the transgenic mice showed a high proportion of 
recombined neurospheres in both types of transgenic mice, showing that these are 
derived from ependymal cells. Barnabé-Heider et al. (2010) took this work a little 
further, when they looked at proliferation and differentiation of all cell types in the 
ependymal cell layer. They showed that ependymal cells are able to generate 
progeny of both astrocytes (identified through Sox9 labelling) and oligodendrocytes 
(identified as either Olig2 or APC positive). In the uninjured cord, oligodendrocytes 
are produced in greater numbers than the ependymal cells or the astrocytes. However 
all cells only self-renew and there is little differentiation. After injury was introduced 
(transverse cut without reaching grey matter or central canal at thoracic level), 
astrocytes, ependymal cells, and oligodendrocytes progenitors showed higher 
progeny production. After injury, glial cells and ependymal cells were produced in 
higher amounts than oligodendrocyte progenitors, but only ependymal cells were able 
to give rise to cells of different fates, producing astrocytes and oligodendrocyte. Other 
studies also support this finding - ependymal cells migrate from the region of the 
central canal after 3 days post injury and differentiate into astrocytes showed by 
nestin expression on a spinal cord injury rat model (Mothe and Tator, 2005). 
Furthermore, after spinal cord compression injury, there was an increase in cells 
expressing proliferating cell nuclear antigen (PCNA) (showing increased proliferation) 
and some of these cells were double labelled with GFAP (a marker of astrocytes) or 
with nestin and GFAP; indicating a differentiation of ependymal cells into reactive 
astrocytes. Nestin or PCNA immunoreactivity showed increases in levels by day 1 
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post injury and showed its peak expression by 7 days post injury. Most of the 
ependymal cells were able to divide and proliferate according to the severity of injury 
without experiencing apoptosis. 
A few studies in the past also showed that spinal cord ependymal cells contribute to 
tissue repair to promote functional recovery after spinal cord injury (Moreno‐Manzano 
et al., 2009; Takahashi, T. et al., 1998). In a recent study by Sabelström et al. (2013) 
the contribution of ependymal cell proliferation to the glial scar formation was 
highlighted by using a mouse with all Ras genes (required for mitosis) deleted in 
ependymal cells (FoxJ1-rasless mouse). This meant that ependymal cells were not 
able to proliferate. These FoxJ1-rasless mice had abnormal scar formation and 
increased neuronal loss and spinal cord atrophy after spinal cord injury, compared to 
control injured mice.  
In contrast, a recent study looked at the contribution of ependymal cells to scar 
formation after spinal cord injuries of varying magnitude and suggested that there was 
no contribution of these cells to the recovery process following small injuries, such as 
stab injuries. Even large crush injuries involving damage to the central canal only led 
to proliferation of minimal numbers of ependymal cell-derived contributing to the scar 
(Ren et al., 2017).  
The ability of ependymal cells to proliferate after injury may also be preserved in 
humans, which is very pertinent for potential therapies for spinal cord injury. In a study 
of post-mortem spinal cords of patients that had experienced a spinal cord injury 
(Cawsey et al., 2015), there was a significant increase in nestin immunoreactive cells 
around the central canal compared to control tissue. Furthermore, there was a 
positive correlation between survival time and numbers of nestin positive cells. Only 
one group has been able to perform in vitro assays with human ependymal cells. This 
ependymal neurospheres may give rise to cells expressing glial and neuronal markers 
but they cannot be passaged. When cultured, even though these cells can be 
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passaged, they produced cells compatible with mesodermal cell types (Garcia-
Ovejero et al., 2015). 
The most recent evidence also questions the role of ependymal cells in contributing 
to a proliferative responses after spinal cord injury in humans. Even with a strong 
stimulus, the ependymal remnant in adult humans does not proliferate at any distance 
from the lesion of injury either at early times and months after injury. The area covered 
by the nuclei of cells in the ependymal region is not significantly different between 
control and spinal cord injury individuals. There were only 6 cells labelled with Ki67 
or MCM2+; out of 7607 cell nuclei counted in the ependymal region including all the 
slices from all the individual tested which they labelled the overall labelling index as 
<0.08%. This result is really small compared to the strong induction of ependymal 
proliferation after spinal cord contusion in rats. They found that in rodent, with 
moderate/severe spinal cord contusion (200 kdyn), the peak of ependymal 
proliferation was 20% in the spinal cord and this occurred at 3 days post-injury. This 
result challenges the view of the spinal cord ependymal cell layer as a neurogenic 
niche and target cell for neural repair in human (Paniagua‐Torija et al., 2018). 
 
1.4.3.3 Ability to be the multilineage progenitors 
In normal spinal cord, Barnabe-Heider et al (2010) suggested ependymal cells, 
astrocytes and oligodendrocyte progenitors were able to self-renew based on their 
constant quantity of cell numbers over the 4 months of observation. They then went 
on to test with an incision at the dorsal funiculus in vivo using transgenic mice left for 
two weeks and four months and the results showed an increase in cell proliferation at 
the site of injury. The FoxJ1-CreEr mice (labelling ependymal cells) showed 4 to 5 
fold increment while Cx30-CreEr (astrocytes) and Olig2-CreER (oligodendrocytes) 
mice showed double increment. Ependymal cells of FoxJ1-CreEr mice were found in 
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the centre of the glial scar caused by the injury compared to astrocytes of Cx30-CreEr 
mice and oligodendrocytes of Olig2-CreER mice which both found at the injured and 
non-injured area. Ependymal cells were suggested to act as multilineage progenitors 
as FoxJ1-CreEr ependymal cells gave rise to neurospheres which then differentiated 
into neurones, astrocytes and oligodendrocytes compared to cells from the other two 
progeny (Cx30-CreEr/Olig2-CreER) which  did not produce new neurospheres. 
Most of the studies have showed that ependymal cell proliferation was induced with 
spinal cord injury; which explains that in intact spinal cord, the turnover and 
proliferation of ependymal cells is limited (Barnabé-Heider et al., 2010; Cizkova et al., 
2009; Meletis et al., 2008). However the ependymal cells were considered as 
neurosphere forming cells that can self-renew after several passages indicating that 
ependymal cell have stem cell potential in adult spinal cord and are able to 
differentiate into all neural cell types (Sabelström et al., 2013). 
Therefore there is dispute about whether spinal cord ependymal cells can be 
regarded as neural stem cells or neural progenitor cells in the adult spinal cord.  
However many studies have focussed on how these cells respond to an injury rather 
than determining whether they can be made to contribute to recovery by specific 
modulation of the intrinsic or extrinsic factors that are known to modulate 
neurogenesis in other brain regions.  
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1.4.4 What may affect the proliferation and differentiation of 
uninjured ependymal cells? 
 
Both cell-intrinsic and -extrinsic factors contribute to changes in cell production and 
affect the growth of central nervous system cells. Similar extrinsic and intrinsic factors 
to those that are important in other neurogenic regions may also modulate the 
ependymal cells which are the spinal cord neural stem cells. For example, adult 
neural stem cells have been reported to proliferate and migrate either laterally or 
dorsally towards the lesion site following experimental spinal cord injury (Cizkova et 
al., 2009). Cizkova group also compared the effects of spinal cord injury with the 
effects of exercise on ependymal cell proliferation. They found that the injured group 
of rats had ependymal cell proliferation mainly dorsally or laterally towards the injured 
site whereas running rats exhibited a different pattern of proliferation, with the BrdU 
nuclei restricted to medial regions and only in a minor population. 
It is critical to understand how these potential neural stem cells in the spinal cord can 
be manipulated. As mentioned, one method is by activation of specific 
neurotransmitter receptors. There is little information regarding the neurotransmitters 
that may regulate proliferation in the spinal cord but some recent research has started 
to address this and we now know that neurotransmitters can influence proliferation 
and differentiation of spinal neural stem cells. Progenitors in stem cell niches in the 
brain have been shown to be regulated by GABA, glutamate, acetylcholine, dopamine 
and serotonin (Jang et al 2008). Ependymal cells of the brain (Alfonso et al., 2012) 
and the spinal cord (Corns et al., 2013) have been shown to respond to a 
neurotransmitter i.e. GABA. Moreover in the dentate gyrus, GABA can modulate both 
proliferation, differentiation and migration of neural progenitor cells (Tozuka et al., 
2005). Application of GABA receptor agonists increased the number of calbindin 
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positive BrdU neurones, suggesting that GABAA receptor activation promotes their 
differentiation. 
In SVZ, GABA released from newborn neurones inhibits the proliferation of 
neighbouring progenitors to control the neurogenesis (Liu, X. et al., 2005; Haydar et 
al., 2000; LoTurco et al., 1995). Although less is known about the regulation of spinal 
stem cell niches by neurotransmitters, some recent studies have shown 
neurotransmitter mediated influences on stem cell niches especially the central canal 
contacting progenitors (Corns et al., 2015; 2013; Marichal et al., 2012; Reali et al., 
2011). One example, acetylcholine was shown to induce cell proliferation in the spinal 
cord neurogenic niche which was mediated by α7*nAChRs (alpha-7 nicotinic 
receptor) and could be enhanced with a selective α7*nAChR positive allosteric 
modulator (PNU 120596) (Corns et al., 2015). A neuropeptide; substance P (SP) can 
influence neural stem/progenitor cell proliferation and neurogenesis in a compression 
type of spinal cord injury (Kim et al., 2015) in adult Sprague Dawley rats. Through 
immunoblot analysis, they were able to show that SP also increases the 
phosphorylated ERK and phosphorylated p38 kinases in neural stem/progenitor cell 
proliferation. 
In my work, I will be examining the role of GABA and 5-HT on ependymal cell 
proliferation and so the next sections will now focus on these neurotransmitters. 
 
1.5 Neurotransmitters and their receptors 
 
The cellular response is determined by which specific receptors the transmitter binds 
to, which can be either excitatory or inhibitory. The magnitude of the response is 
determined by receptor number, the state of the receptors and the amount of 
transmitter released. 
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There are two major classes of neurotransmitter receptors; ionotropic and G-protein 
coupled (GPCR) or metabotropic (Owens and Kriegstein, 2002). Ionotropic receptors 
are ligand-gated ion channels where binding of a ligand to these receptors results in 
a change that opens a pore in the receptor and permits ion transfer across the cell 
membranes. Metabotropic receptors are associated with G proteins which transduce 
the extracellular signal into an intracellular response. 
The ionotropic receptor is a relatively large, multi-subunit complex composed of four 
or five individual proteins that combine to form an ion channel through the membrane. 
According to the amino acid sequence, there are 2 distinct families. One family 
includes the nicotinic acetylcholine (ACh) receptor (nAChR), the GABA receptor, the 
glycine receptor and one of 5-HT receptor, the 5-HT3 receptor. The other family is a 
group of ionotropic glutamate receptors (Traynelis et al., 2010).  
 
1.6  GABA  
 
GABA has been known to exist in brain since 1950 (Awapara et al., 1950; Roberts 
and Frankel, 1950). GABA is a four-carbon, non-protein amino acid found in all 
prokaryotic and eukaryotic organisms as a significant component of the free amino 
acid pool.  
One function of GABA is to act as a neurotransmitter; the most used inhibitory 
neurotransmitter in the mammalian central nervous system. It acts at inhibitory 
synapses in the brain, and plays a key role in modulating neuronal activity. GABA 
acts by binding to specific transmembrane receptors in the plasma membrane of both 
pre and postsynaptic neuronal processes. There are three different receptor subtypes 
which mediate the inhibitory actions of GABA; the ionotropic GABAA and GABAc 
receptors and metabotropic GABAB. 
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GABA is synthesized from glutamate, using the enzyme glutamic acid decarboxylase 
(GAD) and pyridoxal phosphate (active form of vitamin B6) as a cofactor to convert 
into inhibitory neurotransmitter (Bradford, 1995).  
 L-Glu + H+                                     GABA + CO2 
The enzyme GAD appear in two isoforms; GAD65 and GAD67. Most neurones 
express both GAD isoforms. GAD67 is involved in the synthesis of GABA for general 
metabolic activity whilst GAD65 is involved in the synthesis of GABA for vesicular 
release (Erlander et al., 1991). After being synthesized in the cytoplasm, GABA is 
transported to the nerve terminal and packaged into vesicles by a chain of vesicular 
transporters (Erlander et al., 1991). GABA molecules are released from the 
presynaptic terminals to act on postsynaptic receptors and/or as presynaptic auto 
receptors. Action potentials reaching the axon terminals induce Ca2+ influx which 
triggers the release of GABA into the synaptic cleft (Südhof and Rizo, 2011). The 
effect of GABA depends on the type of receptor it binds to and, in the case of the 
ionotropic receptors, on the intracellular Cl- concentration (Bormann, 1988). GABA 
has a chloride equilibrium potential of approximately -70 mV, close to the membrane 
resting potential in neurones (Olsen and Sieghart, 2009). 
The Na+-K+-2Cl- cotransporter 1 (NKCC1) and K+-Cl- cotransporter 2 (KCC2) 
determine the intracellular Cl- concentration. Intracellular Cl- concentration compared 
to extracellular Cl- concentration dictates whether GABA is inhibitory or excitatory. 
Low intracellular Cl- leads to Cl- influx when GABAA receptors are activated as in 
mature neurones while high intracellular Cl- concentrations leads to Cl- efflux when 
GABAA receptors are activated as in neural stem cells and oligodendrocyte progenitor 
cells. GABA can promote or suppress proliferation depending on the developmental 
stage, brain area and the fate of distinct progenitor populations (Duveau et al., 2011). 
GABAergic signalling has already been shown in the neurogenic niche of the 
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postnatal turtle (Dervan and Roberts, 2003) and the mammalian spinal cord (Corns 
et al., 2013; Shechter et al., 2007).  
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1.7  GABA receptors 
 
The most abundant GABA receptor is the GABAA receptor (GABAARs). GABAARs found 
in the CNS can be grouped into two types: synaptic and extrasynaptic GABAARs. The 
first mediate synaptic communication and are located in the underlying postsynaptic 
density. These receptors can be activated by GABA release from presynaptic vesicles 
increasing the membrane permeability to chloride and bicarbonate ions for a brief period 
of time producing inhibitory postsynaptic (IPSC) or excitatory/depolarizing postsynaptic 
(EPSC) currents in mature and immature neurones, respectively. In contrast, the extra 
synaptic GABAARs usually cause slow tonic inhibition. The presence of GABAA 
receptors was also demonstrated in stem-like cells and neuroblasts (Alfonso et al., 
2012). Ambient GABA was shown to derive from neuroblasts and it was proposed that it 
provides a feedback mechanism for neuronal proliferation (Wang, D. et al., 2003; Nguyen 
et al., 2003).  
There are 3 main types of GABA receptor that may be important in neurogenesis and 
they each show different properties and sensitivity to modulators. These receptors are 
GABAA, GABAB and GABAρ (Table 1-1) and I will discuss each in turn and their 
potential role in neurogenesis.
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Table 1-1 Composition of GABA receptors and their actions and antagonists 
RECEPTOR STRUCTURE ACTION MODULATORS ANTAGONISTS REFERENCE 
GABAA Heterooligomeric 
- The subunits are α1-6, 
β1-3, ɣ1-3, ρ1-3, δ, Ɛ, Ɵ 
and π 
 -Ligand gated chloride 
ion channel  
 
 
-entering of chloride ion 
caused hyperpolarisation, 
exit of chloride causes 
depolarisation 
-net uptake of chloride ion 
generates a source of 
inward depolarising current 
- intracellular Ca2+, if the 
spike preceded with Ca2+ 
the GABA receptor 
mediated response 
inhibited 
Benzodiazepine able 
to give enhancement 
and reduction of 
GABAA function 
-Steroids 
-barbiturates 
 
 
Alkaloid bicuculline 
 
Corns et al. (2013); 
Duveau et al. 
(2011); Liu, X. et al. 
(2005); Nguyen et 
al. (2003); Wang, 
D. et al. (2003)  
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GABAB -G protein-coupled 
receptor 
-7 transmembrane 
receptors 
-3 subunits have been 
cloned 
i.e. GABABR1a 
GABABR1b GABABR2 
-activate 2nd messenger 
systems phospholipase C & 
adenylate cyclase 
-activate potassium & 
calcium ion channels via G-
coupled proteins 
-slow prolonged inhibitory 
signals & function 
Methylphosphinic acid 
analogue of GABA (3 
amino-propyl)-potent 
agonist at GABAB 
receptor- with no 
activity of GABAARs 
CGP 55845 
CGP 52342 
Liu, X. et al. (2005); 
Wang, D. et al. 
(2003)  
GABAρ or GABAC -Homooligomeric 
-selective chloride 
channel 
 
-conducted less current 
compared to GABAA  
- had a longer channel 
opening time & 
desensitization. 
Activated selectively 
by CACA (cis-4-
aminocrotonic acid) 
blocked 
competitively by 
TPMPA (1,2,5,6-
Tetra hydropyridin-
4-yl) 
methylphosphinic 
acid) and 
noncompetitively by 
picrotoxinin 
Sigel and 
Steinmann (2012) 
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1.7.1 GABAA receptor 
1.7.1.1 Structure, composition and function of GABAA receptors 
The GABAA receptor is an ionotropic receptor which is a GABA-gated ion channel. 
The endogenous ligand is GABA. The receptors are made up of five subunits, each 
of which contains four transmembrane domains. There are 19 different GABAA 
receptor subunits that have been identified (D’Hulst et al., 2009). The subunits are α1-
6, β1-3, ɣ1-3, ρ1-3, δ, Ɛ, Ɵ and π. The most common receptor is comprised of two α1- 
and two β2-subunits with one ɣ2-subunit (Olsen and Sieghart, 2009; Olsen and 
Sieghart, 2008) see Figure 1-3.  
GABAA receptors are distributed widely throughout the central nervous system and 
they are permeable to chloride and bicarbonate. GABAA receptors that contain an α1-
3, π and ɣ2 subunit are mainly synaptic, whereas α4-6 and 𝛿𝛿–containing receptors are 
mainly peri- or extrasynaptically located (Belelli et al., 1997). Thus there are two types 
of transmission mediated by GABAA receptors, these are synaptic, also be known as 
phasic transmission and extrasynaptic which is also known as tonic/paracrine 
transmission. GABA is known to exert phasic transmission which results in rapid and 
direct transmission of signals from one neurone to another with GABA containing 
vesicles released from presynaptic terminal to bind to GABA receptors at the post 
synaptic density of the postsynaptic terminal while tonic transmission involves the 
extrasynaptic terminals. Many processes are known to modulate GABAA receptor 
number and function and these are likely to be relevant to both phasic and tonic 
inhibition involving their different subtypes (Farrant and Nusser, 2005). 
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Figure 1-3 GABAA subunits  
Diagram showing the GABAA subunits. (A).GABAA receptor subunit consist of four 
hydrophobic transmembrane domains (TM1-4), with TM2 believed to be the line pore 
of the channel. (B & D).The subunits are α1-6, β1-3, ɣ1-3, ρ1-3, δ, Ɛ, Ɵ and π , most 
GABAA receptors expressed in the central nervous system consist of two α subunits, 
two β subunits and one γ subunit; the subunit γ can be replaced by δ, Ɛ, Ɵ and π . 
Binding of neurotransmitter GABA occurs at the interface between the α and β 
subunits and triggers the opening of the channel, allowing the rapid influx of Cl– into 
the cell. BZ binding occurs at the interface between the α and γ subunits, (C) GABAA 
receptors composed of α(1–3) subunits together with β and γ subunits are thought to 
be primarily synaptically localized, whereas α5βγ receptors are located largely at 
extrasynaptic sites. Both these types of GABAAR are benzodiazepine sensitive. By 
contrast, receptors composed of α(4 or 6) βδ are benzodiazepine insensitive and 
localized at extrasynaptic sites (Adapted and modified from Jacob et al. (2008)).
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1.7.1.2 Maturation switch in GABA-mediated effects 
Synaptic GABAergic inputs were detected at postnatal day 7; i.e, when the granule 
cells were integrated to become innervated by synaptic inputs in the pre-existing 
functional circuit (Ge et al., 2006). Mature neurones express the K+-coupled Cl- 
transporter 2 (KCC2), which exports Cl- ions from the cell, leading to a lower 
intracellular Cl- concentration. Binding of GABA to the receptor leads to influx of Cl- 
into the cell, which causing a hyperpolarization of the cell membrane. Thus, in mature 
neurones GABA acts as an inhibitory neurotransmitter. Neural progenitors and young 
neurones express the Na+-K+-2Cl- transporter NKCC1, and have a higher Cl- 
intracellular concentration compared to the extracellular space (Ge et al., 2006). 
GABA is depolarizing when binding to the GABA receptor in immature neurones since 
Cl- exits the cell down its concentration gradient. During neuronal maturation, the 
expression of NKCC1 decreases while KCC2 starts being expressed which leads to 
a reversal of chloride gradient and as a consequence to a switch from depolarising to 
a hyperpolarising action (Ge et al., 2006; Rivera et al., 1999).  
 
1.7.1.3 Modulation of GABAA receptor 
GABA binds to the GABAA receptor at the GABA binding site situated extracellularly 
at the interface between α and β (Ramerstorfer et al., 2011). Most of GABAA receptors 
comprise two α and two β subunits and have two GABA binding site (Sigel and 
Steinmann, 2012). Binding of GABA to one of the site can induce opening of the 
channel and occupation of both sites can enhance the opening probability (Baumann 
et al., 2003). Besides the binding site of GABA between α and β subunits, there is 
evidence of presence of another GABA binding site at the interface of δ subunit in the 
receptors containing it (Stell et al., 2003). 
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GABAA receptors can be modulated by: 1) post-translational modification by different 
protein kinases, 2) receptor associated protein, 3) endogenous molecules and 4) 
exogenous molecules.  
GABAA receptors can be modulated by phosphorylation through several protein 
kinases such as protein kinase A (PKA) (Bohnsack et al., 2016), protein kinase C 
(O’Neill and Sylantyev, 2018; Bohnsack et al., 2016) and other tyrosine kinases such 
as glycogen synthase 3β, which phosphorylates the GABA receptor scaffolding 
protein, gephyrin and subsequently affects GABAA receptor diffusion (Battaglia et al., 
2018). Different receptor associated proteins such as GABARAP also play a role in 
modulating the GABAA receptor function (Wang, H. et al., 1999).  
Examples of modulators are benzodiazepines and other drugs which can act at sites 
on the receptor; barbiturates, etomidate, the competitive antagonist bicuculline and 
the channel blocker picrotoxin (Sigel and Steinmann, 2012). The activity of GABAA 
receptors can also be altered by intrinsic modulators including neurosteroids, 
endozepines and zinc (Bormann, 2000). 
The primary neural action of benzodiazepines and related compounds is 
augmentation of inhibitory transmission which occurs through allosteric modulation of 
the GABA-induced current at the GABAA receptor (Majewska, 1992).  
Based on GABAA receptor structure, the benzodiazepine binding site has been 
mapped to the extracellular part of the receptor at the interface between α and γ 
subunit (Ernst, M. et al., 2003). The discovery of the benzodiazepine binding site has 
uncovered a variety of endogenous ligands such as diazepam binding inhibitor (DBI) 
and its fragment. The next section will discuss more on DBI and its fragment 
octadecaneuropeptide (ODN) and sites of action i.e.; central benzodiazepine receptor 
(CBR) and translocator protein (TSPO). 
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Diazepam binding inhibitor and central benzodiazepine receptor  
DBI also known as endozepine or acyl-CoA binding protein is an endogenous 10 kDa 
peptide (Knudsen et al., 1993). DBI was first characterised and isolated from rat brain 
by Guidotti et al. (1983). DBI is able to bind and displace radiolabelled diazepam from 
GABAA receptors (Guidotti et al., 1983). In the nervous system, DBI is expressed in 
astrocytes, in Bergmann glia, in ependymal cells and also in thalamus (Christian et 
al., 2013). Highest expression levels of DBI in the brain are in dentate gyrus, rostral 
migratory stream, SVZ, in the ependymal layer lining of third ventricles, in area of 
postrema, in cerebellar cortex, in hypothalamus, in amygdala and certain area of 
thalamus and cerebral cortex (Alfonso et al., 2012). There are high concentrations of 
DBI mRNA in ependymocytes bordering the third ventricle and tanycytes in the 
median eminence (Burgi et al., 2000). 
DBI binds to an extracellular domain between α and γ2 subunits of the GABAA 
receptor i.e., central benzodiazepine receptors (D’Hulst et al., 2009) and also can 
bind to peripheral benzodiazepine receptor (PBR) also known as translocator protein 
(TSPO) (Papadopoulos et al., 2006). The CBR is in fact a part of GABAA receptor 
while TSPO is localized mainly in the mitochondrial membrane in the cells of the 
central nervous system and peripheral organs and there is also some evidence that 
it may be in plasma membranes (Gandolfo et al., 1997). In the postnatal central 
nervous system, DBI is present in glial and ependymal cells but not in neurones 
(Papadopoulos, Vassilios et al., 2006; Bormann, 2000; Bormann, 1988). DBI 
undergoes tryptic digestion within cell to forms its two main processing products; ODN 
and triakontatetraneuropeptide (TTN) (Alfonso et al., 2012; Slobodyansky et al., 
1989). There are no in depth studies addressing the question whether DBI is cleaved 
intra- or extracellularly. Also the identity of the enzymes responsible for DBI cleavage 
has remained elusive. DBI might be capable of self-cleavage and self-activation as it 
comprises several putative endoproteases (Farzampour et al., 2015). DBI and its 
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cleavage products have the ability to displace benzodiazepines from the binding site 
and therefore considered as endozepines. However only DBI and ODN preferentially 
bind to CBR site of GABAA receptor while TTN had a preferential affinity for the PBR 
(Costa and Guidotti, 1991). DBI and its cleavage products ODN, and to a lesser 
extent, TTN bind to CBR site of GABAA receptor and act to reduce GABAA receptor 
mediated Cl- currents. 
DBI has multiple roles within CNS. One important action of DBI, pertinent to this 
thesis, is that it affects proliferation of cells within the neurogenic niche of the SVZ 
(Alfonso et al., 2012). Using primary SVZ cultures which are allowed to differentiate 
and form neurospheres treatment with specific CBR and TSPO ligands; flumazenil 
and PK-11195 induced cell proliferation, (Alfonso et al., 2012). This DBI induced 
proliferation was blocked by flumazenil, not PK-11195 suggesting that the effects of 
DBI on proliferation are likely to be mediated via CBR within the GABAA receptor. The 
actions of DBI at CBR is to reduce the GABA activity and counterbalance the effect 
on neurogenesis, therefore promoting proliferation. 
Alfonso et al. (2012) characterised the expression of DBI in SVZ and rostral migratory 
stream (RMS) using immunohistochemistry and found that DBI was detected in 
astrocyte like GFAP/Nestin+ stem cells and also in Mash1+ fast dividing progenitors; 
however it was absent from doublecortin (DCX+ cells, marker of neuronal precursor 
and immature neurones) migrating neuroblasts. This finding suggests that DBI is 
expressed in the early stages of neurogenesis and subsides when cells progress to 
the neuroblast stage. While DBI is shown to expressed strongly in neural stem cells 
and transit amplifying cells of SVZ (Alfonso et al., 2012), Dumitru et al. (2017) 
investigated the presence of DBI in SGZ, both in juvenile (3 weeks old) and adult (2 
months) mice. The site of expression localized in the radial glial-like stem cells and 
amplifying neural progenitors. DBI expression reduced in level along with the 
developmental stage of SGZ neural progenitors, shown as no co-localization with 
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DCX+ and NeuN marker, resembling its expression pattern in the SVZ as done by 
Alfonso et al. (2012). In addition to SGZ, Dumitru and group also found that DBI is 
strongly expressed in all Nestin+, SOX2+ in tanycytes lining the walls of 3rd ventricle. 
These tanycytes were previously shown to act as neural stem cells (Dumitru et al., 
2017). 
Dumitru and colleagues (2017) also showed the presence of DBI is important for 
regulating the balance between preserving the progenitor pool and generating 
neurones. They manipulated DBI expression in SGZ neural stem cells using 3 
mechanisms : they induced a genetic mouse line in which DBI can be deleted 
specifically in the nestin expressing stem cells and their progeny using tamoxifen 
administration, a combination of Nestin-cre mouse with lentiviral injection in dentate 
gyrus which caused DBI knockdown (KD) and strong DBI overexpression (OE) in 
stem cells and the progeny and injections of lentiviruses that knockdown or 
overexpressed DBI in dentate gyrus of wild type mice. All three manipulations 
produced changes in the population of SGZ neural stem cells. The viral DBI KD group 
showed a decrease in number of transit amplifying cells, astrocytes and neuroblasts 
and an increase in number of adult born neurones. However the DBI OE group 
demonstrated on increase in transit amplifying cells, neuroblasts and astrocytes and 
a decrease in number of adult born neurones. In a long-term group of mice (3 months 
post injection), the number of neuroblasts and adult-born neurones produced by the 
cells overexpressing DBI were comparable to controls. After a long period of DBI OE 
the progenitors overexpressing DBI would have enough time to exit the cell cycle and 
become adult-born neurones. Thus, DBI knockdown increases neuronal 
differentiation while DBI OE expands the pool of early progenitors.  
DBI was shown before to act as a negative modulator of the GABAA receptor through 
the CBR receptor in cultured spinal cord neurones (Costa and Guidotti, 1991; 
Bormann, 1991). The DBI cleavage product ODN, when overexpressed, reproduced 
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the phenotype of DBI OE. ODN is known to bind with high affinity to the CBR receptor, 
but not to the peripheral one (Alfonso et al., 2012). Furthermore, electrophysiological 
recordings showed that ODN inhibits GABA receptor-mediated currents in transit 
amplifying cells in SVZ area. Similar effects of ODN were seen on SGZ stem cells 
(Dumitru et al., 2017). To investigate whether DBI exerts its effects on dentate gyrus 
neurogenesis by binding externally to GABAA receptor, they injected in the dentate 
gyrus of wild type and gamma2 F77I mice at postnatal day 7 with DBI OE and control 
lentiviruses and these animals were sacrificed after 2 weeks. The proportion of DBI-
overexpressing SOX2+ precursor cells was significantly increased compared to that 
of control infected SOX2+ cells in wild type mice. If DBI is regulating SVZ and SGZ 
neurogenesis by modulating GABAA currents, DBI and ODN should have a much 
smaller effect in the mutant mice. Indeed overexpression of DBI in mutant mice 
prevented the phenotype found in wild type mice; namely an expansion of the pool of 
SOX2+ cells. Their results (Dumitru et al., 2017; Alfonso et al., 2012) provide 
evidences that DBI/ODN affects SVZ and SGZ niche by modulating the GABAA 
receptor in stem cells. Thus, DBI and ODN enhance postnatal and adult SVZ 
neurogenesis by negatively modulating the GABA induced currents (Alfonso et al., 
2012). 
ODN-immunoreactive material was only detected in glial and ependymal cells (Tonon 
et al., 1990), contradicting findings from (Alho, H et al., 1991) who reported that DBI 
immunoreactivity is located in non-GABAergic neurones of cerebral cortex and 
GABAergic neurones of cerebellum and hippocampus. There is therefore some 
controversy about expression patterns of ODN. To add to the complexity of the story, 
ODN was initially reported to act just as an agonist at CBR (Ferrero et al., 1986), 
however more recently it has been shown that ODN can also act as agonist at a 
metabotropic receptor coupled either to adenyl cyclase (AC) or to phospholipase C 
(PLC) (Leprince et al., 2001). Astrocytes synthesize and released endozepines 
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including DBI and ODN. More recently, an endogenous molecular form of ODN; 
bisphosphorylated ODN has been found to have stronger affinity for CBR than ODN 
(Gach et al., 2015). As well as being shown to stimulate neurogenesis in the adult 
mouse brain (Alfonso et al., 2012), ODN endogenously also contributes to the 
protection of astrocytes and neurones (Ghouili et al., 2018).   
These data suggest that ODN might play a role in function of glial and ependymal 
cells perhaps through interaction at both CBR and metabotropic receptors as a 
modulator regulating proliferation and/or survival of neuronal cells. 
Numerous reports show that DBI acts as a negative allosteric modulator of the GABA 
receptor both in cultured spinal cord neurones as well as in neural progenitors 
(Dumitru et al., 2017; Alfonso et al., 2012; Costa and Guidotti, 1991; Bormann, 1991). 
However, a study found out that DBI can also enhance GABA currents (Christian et 
al., 2013). DBI has been shown to act as a positive allosteric modulator in reticular 
thalamic nucleus. Mice lacking DBI gene showed an absence of endogenous 
potentiation of GABAergic synaptic transmission within the reticular thalamic nucleus. 
The potentiation was absent in the DBI knockout mice (nm1054- a deletion of 400 kb 
on chromosome 1 that includes DBI gene) and in the mice with a mutation that 
abolishes the binding of benzodiazepines at the benzodiazepine binding site in the 
α3 subunit. These data suggested that DBI in the thalamic reticular nucleus acts as a 
positive modulator of GABAA receptors by binding to the benzodiazepine site. 
Christian and colleagues also found that DBI reduces thalamo-cortical oscillations 
which might be the mechanism to prevent seizures. Therefore they proposed low DBI 
concentrations enhance GABA induced currents, while high DBI concentrations 
would negatively modulate the activity of the receptor. 
In summary, GABA negatively regulates cell division by inhibiting proliferation and 
promotion of progenitor differentiation (Tozuka et al., 2005) and DBI opposes this 
inhibition. If DBI is indeed found in the central canal of spinal cord, it is possible that 
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it is also reside within the niche to counter balance the negative effects of GABA on 
proliferation. 
 
Translocator protein (TSPO) 
In addition to CBR, DBI binds to a second benzodiazepine receptor named as 
peripheral benzodiazepine receptor (PBR).This receptor was discovered in 1977; 
primarily within the outer mitochondrial membrane of peripheral tissues (Braestrup 
and Squires, 1977). PBR, also known as translocator protein (TSPO) is a 18 kDa 
protein. It consists of five transmembrane α helices (Papadopoulos, Vassilios et al., 
2006). It is the minimal functional unit that acts as a binding site for all PBR ligands 
(Papadopoulos et al., 2006). In the CNS, TSPO is mostly found in glia, particularly 
within microglia and astrocytes. It was discovered due to its ability to bind to diazepam 
with an affinity closest to that of CBR. But this receptor shows no other structural or 
pharmacological similarities to GABAA receptors (Papadopoulos et al., 2006). TSPO 
roles include a role in steroid biosynthesis (Papadopoulos, V et al., 1997), acting as 
a component of the mitochondrial permeability transition pore complex in the inner 
and outer mitochondrial membranes which contain the anion channel and proteins 
necessary for benzodiazepine and endozepine binding (McEnery et al., 1992). 
The DBI cleavage product TTN binds with low affinity to the GABAA receptor but 
binds with high affinity to TSPO (Mukhin et al., 1989). There are a number of drugs 
that have been established as typical TSPO-binding compounds, the 
benzodiazepine Ro5-4864, which has no affinity for GABAA receptors, instead 
acting as a ligand at TSPO, the anxiolytic drug FGIN-1-27 and a non-
benzodiazepine antagonist, PK11195 [1-(2-Chlorophenyl)-N-methyl-N-(1-
methylpropyl)-3 isoquinolinecarboxamide] which bind to TSPO but not to GABAA 
receptor. An indirect role of DBI in steroidogenesis is through the handling of 
mobilisation of cholesterol which involves the function of TSPO.  
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Allopregnanolone is a neurosteroid formed in response to ligand binding at TSPO and 
this neurosteroid is known to have potent positive allosteric modulator effects on 
GABAA receptor (Belelli and Lambert, 2005; Belelli et al., 1997). Thus TSPO 
activation may have downstream positive modulatory effects on the GABA response 
due to a neurosteroidogenic pathway. This is supported by the observation that in 
isolated mitochondria from a glioma cell line, endozepines activate the formation of 
the steroid hormone precursor pregnenolone (Papadopoulos, V et al., 1997) 
suggesting that endozepines also act as intracrine factors stimulating the synthesis 
of neurosteroids in astrocytes.  
Because several neuroactive steroids are potent allosteric modulators of the GABAA 
receptor, it seems that endozepines can indirectly regulate the activity of the GABAA-
benzodiazepine receptor complex through their ability to control the production of 
neurosteroids through TSPO (Tokuda et al., 2010). TSPO can also be located at the 
plasma membrane, leading to an influx of Ca2+ through voltage-dependent calcium 
channels in glial cells (Papadopoulos, V et al., 1997).  
Regulation and manipulation of neurotransmitter levels and GABA receptors within 
the area of the spinal cord may play a major role in determining how resident neural 
stem cells in this area behave. Studies into the effects of exogenous compounds 
which can affect the environment in which neural stem cell exist may explain the 
importance of particular neurotransmitters in the maintenance of the niche. 
 
1.7.1.4 Role of GABAA receptor activation in neurogenesis 
GABA plays a different role in regulating neurogenesis in the early postnatal period 
compared to the adult brain (Stefovska et al., 2008). The activity of GABA receptors 
can be altered by modulators including neurosteroids. Precise targeting of such 
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treatments depends on identification and characterization of the different subunit 
complexes that exist.  
It has been proposed that the effects of GABA in embryonic CNS is to stimulate 
proliferation. GABA is important for development as injection of pentobarbital (a 
GABAA receptor agonist) stimulated dendritic growth of dentate gyrus cells (Ge et al., 
2006). In adults, the most common reported action of GABA on proliferation is 
inhibitory.  
GABA also promotes migration of spinal cord cells during development. Embryonic 
spinal cord cells of rat were dissected and dissociated into single-cell suspension for 
a microchemotaxis assay experiment. This chemotaxis assay revealed that these 
cells migrated toward GABA and muscimol (GABAA agonist). In contrast, bicuculline 
and picrotoxin (GABAA antagonist) inhibited this muscimol-induced migration (Behar 
et al., 1994). 
In the spinal cord, the electrophysiological effect of GABA on GABA receptors in 
CSFcCs has been shown in rat (Marichal et al., 2009). In whole cell patch clamp 
recordings in spinal cord slices, 100 μM GABA produced currents that reversed at the 
Cl- equilibrium potential. 10 μM Gabazine (a GABAA receptor antagonist) blocked this 
GABA-induced current, suggesting that it was mediated through GABAA receptors.  
Most of the research on ependymal cells has focussed on the role of ependymal cells 
as neural stem/progenitor cells and their importance in neurogenesis following spinal 
cord injury. Thus to date, little is known about GABA-mediated changes in 
proliferation but it is known that ependymal cells can respond to GABA. The effects 
of GABA on ependymal cells in turtle spinal cord showed that GABA depolarised the 
brain lipid binding protein progenitor cells (BLBP+) (Reali et al., 2011). A GABA 
transporter 3 (GAT3) selective blocker (SNAP 5114) and non-selective GABA 
transporter blocker (nipecotic acid) were able to reduce, but not abolish the GABA-
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induced currents in these BLBP+ progenitor cells. BLBP+ progenitor cells showed 
positive staining for anti GAT3, S100β (marker for ependymal cells) and anti-NKCC1. 
When gabazine or bicuculline and nipecotic acid were applied onto to the cells, the 
GABA-induced current was abolished, which suggests that both GABA transporters 
and receptors were involved in the response (Reali et al., 2011). 
Furthermore in rat, ependymal cells were depolarised by GABA, mediated through 
GABAA receptors (Corns et al., 2013) suggesting that neural stem cells can respond 
to the pressure application of GABA, although whether this effect was direct was not 
investigated. Bicuculline or gabazine decreased the amplitude of the depolarisation 
but nipecotic acid had no effect, suggesting that GABA transporters were not involved 
in these responses, unlike the turtle. The subunit composition of this response was 
also not investigated. This is important since in other regions, involvement of more 
unusual GABA subunits is reported. For example, the influence of GABA on 
ependymal cells was shown by work on cerebellar slices from P13-P15 mice (Reyes‐
Haro et al., 2013). GABA applied to ependymal cells was blocked by the GABAρ 
subunit antagonist TPMPA as well as the GABAA antagonist bicuculline.  
Both in the SVZ and SGZ, GABA regulates the activation and proliferation of stem 
cells (Song et al., 2016; Song et al., 2014; Liu et al., 2005). At the level of the SGZ, 
GABA regulates also the survival and development of transit amplifying cells (TACs) 
and neuroblasts (Song et al., 2013). 
The table (Table1-2) below summarizes the effects of a few drugs and neurosteroids 
on the receptors and any known effect on neurogenesis. 
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Table 1-2 The effects of a few drugs and neurosteroids on the receptors and any known effect on neurogenesis: 
  
  
DRUG/MODULATOR RECEPTOR 
INVOLVED 
EFFECTS INCLUDING ANY KNOWN EFFECT ON 
NEUROGENESIS 
REFERENCE 
Neurosteroids: 3α, 21-
dihydroxy-5α-pregnan-
20-one (THDOC), 
pregnanolone  
GABAA receptors 
(specifically on 
delta subunit) and 
γ2 subunit   
Acting with 2-arachidonoyl glycerol (2-AG) (lipid signalling network) 
potentiates phasic inhibition in synaptic receptors, and tonic inhibition 
in extrasynaptic receptors during neurogenesis 
Sigel et al. (2011), 
Ranna et al. (2006)  
Etomidate GABAA receptors 
(β2- or β3 subunit) 
Gave a large direct inward current in cerebellar granule cells mediated 
through the GABAA receptors 
Ranna et al. (2006), 
Belelli et al. (1997)  
Pentobarbitone GABAA receptors 
α3, α2, β1 and β3 
subunits 
Significantly increased the number of new neurones in the adult 
dentate gyrus 
Tozuka et al. (2005) 
Phenobarbital GABAA receptor Significantly increased the number of new neurones in the adult 
dentate gyrus 
Tozuka et al. (2005) 
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DRUG/MODULATOR RECEPTOR 
INVOLVED 
EFFECTS INCLUDING ANY KNOWN EFFECT ON NEUROGENESIS REFERENCE 
Diazepam GABAA receptor Acts on α and γ2 subunit to enhance response. Does not induce any 
current by themselves but increase the current amplitude 
Sigel and 
Steinmann (2012)  
Bicuculline GABAA receptor Widespread effect on tonically active GABA receptors on sympathetic 
neurones of intermediolateral region of  rat spinal cord 
Wang, L. et al. 
(2008) 
Gabazine GABAA receptor Gabazine will modulate tonic inhibition and influences firing properties Wang, L. et al. 
(2008) 
Endocannabinoid GABAA receptor The endocannabinoid 2-arachidonyl glycerol (2-AG) potentiates GABAA 
receptors at low concentrations of GABA. Tonic inhibition in extrasynaptic 
receptors 
Sigel et al. (2011) 
 
Dehydroepiandrosterone 
(DHEA)  
 
- 
 
Neural stem cell renewal, differentiation i.e. induces neurogenesis in 
human cortical-derived neural stem cells and enhances proliferation of 
newly formed rat neurones, blocking corticosterone effects 
Charalampopoulos 
et al. (2008)  
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1.7.2 GABAB receptors 
GABAB receptors were identified by Bowery et al. (1980). GABAB receptors are 
defined by their selective activation by baclofen (Kerr and Ong, 1995; Bowery et al., 
1980) and lack of sensitivity to bicuculline. GABAB receptors belong to the family III 
G protein-coupled receptors (GPCRs) that are activated by GABA. These receptors 
use second messenger systems through binding and activation of guanine 
nucleotide-binding proteins (G proteins) (Bettler et al., 2004). The receptor has a 
central core domain, consisting of 7 transmembrane helices, that is responsible for 
G-protein coupling. It is an obligatory heterodimer and is formed by 2 subunits; i.e., 
GABAB1 and the GABAB2 (Kaupmann et al., 1998). The GABAB1 subunit contains a 
large extracellular domain that binds GABA or other ligands such as baclofen, and 
GABAB2 subunit couples the receptor with the effector G protein (see Figure 1-4). 
G protein activation causes interactions with ion channels and other proteins to open 
or close ion channels through intracellular messengers (Bettler et al., 2004). They 
produce slow postsynaptic responses and can be activated in conjunction with 
ionotropic receptors to induce both fast and slow postsynaptic potentials. The delayed 
action of GABAB is due to the relay action of the second messenger, G protein to 
mediate its response. These metabotropic GABA receptors use potassium channels 
instead of chloride and opening of these channels causes hyperpolarisation of 
postsynaptic cells through efflux of potassium. They can also close calcium ion 
channels presynaptically to reduce neurotransmitter release (Kerr and Ong, 1995).  
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1.7.2.1 Mechanism of action  
GABAB receptors are present both pre- and postsynaptically. Pre- and postsynaptic- 
GABAB receptors have different properties. The pre-synaptic receptors are composed 
of GABABR1a and GABABR2 subunits. At the presynaptic site, GABAB receptors 
mediate inhibition of neurotransmitter release through an autoreceptor-like 
mechanism by activation of K+ conductances and inhibition of Ca2+ conductances 
(Dunlap and Fischbach, 1981). The post- synaptic receptors are composed of 
GABABR1b and GABABR2 subunits (Koulen et al., 1998).  
GABAB receptor activation leads to three major effector cascades: adenyl cyclases, 
voltage-sensitive Ca2+ channels and inwardly rectifying K+ channels (Benke et al., 
2012) (Figure 1.4). 
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Figure 1-4 Structure and effector mechanism of GABAB receptors.  
When the GPCR is activated by its extracellular ligand, a conformational change is 
induced in the receptor is transmitted to an attached intracellular heterometric G 
protein complex. The Gi/o alpha subunit of the stimulated G protein complex 
exchanges GDP for GTP and is released from the complex. The activated Gi/o alpha 
subunit binds to and inhibits adenylyl cyclase which in turn catalyzes the conversion 
of ATP into cyclic adenosine monosphosphate (cAMP). GABA = γ-aminobutyric acid; 
AC = adenylyl cyclase; ATP = adenosine triphosphate; cAMP = cyclic adenosine 
monophosphate (Edited from Kumar et al. (2013) and Xu et al. (2014)).  
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One target of excitability control mechanism at post-synaptic membranes are G-
protein-gated inwardly rectifying K+ (GIRK or Kir3) channels, which generate slow 
inhibitory post-synaptic potentials following activation of Gi/o-protein-coupled 
receptors and leads to decreasing neuronal excitability. The GIRK also can play a 
role at presynaptic sites (Fernández‐Alacid et al., 2009).   
Postsynaptic GABAB receptors inhibit adenylate cyclase via the Gi/o subunits of the 
G-protein, resulting in a reduced level of intracellular cyclic adenosine 
monophosphate (cAMP) (Knight and Bowery, 1996). The βγ complex released from 
the G protein is coupled to inwardly rectifying potassium channels (GIRK) which 
mediate the membrane potential response (Nicoll, 2004). The receptor agonist 
baclofen hyperpolarizes neurones expressing postsynaptic GABAB  receptors in vitro, 
associated with decreased input resistance (Howe et al 1987).The hyperpolarisation 
has a reversal potential close to the potassium equilibrium potential. Postsynaptic 
GABAB receptors mediate slow GABAergic currents which can be blocked by GABAB 
antagonists. The current induced by GABAB receptors hyperpolarizes the membrane 
and shunts the current by coupling to GIRK3 via G proteins (Lüscher et al., 1997). 
Baclofen remains the only available GABAB medication. Baclofen, a lipophilic 
derivative of GABA, was synthesized in 1962 in an attempt to enhance blood brain 
barrier penetrability of the endogenous neurotransmitter. Baclofen is used to treat 
spasticity and skeletal muscle rigidity in patients with spinal cord injury and multiple 
sclerosis (Fox et al., 1978). 
 
1.7.2.2 G protein-coupled inwardly-rectifying potassium channels 
G protein-coupled inwardly-rectifying potassium channels (GIRK) channels are 
members of a large family of inwardly rectifying K+ channels. GIRK channels are 
mainly concentrated at postsynaptic sites. Studies in cerebellum showed that GIRK 
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channels contain three subunits, GIRK 1, GIRK 2 and GIRK 3 where they associate 
with GABAB receptors (Lüscher and Slesinger, 2010). The three primary GIRK 
subunits exist in the brain and form heterotetramers (GIRK1–GIRK2, GIRK2–GIRK3 
and GIRK1–GIRK3; (Krapivinsky et al., 1995)) and homotetramers (GIRK2–GIRK2; 
(Lesage et al., 1995)). Electrophysiological studies have shown that the binding of 
GABA to GABAB receptors activates GIRK channels at postsynaptic sites (Jones et 
al., 1998). GIRKs associated with GABAB receptors are also present at presynaptic 
sites - the mechanism of GIRK-dependent effects here is not fully clear, but it might 
involve the inhibition of neurotransmitter release following activation of GABAB 
receptors (Luján et al., 2014; Fernández‐Alacid et al., 2009; Ladera et al., 2008). A 
study has shown that excess accumulation of GABA which is released in the synaptic 
cleft will diffuse to neighbouring GABAB-GIRK complexes (Nicoll, 2004). 
 
1.7.2.3 Interaction of GABAB with other receptors 
 
Interaction of GABAA and GABAB 
GABAB receptors may be located at different regions on neurones in relation to the 
other GABA receptors. GABAA receptors are Cl- ion channels which produce fast 
electrical signals, whereas GABAB receptor activation induced long term modulation 
through G protein regulated gene transcription and protein synthesis (Lüscher et al., 
1997). There is some evidence showing that in rat hippocampal pyramidal cells, 
GABAB receptors are not located on the cell soma but rather on the dendrites while 
GABAA receptors are located in both regions. This means that GABAA and GABAB 
receptors on the dendrites may both be activated by synaptic release of GABA and 
the GABAB receptor activation may modulate the effectiveness of fast GABAA 
receptor-mediated inhibitory postsynaptic potentials (Newberry and Nicoll, 1985). In 
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some situations, GABA released spontaneously or driven by a single action potential 
produces a fast inhibitory post-synaptic potential mediated by GABAA channels. In 
contrast to this, a stronger stimulation is needed to elicit the slow inhibitory potential, 
suggesting that GABA released into synaptic cleft diffuses and activates perisynaptic 
GABAB receptors coupled to GIRK channels (Nicoll, 2004). 
It appears that activation of GABAA receptors containing γ2 subunits can potentially 
cause internalization of the GABAB receptors comprised of GABABR1/R2 subunits 
through an interaction of this γ2 subunit with the GABAB receptor (Balasubramanian 
et al., 2004). Although this work was only done in oocytes, it may be relevant to 
ependymal cells. Furthermore, GABAB receptors may also be able to influence the 
cell surface expression of GABAA receptors through GABAB receptor mediated 
secretion of brain-derived neurotrophic factor (BDNF). This in turn increases 
expression of GABAA receptors that contain β2/3 subunits (Kuczewski et al., 2011). 
These experiments provide a mechanism for quite complex co-ordination of the 
neuronal responses to GABA, depending on the subunit composition of neighbouring 
receptors. 
 
Interaction of GABAB and 5-HT  
Interaction of 5-HT and baclofen works by activation of separate receptors which use 
a common conductance mechanism (Andrade et al., 1986). 
In hippocampal neurones, it is possible that some serotonin receptors (5-HT1 and 5-
HT5) and GABAB receptors are coupled via the G proteins to the same GIRK 
channels. Andrade and colleagues (1986) showed that simultaneous activation of 
both receptors elicited slow currents in these neurones that were smaller than what 
would be expected. If there was a simple summation of the currents due to activation 
of the two receptors separately. They concluded from their various manipulations of 
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the second messenger pathway that the G protein enabled this direct coupling of the 
receptors to the same potassium channels.  
Looking at the multiple interactions of GABAB receptors, we can say these differences 
may be due to variation in the composition of tetramers of GABAB receptors, variants 
of subunits and isoforms, cell surface expression and also crosstalk with interacting 
proteins. 
 
1.7.2.4 Role of GABAB receptors in neurogenesis  
Adult hippocampal neural stem cells are quiescent but reversible in response to 
stimuli such as neurotransmitter modulation (Bonaguidi et al., 2012). Excitation of the 
cell with extrinsic and intrinsic factors such as growth hormones, neurogenic factors, 
cytokines and as well as specific neurotransmitters can activate the quiescent stem 
cell pool and there is evidence showing that GABAB receptors can contribute to the 
process (Giachino et al., 2014; Felice et al., 2012). Most mouse hippocampal neural 
stem cells and their progeny express metabotropic GABAB receptors (Schuler et al., 
2001). A study done by Giachino et al. (2014) showed newly generated adult granule 
neurones express GABAB receptors. Next they used GABAB genetic deleted mice 
GABAB1-/- or GABAB2-/- and compared them with the wild type for numbers of 
proliferating cells. Thirty days after injection of BrdU, newborn neurones were 
identified by BrdU and in the GABAB1−/− or GABAB2−/− mice, the number of newly 
generated cells was significantly higher in these animals and these showed enhanced 
neuronal differentiation. The increased progenitor proliferation in GABAB1-/- mice 
suggested that activation of GABAB receptors is needed to maintain neural stem cells 
in a quiescent state.  
Felice et al. (2012) studied how the GABAB receptor antagonist CGP 52432 can 
increase hippocampal neurogenesis in the ventral hippocampus. The increase in cell 
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proliferation in the adult hippocampus in response to CGP 52432 was observed after 
chronic (21days) administration of CGP 52342 but not the subacute (7 days) or acute 
(1 injection). Cell proliferation was upregulated following chronic administration of 
CGP 52342; consistent with the lags for actions of drugs. They proposed the 
molecular mechanism of cell proliferation may due to brain-derived neurotrophic 
factor. BDNF is important in the regulation of antidepressant-induced increases in 
hippocampal neurogenesis as in previous study (Enna and McCarson, 2006). In 
another study, acute administration of baclofen induced a decrease of BDNF mRNA 
expression in the dentate gyrus (Khundakar and Zetterström, 2011). The decreased 
of BDNF was attenuated by pre-treatment with GABAB antagonists CGP 46381 and 
CGP 55845. 
Little is known about the role of GABAB receptors in spinal cord proliferation but they 
are widely expressed in the spinal cord (Wang, L. et al., 2008) and may have effects 
on the neurogenic niche of the spinal cord. 
Since GABA has significant effects on ependymal cells in the spinal cord and 
modulators of GABA receptors are expressed in these cells, I sought to determine 
how responses of ependymal cells to GABA were affected by application of specific 
drugs acting on or modulating different GABA receptors. 
 
1.7.3 GABAρ receptor 
The third type of GABA receptor, termed GABAC has been proposed to have a distinct 
molecular subunit composition and can be distinguished pharmacologically from 
GABAA receptors even though it also gates the Cl- currents (Johnston, G., 1996). 
GABAC receptors, which were insensitive to bicuculline, were found in various parts 
of vertebrate brain and were first described in interneurones of the mammalian spinal 
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cord (Johnston, G.A., 1997), although the name of GABAC was not used by this 
group.  
It was in a study on rat cerebellum by Drew et al. (1984) where this new receptor was 
designated the GABAC receptor. CACA; the folded conformationally restricted 
analogue of GABA did not inhibit the binding of (3H-)-baclofen to rat cerebellar 
membranes. Since this compound was also known to act at GABA receptors that 
were bicuculline insensitive and therefore was not a GABAA receptor ligand the 
authors suggested that there was a third type of receptor, GABAC receptors. In further 
experiments in retina, GABAC receptors were shown to be insensitive to GABAA 
receptor antagonists particularly bicuculline and not activated by the GABAB receptor 
agonist baclofen (Bormann and Feigenspan, 1995), providing further support for a 
new receptor. 
Most of the studies on GABAC were done in the retina (Feigenspan et al., 1993; Qian 
and Dowling, 1993; Cutting et al., 1992; Woodward et al., 1992) to establish the native 
GABAC receptor. Later, GABAC receptors were observed by Polenzani et al. (1991), 
who showed that GABA activated Cl- currents were made up of two different 
components, one mediated by GABAA receptors and the other mediated by GABAC 
receptors. This gave evidence of different receptors with distinct protein subunits 
which associate with each other.  
Identification of ρ subunits in the GABAC receptor was based on Cutting et al. (1991) 
where they cloned the ρ1 subunit from human retina complementary DNA (cDNA) 
library. When expressed in Xenopus oocytes, the ρ subunits formed a channel that 
was sensitive to GABA and these responses were not blocked by bicuculline. Two 
distinct clones were isolated differently through DNA sequencing. The clone 
contained a single exon from the rho1 gene (GABBR1) while the second clone 
encompassed an exon with 96% similarity to rho1 gene. The second gene had an 
amino acid sequence of cDNA with 30-38% similarity to α,β,γ and δ GABA receptor 
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subunits and 74% similarity to GABA rho1 subunit and this suggested that this was a 
newly member of rho subunits. The ρ2 subunits were cloned from human retina in 
1992 (Cutting et al., 1992) and were also found in hippocampus, cerebellum and 
pituitary gland (López-Chávez et al., 2005a). The subunit ρ3 has been detected in 
retina and also in higher brain regions (Boue‐Grabot et al., 1998). Currently the name 
GABAC is in disuse and the three GABAρ genes are included in the GABAA receptor 
family. However, for the sake of this thesis, I will consider these receptors as 
potentially mediating different effects. 
 
1.7.3.1 Structure and properties of GABAρ 
GABA ρ-subunits have been found in retina (Enz et al., 1995), cerebellum (Pétriz et 
al., 2014) , hippocampus (Rozzo, Aldo et al., 2002; Enz et al., 1995), pituitary gland 
(Boue-Grabot et al., 1998), spinal cord (Rozzo, Aldo et al., 2002; Rozzo, A et al., 
1999), gastrointestinal (Jansen et al., 2000) and sperm cells (Li, S. et al., 2008).  
The GABAρ receptors were originally thought to be homopentameric ligand gated ion 
channels composed of ρ subunits (Figure 1-5). It required five subunits to assemble 
a single ion channel. Subunits in the ligand gated ion channels exhibit 10-20% 
sequence homology and have a similar distribution of hydrophobic and membrane-
spanning segments and are assumed to have similar structure. Hence, GABAA and 
GABAC/ρ receptors are believed to be comprised of five subunits which assemble to 
form an ion channel. The general structure of every subunit consists of an 
extracellular amino terminal domain, four transmembrane domains, and an 
extracellular carboxy terminus. Each subunit is thought to have four transmembrane 
domains: TM1-TM4 (Chebib and Johnston, 2000). TM2 is a significant 
transmembrane domain. It crosses the membrane as an α–helix, forms the wall of the 
channel pore and is involved in the gating process (Chebib and Johnston, 2000). The 
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binding site of GABA is located in the extracellular amino-terminal domain which when 
activated, leads to the opening of ion channel with subsequent flux of Cl- through it 
(Figure 1-5). 
 
 
 
Figure 1-5 GABAρ receptor structure.  
Five ρ subunits assemble to form a pentameric protein complex with the Cl- channel 
as a central pore. The binding sites for agonists (e.g. GABA) as well as antagonists 
and modulators are located in the extracellular part of the protein complex. 
Picrotoxinin binds in the channel pore but shows also an use-dependent effect, 
indicating an allosteric mechanism. The intracellular loop between transmembrane 
regions 3 and 4 may contain sequences for protein kinases such as PKC (Image 
modified from Enz and Cutting (1998)).
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A study regarding GABAρ subunits also suggests pseudoheteromeric channels 
consisting of different ρ subunits (Connolly et al., 1996). Some studies also support co-
assembly of ρ subunits with GABAA subunits i.e. with α1 and γ2 (Milligan et al., 2004; 
Pétriz et al., 2014) and also with α1 and α2 subunits (Duke et al., 2000). There are three 
specific types of ρ–subunits, ρ1-ρ3 and these form different complexes depending on 
their distribution. In adult rats, the distribution of heteromeric complexes of ρ subunits is 
scattered and the presence of the different complexes is reported by researchers who 
found only receptors composed of ρ1,2 (Cutting et al., 1991) while others found only ρ2,3 
heteromers (Ogurusu et al., 1995). In 2005, Alakuijala demonstrated all three ρ subunits 
are expressed in several regions in rats’ postnatal developing brain.  
To group the GABAρ receptors based on pharmacological interaction, basically this 
receptor has greater sensitivity to GABA and shows bicuculline and baclofen 
insensitivity. Their currents are smaller than other receptor currents and do not 
desensitize. In general, GABA is between 10-100 fold more potent at GABAρ receptors 
than GABAA receptors. Furthermore, GABA acting at GABAρ receptors produces 
responses with slow activation and deactivation (Feigenspan and Bormann, 1994; 
Feigenspan et al., 1993). 
EC50 values for GABAρ1 and GABAρ2 are in the range of 0.8 to 2.2 μM (Polenzani et al., 
1991; López-Chávez et al., 2005b) and around 7.5 μM for GABAρ3 receptors (Zhang et 
al., 2001). However a study by (Schmidt et al., 2001) on rat superior colliculus showed 
that at lower agonist concentrations, which most likely activate GABAρ, the effects of 
GABA on evoked excitatory and inhibitory responses were not uniform. Evoked 
responses were suppressed by GABA (applied at concentrations of between 10 and 50 
µM) in 48% of neurones, the remaining cells exhibited enhanced responses. But all 
effects of GABA at low concentrations were blocked by TPMPA but not bicuculline. 
There are a number of compounds available that seem to selectively or preferentially act 
on ρ subunit-containing receptors. An early study by Drew et al., (1984) showed that the 
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GABA analogue cis-4-aminocrotonic acid (CACA) had activated selectively GABAρ 
receptors in cerebellar neurones. The study showed CACA had a bicuculline insensitive 
depressant action on firing neurones, but had no effect on the binding of (3H)-baclofen 
to the rat cerebellar membranes and thus it is unlikely that this drug acts as an agonist 
on GABAA or GABAB receptors. 
Other than GABA and CACA, trans-3-aminocrotonic acid (TACA) has greater potency 
than GABA at ρ receptors but is non-selective, also acting as an agonist at heteromeric 
GABAA receptors (Kerr and Ong, 1995; Woodward et al., 1992). 
GABAρ receptors are not sensitive to other modulators of GABAA receptors such as 
benzodiazepines, and barbiturates. There are no benzodiazepine (diazepam 10-4 M, β-
CCE 10-4 M and bicuculline 10-6 M) and barbiturate (pentobarbital 10-4 M) sites on this 
receptor (Shimada et al., 1992).  
Neuroactive steroids can modulate the ρ1 subunit in xenopus laevis oocytes (Morris et 
al., 1999). The modulation of ρ1 receptors by neurosteroids compounds were dependant 
on GABA concentration. These effects were prominent in the presence of low 
concentrations of GABA (0.2-0.4 μM). The differential modulation by neurosteroids 
depends on the type of derivatives. The 5α derivatives (allopregnanolone, alphaloxone 
and 5α-tetrahydro- deoxycorticosterone (5α-THDOC)) were potentiators of GABAρ while 
the 5β-tetrahydrodeoxy- corticosterone (5β-THDOC) were the inhibitors to GABAρ. 
Finally the effects of the neuroactive steroids on ρ1 receptor were shown to be long 
lasting because the application of GABA did not return to the control level for few minutes 
after neuroactive steroid treatments. Differently, these effects of neurosteroid modulation 
did not occur in an earlier study by (Woodward et al., 1992) using GABA (1-2 μM) on 
retina RNA of Xenopus oocytes. 
A study by Shimada et al., (1992) expressed the GABAρ subunits in oocytes and 
reported no effects of benzodiazepine on responses to GABA 1 µM but these responses 
were blocked by both the GABAA receptor Cl- channel blocker (picrotoxin 10-4 µM) and 
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the GABA receptor antagonist (tert butylbicyclo- phosphoro- thionate 10-6 µM). This 
suggests that some antagonists have effects at both types of receptor. 
Picrotoxinin is an active isomer from picrotoxin and a pore blocker at the GABAρ receptor 
ligand site (Goutman and Calvo, 2004). It binds to TM2 to inhibit chloride flux through 
the anionic ligand-gated channels (Olsen, 1982). Picrotoxinin has different effects at ρ1 
and ρ2 homomeric receptors and from different species. Picrotoxinin is able to block 
current induced in GABAρ1 mRNA-injected Xenopus oocytes superfused with GABA (1 
μM) (Shimada et al., 1992) but rat GABAρ2 receptors are relatively insensitive to 
picrotoxinin (Feigenspan et al., 1993).  
There are relatively few antagonists that selectively distinguish GABAρ receptors from 
GABAA receptors; the most highly used being (1, 2, 5, 6-Tetrahydropyridine-4-yl) 
methylphosphinic acid (TPMPA). The distinct antagonist profiles of GABAA and GABAρ 
showed that the agonist and antagonist binding area/site is not the same for these 
receptor classes. TPMPA is a selective GABAρ antagonist that is 8 times more potent at 
ρ1 over ρ2 subunit containing receptors (Chebib et al., 2007) and is 100 times weaker as 
an inhibitor of GABAA receptors (Murata et al., 1996). In astrocyte primary culture, only 
10 μM TPMPA was needed to antagonise the effect of GABA by 80% (Pétriz et al., 2014). 
In contrast, 100 μM was needed to block 68% of GABA responses in ependymal cells 
from mouse cerebellar slices ages postnatal days13 to 35 (Reyes‐Haro et al., 2013). 
Similar concentrations were needed to block 52% of GABA responses in striatal 
astrocytes (Reyes-Haro et al., 2017). However in a study by Schlicker et al. (2009), in 
the presence of TPMPA, a TPMPA sensitive current persisted in GABAρ1 knockout 
stratum griseum superficial cells. The differences of results in the studies may due to the 
drug potency using TPMPA or it may involve a particular subunit arrangement.  
GABAρ may even coassemble with subunits of GABAA receptor (Harvey et al., 2006; 
Pan et al., 2005; Hartmann et al., 2004; Qian and Ripps, 1999). Qian and Ripps (1999) 
and Pan et al. (2005) examined the interactions between GABAρ and γ2 subunits. In 
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heteromeric ρ1γ2 receptors they found that responses to GABA were not affected by 
bicuculline and diazepam but were antagonised by picrotoxin (Qian and Ripps, 1999). 
The γ2 subunit co-immunoprecipitated with ρ1A, ρ1B and ρ2B but not with the ρ2A when 
co-expressed (Pan et al., 2005). Using GABA induced currents in CA1 pyramidal cells in 
rat hippocampal slices, the currents were partially suppressed by TPMPA while 
responses to CACA were more fully antagonised. Both GABA and CACA currents were 
sensitive towards bicuculline and this showed a differences between the features of this 
receptor and features of GABAρ (Hartmann et al., 2004). In brainstem neurones, 
application of CACA requires the ρ1 subunit to elicit responses but these are blocked by 
bicuculline and TPMPA. The responses were also modulated by the GABAA modulator 
(pentobarbitone) (Milligan et al., 2004). In addition to these, zolpidem (500 nM) which 
acts on α1 and γ2 enhanced the action of CACA. From immunohistochemistry analysis, 
it was indicated that ρ1 and α1 subunits were colocalized at both at both light and electron 
microscopic level. Furthermore they showed that co-immuno- precipitation indicated that 
ρ1 subunit formed complexes with α1 and γ2 subunits. Harvey et al. (2006) also reported 
that an ionotropic GABA receptor in mouse cerebellar Purkinje cells showed atypical 
mixed GABAA and GABAρ when the currents were not affected by TPMPA but were 
blocked by bicuculline. Immunohistochemical analysis showed the presence of ρ subunit 
and it was co-immunoprecipitated with α1 subunit. This might mean that responses in 
ependymal cells may be mediated through GABAA, GABAC or mixed GABAA/C receptors. 
 
1.7.3.2 Role of GABAρ in neuronal function and neurogenesis 
To date, the precise function of GABAρ is unknown. GABAρ has been suggested to have 
physiological roles in the apoptosis process in hippocampal neurones (Yang, L. et al., 
2003), hormone release in pituitary (Boue‐Grabot et al., 1998), and may be involved in 
paired-pulse depression of inhibitory postsynaptic currents (Jacquet et al., 2009). 
Receptors expressing ρ1 subunits are involved in learning and memory of chicks and 
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rats (Chebib et al., 2009), in the inhibitory modulation of olfactory bulb (Chen et al., 2007), 
and in inhibitory pain transmission in spinal cord (Zheng et al., 2003). 
The role of GABAρ in neurogenesis is unknown. It is proposed that GABAρ1 and ρ2 
subunits may contribute to the regulation of glial development in cerebellum. GABA ρ1 
and ρ2 subunits, either in homomeric form or combination with other GABAA subunits 
(α1 and γ2) have been identified in cultured astrocytes. Coimmunoprecipitation 
demonstrated that there is interaction between GABAρ1 and GABAα1 and double 
immunofluorescence showed that these subunits were co-localised in in the plasma 
membrane of astrocytes (Pétriz et al., 2014).  
Initial studies indicate that the spinal cord contained only ρ2 subunits (Enz et al., 1995), 
later more studies indicated that spinal cord expressed ρ1 and ρ2 subunits (Rozzo, 
Aldo et al., 2002). Detailed investigations of GABAρ at spinal cord level are still lacking 
and its functional role in spinal cord remains to be established.
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1.8 5-hydroxytryptamine  
 
Serotonin, also referred as 5-hydroxytryptamine (5-HT), is a monoamine 
neurotransmitter and has numerous roles in CNS. It is a neurotransmitter that appears 
early in development and extends widely in the CNS. Serotonin is synthesized in 
neurones of the brain stem raphe nuclei (Gaspar et al., 2003). It is also synthesized 
extensively in the enterochromaffin cells of the gastrointestinal tract. It is synthesized 
from the amino acid tryptophan by a short metabolic pathway, by hydroxylation and 
decarboxylation of the amino acid L-Tryptophan using the neurone-specific enzyme 
tryptophan hydroxylase (THP) 2 (Walther et al., 2003). Once synthesized, serotonin is 
packed in synaptic vesicles by the vesicular monoamine transporter. Serotonin is 
released from serotonergic vesicles (mediated through increased intracellular Ca2+-level) 
and activates 5-HT receptors located on the dendrites, cell bodies and presynaptic 
terminals of adjacent neurones. 5-HT receptors are located on membrane of neurones 
and other cells. Extracellular levels of serotonin are regulated by its re-uptake into the 
presynaptic cell through the serotonin transporter (SERT) (Gaspar et al., 2003).  
Serotonin plays two key roles: 1) in early developmental periods, it acts as a growth 
factor to regulate the development of its own (Bonnin et al., 2007) and related neural 
systems; and 2) as a neurotransmitter (Lauder, 1990) regulating cognition, attention, 
emotion, pain, sleep and arousal. In its developmental role as a trophic factor, 5-HT 
regulates processes such as cell division, differentiation, migration, myelination, 
synaptogenesis and dendritic pruning (Gaspar et al., 2003). The concept of 5-HT as a 
neurotransmitter which also works as hormone/growth factor and differentiation factor in 
foetal brain emerged decades ago (Lauder and Krebs, 1976). 
Studies in animal models have shown that 5-HT modulates neuronal progenitor cell 
proliferation, neuronal migration and axonal wiring during foetal and early postnatal 
periods which did not occur in adult brain (Banasr et al., 2004). 
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1.9 5-HT receptors 
 
5-hydroxytryptamine receptors or 5-HT receptors or serotonin receptors are a group of 
G protein-coupled receptor and ligand gated ion channels found in the central and 
peripheral nervous system (McCorvy and Roth, 2015). They mediate both excitatory and 
inhibitory neurotransmission. The serotonin receptors are activated by the serotonin 
neurotransmitter which acts as their natural ligand (McCorvy and Roth, 2015). 
Fifteen different transmembrane receptors have been classified into seven groups (5HT1 
to 5HT7) largely based on their structural and functional characteristics. The receptors 
have been further classified as 5-HT1A-F, 5-HT2A-C, 5-HT3, 5-HT4, 5-HT5, 5-HT6 and 5-
HT7. Among these, 5-HT3A-3B are ionotropic (Mattson et al., 2004) while the remaining 
receptors are coupled to different G proteins (Albert and Tiberi, 2001). The receptors 
which are coupled to G proteins are further categorized into four groups according to 
their second messenger coupling pathways (Raymond et al., 2001). The 5-HT1 (5-HT1A, 
5-HT1B-C and 5-HT1D-F) receptors are coupled to Gi/o proteins, 5-HT2 (5-HT2A-C) receptors 
are coupled to Gq proteins, 5-HT4, 5-HT6 and 5-HT7 receptors, which are coupled to Gs 
proteins, and 5-HT5 (5-HT5A and 5-HT5B) receptors whose transduction cascade is not 
clear (Raymond et al., 2001) (see Figure 1.6). 
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Figure 1-6 Classification of serotonin (5-HT) receptors. 
They belong to a G-protein coupled family with one exception; the 5-HT3 receptors 
are ligand-gated ion channels. Regulation of adult hippocampal neurogenesis is 
mediated by 5-HT1A, 5-HT2A and 5-HT2B (red squares). (–ve, negative; +ve, positive; 
cAMP, cyclic adenosine monophosphate; PLC, phospholipase C; G, guanine 
nucleotide binding proteins: Gi/o, heteromeric G protein subunit that inhibits cAMP-
dependant pathway; Gs, heteromeric G protein subunit that activates cAMP-
dependant pathway and Gq, heteromeric G protein subunit that activates 
phospholipase C) (Image edited from Hoyer et al. (1994)). 
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Because of the diversity of 5-HT receptors, it is quite difficult to define their actions on 
brain development. Most immunohistochemical studies showed that these receptors 
are expressed early during embryonic development and regulated postnatally 
(Gaspar et al., 2003). In human brain, the serotonergic neurones are first evident as 
early as 5 weeks of gestation (Sundström et al., 1993). By 15 weeks of gestation, the 
raphe nuclei already contain a typical arrangement of serotonin neurones (Takahashi, 
H. et al., 1986).  
Developmental studies however have paid little attention to spinal cord even though 
it constitutes one of the major targets of 5-HT neurones. One day after serotonergic 
neuronal generation, raphe neurones can synthesize 5-HT and begin to extend to 
axon tracts, the caudal group project into spinal cord and descend in the lateral and 
anterior funiculi to terminate in gray matter (Carlsson et al., 1964). Most of 5-HT 
containing fibres in the spinal cord descend ipsilaterally and some fibres may cross 
the midline in thoracic and lumbosacral cord (Ni et al., 2014).  
 
1.9.1 Distribution of 5-HT receptors  
Very high concentrations of 5-HT1 receptors are localized in the choroid plexus, 
lateroseptal nucleus, globus pallidus and ventral pallidum, dentate gyrus, dorsal 
subiculum, olivary pretectal nucleus, substantia nigra, reticular and external layer of 
the entorhinal cortex, hippocampus, amygdaloid complex, hypothalamic nuclei and 
also dorsal raphe (Pazos and Palacios, 1985). In claustrum, olfactory tubercle, 
accumbens, central grey and lateral cerebellar nucleus there were intermediate 
densities, while in other brain areas; pons, medulla and spinal cord, only low or very 
low concentrations of 5-HT1 receptors were found. From the areas strongly enriched 
in 5-HT1, dentate gyrus and septal nucleus contained 5-HT1A while globus pallidus, 
dorsal subiculum, substantia nigra and olivary pretectal nucleus were enriched in 5-
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HT1B (Pazos and Palacios, 1985). For 5-HT2 mapping, very high concentrations were 
localized in claustrum, olfactory tubercle, anterior olfactory nucleus, piriform cortex, 
and layer 1 and IV of neocortex while in thalamus, hippocampus, brainstem, medulla, 
cerebellum and spinal cord showed lower densities (Pazos and Palacios, 1985). 
Cross sections of brain ventricular walls of mice and rats revealed the presence of 
axons containing serotonin; 5-HT (Aghajanian, G. and Gallager, 1975; Mathew, 
1999). The importance of this is that the axons are not within the SVZ itself but are 
found inside the ventricles on the ependymal surface (Mathew, 1999). An in depth 
study of these cells showed that serotonergic axons originating from the raphe 
nucleus form intimate contacts with the B1 cells (morphological properties and 
expression profiles of astrocytes) and ependymal cells of SVZ. B1 cells expressed 
the 5-HT receptors 2C and 5A (Tong et al., 2014).  
Although multiple 5-HT receptor subtypes have been defined in the central nervous 
systems, four types (5-HT1, 5-HT2, 5-HT3, and 5-HT4) of 5-HT receptors have been 
identified in the spinal cord (Fonseca et al., 2001; Hoyer et al., 1994; Marlier et al., 
1991). 
A study by Nagatsu et al. (1988) showed there was no serotonin immunopositive 
staining in central canal area; evidenced in CSF-contacting neurones as well as the 
non-CSF-contacting neurones of rats and mice. However unpublished observations 
from our laboratory report dense innervation of 5-HT immunopositive fibres around 
the central canal.   
The abundance of several types of 5-HT receptors in nervous system may explain 
why and how each receptor, alone or combination with others may influence brain 
development. With different cellular localisation of the receptors which is not well 
understood, finding the exact receptor which may be responsible in the cellular 
proliferation and differentiation is extremely complex. However a few studies showed 
that each of main 5-HT receptors are expressed early in embryonic life and regulated 
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during pre and postnatal development and a few studies of effects of 5-HT on neural 
stem cells are considered here. 
 
1.9.2 Role of 5-HT on regulation of neurogenesis 
5-HT influence and modulation of neurogenesis can be divided according to the 
effects of pharmacological 5-HT depletion (Brezun, J.M. and Daszuta, A., 2000; 
Malberg et al., 2000; Yan et al., 1997), pharmacological receptor targeting studies 
(Banasr et al., 2004; Malberg et al., 2000; Yan et al., 1997), genetically modified 5-
HT system using mouse models specifically on the receptor which can cause 
neurogenesis (Santarelli et al., 2003), the effects of antidepressant action on 
neurogenesis and functional role of serotonin in neurogenesis (Klempin et al., 2010; 
Abbas et al., 2007) .  
Since 5-HT1A, 5-HT2A and 5-HT2C have been shown to have established effects on 
neurogenesis, this section will elaborate on these receptor effects on neurogenesis. 
5-HT is one of the most important neurotransmitters in the brain. A depletion or low 
supply of serotonin can contribute to symptoms of neurogenic decline, changes in 
appetite and mood disorders (depression) due to impaired serotonin synthesis, 
release, reuptake or serotonin receptor abnormalities. In the case of 5-HT depletion, 
the effect of the depletion can decrease adult hippocampal neurogenesis (Brezun, J. 
and Daszuta, A., 2000; Malberg et al., 2000). Thus 5-HT stimulates granule cell 
proliferation in adult hippocampus. A lesion induced by injection of 5, 7-
dihydroxytryptamine (5,7-DHT) into the medial and dorsal raphe nuclei caused 
complete serotonergic denervation of hippocampus (Brezun, J.M. and Daszuta, A., 
2000). In these animals, there was a 50% reduction in BrdU labelled proliferating cells 
in the hippocampus. In another group of animals, one month after 5, 7-DHT injections, 
a unilateral graft of mesencephalic raphe (for n=10 rats) or spinal tissue (for n=5 rats, 
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serving as control) from embryonic day-14 rat foetuses was placed into the right 
hippocampus. The rats were sacrificed one month after the graft. Results showed by 
1 month after transplantation, the hippocampus exhibited intense 5-HT re-innervation 
from raphe (but not spinal cord) graft and in these raphe grafted animals, the levels 
of proliferation were restored.  
Cell proliferation and the numbers of newborn neurones derived from the neurogenic 
niche in adult hippocampal dentate gyrus are increased after prolonged treatment 
with the selective serotonin reuptake inhibitor (SSRI) fluoxetine (Malberg et al., 2000; 
Jacobs and Fornal, 1999). Malberg et al. (2000) used a selective serotonin reuptake 
inhibitor (SSRI); fluoxetine (5mg/kg) which was administered for 14 days 
intraperitoneally to adult male Sprague Dawley rats (250-300gm) followed by BrdU 
labelling 4 d after the last drug treatment. In this chronic treatment, the numbers of 
proliferating cells were increased. However, acute administration of fluoxetine for 1 
or 5 days did not significantly affect the number of BrdU-positive cells compared with 
control. Therefore there is no acute effect of fluoxetine but a delayed increase in the 
number of proliferating precursors cells in dentate gyrus after 14 days. The finding is 
quite similar with the preliminary study by (Jacobs and Fornal, 1999).  
The dentate gyrus is enriched with 5-HT1A receptors (Pazos and Palacios, 1985; 
Azmitia et al., 1996) and may have an effect on developing dentate granule cells (Yan 
et al., 1997). Yan et al. (1997) used buspirone (1.0mg/kg) as an agonist and NAN-
190 (1.0 and 3.5mg/kg) as an antagonist to 5-HT1A in vivo and used 
parachloroamphetamine (PCA) to deplete 5-HT in postnatal rats (given on postnatal 
day 3 and postnatal day 4). PCA reduced total dendritic length, an effect that was 
reversed with treatment of buspirone. If NAN-190 (3.5mg/kg) was injected from 
postnatal day 3 to 14 these animals exhibited a significant reduction in total dendritic 
length that was comparable to the reduction seen with PCA alone. This drug study 
showed that specific 5-HT receptors are responsible for the structural changes in 
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neuronal cell. Loss of dendritic spines is a function of decreased 5-HT1A receptor 
stimulation.  
Several studies report that 5-HT1A receptors contribute to the modulation of mood as 
well as to induce hippocampal neurogenesis (Abbas et al., 2007; Banasr et al., 2004; 
Santarelli et al., 2003). Santarelli et al. (2003) compared the effect of increased 5-HT 
levels for antidepressants (fluoxetine) delivered to wild type mice and 5-HT1A receptor 
knockout mice. The results indicated that fluoxetine had no effect in knockout mice. 
This suggests that 5-HT1A receptors are required for fluoxetine-induced 
neurogenesis. Receptor subtypes other than 5-HT1A may be involved in the 
stimulation of cell proliferation and neurogenesis in brain induced by activation of 5-
HT transmission (Banasr et al., 2004). Using 8-OH-DPAT (1 mg/kg) for 5-HT1A 
receptor activation, significant increases in numbers of BrdU labelled cells were found 
in dentate gyrus, SVZ and olfactory bulb after 15 days of treatment. Banasr and group 
also compared with 5-HT2A receptor blockade using (ketanserin, 1mg/kg), a 5-HT2 
antagonist and observed decreased cell proliferation in the dentate gyrus area while 
RO 600175 a 5-HT2C agonist was able to increase cell proliferation in SVZ of adult 
mice. In contrast to Banasr et al. (2004), Abbas et al. (2007) found out that the 
antagonist to 5-HT1A; WAY 100635 induced an increase in 5-HT1A receptor 
expression. However, the antagonistic action may naturally lead to more receptor 
expression as a compensating effect. More recent work showed that activation of 
serotonin receptors 5-HT1A, 5-HT2 and 5-HT2C affected different stages and aspects 
of the adult neurogenesis and cell survival process (Klempin et al., 2010). They 
suggested that effects mediated by these different receptors may be responsible for 
the fact that 21 days treatment with fluoxetine increased the number of BrdU-positive 
cells in the dentate gyrus, while a single injection of the drug followed by 20 days of 
saline had no effect. They found that in the acute stages, 5-HT exerts opposing effects 
on proliferation and differentiation through effects of different receptors. In vivo, acute 
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treatment with 8-OH-DPAT (2 h pre BrdU treatment) significantly increased precursor 
cell proliferation whereas 1 week of treatment had no significant effect. However, in 
vivo treatment with the 5-HT2 receptor antagonist cinanserin resembled the effects of 
the 5-HT1A receptor agonist. There was an acute increase in cell proliferation but no 
effect after 7 days of treatment of cinanserin. Furthermore the 5-HT2 receptor agonist 
α- methyl-5HT decreased cell proliferation after both 1 and 7 days of treatment. To 
define the receptors further, the 5-HT2C agonist WAY 161503 elicited a shift in the 
numbers of cells at different developmental stages such that there was a decrease in 
type 1 cells but an increase in type 3 precursor cells, which indicated that this receptor 
was more critical for the differentiation of proliferating cells. They suggested an 
indirect effect of activation of 5-HT2C receptors on surrounding GABAergic cells rather 
than neural progenitor cells themselves (Klempin et al., 2010).  
This suggestion that there are mechanisms that involve 5-HT2C receptor mediated 
activation of GABAergic neurones is supported by other studies (Boothman et al., 
2006; Cumming-Hood et al., 1993). Given the synaptic contacts of 5-HT fibres onto 
GABAergic neurones, GABA release may lead to an inhibitory action on cell 
proliferation but may affect differentiation. Thus, it is possible that activation of 5-HT2 
receptors via serotonin may affect neurogenesis in the spinal cord. 
All interactions of GABA receptors, and 5-HT receptors raise the possibility that 
GABA and 5-HT induced effects on spinal cord neurogenesis are worth 
consideration but firstly it is critical to establish what effects if any are observed by 
activation of specific receptors on ependymal cells in the spinal cord.
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1.10  Aims and Hypothesis  
 
There is currently little understanding of how cells at the central canal of spinal cord 
especially ependymal cells are affected by GABA and serotonin neurotransmitters. 
There are therefore a number of hypotheses and aims designed to examine this:   
1. To characterise further the ependymal cells, which are the proposed neural stem cells 
of spinal cord central canal. Ependymal cells recorded from postnatal mouse spinal cord 
will be characterised using whole cell patch clamp recordings, dye fills and gap junction 
blockers. 
2. To identify the GABAA receptor subunits expressed by postnatal spinal cord 
ependymal cells. It is hypothesised that ependymal cells express GABAA, GABAB, 
GABAρ. Using whole cell patch clamp and immunohistochemistry, ependymal cells 
isolated from postnatal mouse spinal cord will be examined for the presence of GABAA 
receptor subunits, GABAB and GABAρ receptors.  
3. To characterise the responses of ependymal cells to GABA after application of specific 
modulators. It is hypothesised that these modulators will change the GABA actions on 
ependymal cells. 
4. To test the outcome of manipulation of GABAB receptor on cell proliferation at the 
central canal of postnatal spinal cord. Using Edu labelling to reveal the effects of receptor 
manipulation on newly divided cells in spinal cord acute slice cultures, it is hypothesised 
that GABAB will contribute to the proliferation process.  
5. To characterise the effects of 5-HT receptor activation on ependymal cells.  It is 
hypothesised that these cells will respond to 5-HT application potentially through a 
number of different receptors. 
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General Methods 
 
2.1 Animals and ethical approval 
 
Animals were obtained internally from the Central Biological Services with approval of 
animal ethics under ethical review committee at the University of Leeds. All experiments 
were conducted under UK Home Office License and in accordance with the regulations 
of the UK Animals (Scientific Procedures) Act, 1986. Postnatal 8 to 15 day wild type 
C57BL/6 mice of either sex were used in electrophysiology and acute slices for study of 
proliferation. Every effort was made to minimize the number of animals used and their 
suffering. 
 
2.2 Spinal cord slice preparation 
 
Animals were anaesthetized with Euthatal (sodium pentobarbitone, 60 mg/kg Merial 
Animal Health Ltd, UK) intraperitoneally. Using scissors, an incision was made through 
the skin from the caudal aspect of the sternum to the distal aspect of the clavicle on 
each side of the animal to allow access to the rib cage. The rib cage was removed to 
expose the heart. The mice were perfused transcardially through the left ventricle with 
ice cold sucrose artificial CSF (aCSF) which was previously gassed (95% O2: 5% 
CO2) (for composition of aCSF see Table 2-1). 
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Table 2-1 Composition of extracellular solutions for electrophysiological 
experiments 
Composition Sucrose aCSF 
Concentration (mM) 
aCSF 
Concentration(mM) 
Sucrose 217  
Sodium chloride  124 
Sodium bicarbonate  26 
Potassium chloride 3 3 
Magnesium sulphate heptahydrate 2 2 
Sodium phosphate monohydrate 2.5 2.5 
Glucose 10 10 
Calcium chloride 1 2 
 
Animals were considered sufficiently perfused when blanching of liver, tail, and paws 
became apparent. Animals were then killed by decapitation using scissors. A dorsal 
laminectomy was performed using blunted scissors, starting from the rostral end. First 
the skin and muscle were removed followed by cutting of vertebrae surrounding the 
spinal cord using Vannas Scissors (8 cm, angled, standard; World Precision 
Instruments UK). The nerve rootlets were severed to allow the whole spinal cord to 
be removed and then it was transferred into a petri dish containing ice cold, gassed 
(95% O2: 5% CO2) sucrose aCSF. Under a dissecting microscope (SM2 2B, Nikon, 
Japan) for visualisation, fine forceps (Dumont # 55, Dumostar, 11cm straight) were 
used to remove the dura and pia mater. The spinal cord then was embedded in a 3% 
agar (Sigma Aldrich, UK made at 3% in aCSF) which was allowed to cool before 
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cutting. The block of agar containing spinal cord was then attached to a larger 
supporting block of agar (4% in 0.9% saline) before gluing onto a cutting platform and 
then was cut into 300 µm thick transverse spinal cord slices using an Integraslice 
7550 PSDS, Campden Instruments, UK with ceramic blades. The settings of the 
integraslice were 108 Hz, 0.8 mm amplitude and 0.5 mm/s advance speed. Slices 
were mostly originated from thoracic and lumbar spinal segments. Slices were 
transported to a holding chamber containing aCSF at room temperature (gassed with 
95% O2: 5% CO2). They were left for 60 minutes at room temperature to equilibrate. 
 
2.3 Electrophysiology 
 
Spinal cord slices were immersed in a recording chamber and the border of 3% agar 
was securely pinned under tightly stretched crossed threads to immobilise the slice. 
From a storage flask, the oxygenated aCSF was gravity fed to flow across the 
recording chamber at a rate of 2-5 ml/minute and was subsequently removed by 
suction and discarded. A silver chloride coated wire was attached to the electrode 
holder, this allowed application of positive and negative current to the electrode tip. A 
reference electrode which is a silver chloride pellet (1 mm X 2.5 mm, 70 mm exposed 
wire, Science Products, GmbH, Germany) placed in the bath was connected to 
complete the circuit. A micromanipulator (Burleigh, Thorlabs) which was attached to 
a head stage (Axon Instruments, USA) allowed coarse and fine control of the 
microelectrode. Signals from the recording electrode were preamplified by the head 
stage, filtered by a Bessel low pass filter set at 2-5kHz and fed into an Axopatch-1D 
amplifier (Axon Instruments, USA before being filtered for mains noise by a Humbug 
(Quest Scientific via Digitimer, UK). The signals were then converted from analogue 
to digital using an analogue to digital converter unit (Digidata, DD1440) before being 
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captured by Signal version 1.903 and Spike2 version 7 (CED) or Clampex 10.5 (Axon 
Instruments) software on a PC (Figure 2-1).  
A Master-8 stimulator (A.M.P.I., Israel) was used to control the timing and duration of 
current and voltage pulses. Channel 1 of the Master-8 triggered the start of a sweep 
in the pClamp or Signal software via the Digidata DD1440, whilst also triggering 
channel 2 of the Master-8. Channel 2 of the Master-8 then initiated a current or voltage 
pulse from the Axopatch 1D amplifier down to the electrode. 
 
2.3.1 Positioning of electrodes and obtaining whole cell patch 
recording  
The first electrode lowered down into the recording chamber was the puffing electrode 
which was filled with either GABA or ODN. The electrode was fully filled with the drug 
and was ejected at desired controlled puff after positioned at the central of the slices. 
Firstly, the electrode was viewed by x10 objective, the tip of the electrode was 
positioned above the central canal using the coarse controls of the micromanipulator 
(Burleigh®). The microscope was changed to x60 magnification and the tip of 
electrode was then lowered towards a cell of interest using the fine controls of the 
micromanipulator (Burleigh®). Then the recording electrode was filled about a 1/3 of 
the way with intracellular solution (see table 2-2 for composition of intracellular), such 
that it just contacted the silver wire and thus electrically connected the electrode tip 
to the silver wire of the electrode holder (QSW A12P, Warner Instruments, USA). 
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Table 2-2 Composition of intracellular solution 
 
Composition Working concentration 
(mM) 
For 25 ml intracellular solution: 
Potassium gluconate 110 mM 
Ethylene glycol tetraacetic acid 11 mM 
20 ml distilled water were added to the above mixture and the solution was adjusted 
to pH 9 using potassium hydroxide 1M solution, the solution then was stirred for 2 
hours before adding the following: 
Magnesium chloride  2 mM 
Calcium chloride  0.1 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) 
10 mM 
Disodium salt hydrate (Na2ATP) 2 mM 
Guanosine 5′-triphosphate sodium salt hydrate (NaGTP) 0.03 mM 
The solution was adjusted to pH 7.2 using potassium hydroxide 1M solution 
(usually 1or 2 drops). To 20 ml of solution, 100 mg of Neurobiotin tracer (Sp-1120, 
Vector Laboratories, Peterborough, UK) were added. Remnant of solution was 
discarded.  *The final solution was adjusted to osmolarity of 285 mOsm using 1M 
Potassium gluconate or with distilled water; 0.5 ml aliquots of solution were stored 
in -40°C freezer for no longer than 1 month. After this time, unused aliquots were 
discarded. 
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Positive pressure was applied to the electrode tip before lowering it into the solution. 
Viewed by x10 objective of Nikon Eclipse E600FN microscope, the tip of the electrode 
was positioned above the central canal using the coarse controls of the 
micromanipulator. Once in the solution, and in the small distance just above the slice, 
in current clamp mode, the off-set and resistance of the electrode due to a -250 pA 
current pulse, were compensated for using the amplifier’s offset and the series 
resistance dials respectively. This brought the baseline voltage reading to 0 mV. The 
amplifier was then switched to voltage-clamp and track modes with a voltage pulse 
of -25 mV. The microscope was changed to x60 magnification The visualisation was 
switched over to differential interference contrast (DIC) imaging using a camera 
(QImaging Rolera-XR, QIMaging, Canada) attached to the microscope, which 
transmitted the images to the QCapture Pro7 software to enable the individual cells 
to be seen and guide the recordings. This also helped with the identification of the 
cell and the tip of electrode was then lowered towards a cell of interest until the 
positive pressure caused a dimple to appear in the cell membrane. The positive 
pressure was released and the seal formation was observed by monitoring the current 
response to a voltage pulse of 25 mV. The holding voltage of -60 mV was removed. 
The amplifier was switched back to current clamp; the current pulse was reduced to 
-50 pA and a continual current was also applied to maintain the cell at -60 mV to -80 
mV. A seal was considered enough when the current response equated to a 3GΩ 
resistance. A sharp suction was applied to achieve whole cell patch clamp 
configuration and seal formation. A staggered current step was applied to the patched 
cell and voltage responses monitored. The effects of drugs applied (Table 2.3 and 
Table 2.4) were monitored for each cell type.  
The recordings were set up to identify the cell type and responses to drugs. The bath 
application of drug solutions was achieved by switching a three way tap to allow the 
drug to be fed into the recording chamber. A micropipette was filled with intracellular 
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solutions (Table 2.2). The micropipette was pulled using a Sutter P97 micropipette 
puller (Sutter Instruments, USA), from borosilicate glass capillary tubes (inside 
diameter 0.94mm, and outside diameter 1.2mm; Warner Instruments, USA). The 
pulled electrodes had resistance of 7-14 MΩ and a tip diameter of approximately 1-3 
µM. Neurobiotin (0.5%; Vector Laboratories, Peterborough, UK, https: // www. Vector 
labs.com/ UK) and tetramethylrodamine (0.02%; Life Technologies, Paisley, UK), 
were added to the intracellular solution to visualize the cells post-recording. 
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Figure 2-1 Experimental set up for whole cell patch clamp      
Illustration of the electrode placement during the electrophysiology recordings. 
Recording electrode (filled with intracellular solution; numbered as i) was attached to 
and recording from either ependymal cell or CSFcC. The pressure ejection electrode 
containing drug to be pressure ejected (numbered as ii) was positioned near the cell 
being recorded from but not directly pointing towards it to minimise movement of the 
cell.  
ii i 
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2.3.2  Application of drugs  
The main drugs (GABA, ODN and TACA) were used in a pressure ejected manner 
through a borosilicate glass electrode (drug ejection electrode) (Borosilicate with 
filament, internal diameter 0.94, Model G 120 TF-4; Warner Instruments,USA) 
(resistance 3-5 MΩ, tip diameter 3-4 µm). It was attached to a PV800 pneumatic pico 
pump (World Precision Instruments, UK) that was connected to a pressurised gas 
cylinder. Positioning of the pressure ejection electrode was controlled by a 
micromanipulator (Scientifica Patchstar, UK). The PV800 was connected to the 
pClamp9/Clampex program via the molecular devices Digidata1440A, and thus allowed 
the program to record the timing of the pressure ejection of the drug.  
The cells were hold at least at -40 mV if it is a CSFcC and at more negative potentials 
≥-70 mV for ependymal cells. When recording started, an even baseline recording was 
maintain before any drugs were given.  If the cell is not stable, the recording were either 
repolarised or tried to stabilise the baseline recording or the recording were get rid of. 
Only one successful recording was done per slices. 
The two drug application methods were used to apply GABA or ODN or TACA. At my 
initial trials, GABA was introduced via bath method, 2 consecutive bath applications with 
5 minutes bathing and 5 minutes gap each of bath applications. Due to unstable bathing 
controlled set and stable recording results of GABA via puff application, GABA, ODN 
and TACA then were introduced via puff ejection before, during and after bath 
application of modulators. GABA or ODN or TACA were set for ejection at 2 puffs before 
bath application of modulators, each ejection lasted for 1-2 sec, with a pressure of 20 
mmHg with a gap of 3-5 minutes each ejection and the application of modulators will 
commence 5 minutes after the second ejection of GABA or ODN or TACA. At each step, 
the recordings were repolarised to the baseline. Modulators will be applied for 10-15 
minutes before GABA or ODN or TACA were puffed again within bath of modulators. 
Before starting any drugs or modulators, and at the end of modulators bathing, the 
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recordings were repolarised accordingly. Washout were done for 10-15 minutes after 
stopping any modulators and were proceeded with post recording puffer of GABA or 
ODN or TACA. 
A list of drugs applied during the electrophysiological experiments are listed in Table 2-
3 and Table 2-4. For bath application of drugs, a concentrated solution was dissolved in 
water or DMSO and stored frozen in aliquots and then diluted at 1:1000 in the aCSF for 
applying to the bath.  This ensured that the DMSO was at very low concentration 
(1:1000) in the bath. For puff experiments, all drugs were dissolved in aCSF solutions. 
Pressure ejection electrode was kept opposite but a bit lower position to the recording 
electrode with a gap of 30 nm (as in Figure 2-2). 
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Table 2-3 Drugs used in puffing electrode 
DRUG NAME KNOWN 
FUNCTION 
SUPPLIER CONCENTRATION 
USED 
REFERENCE 
GABA (γ-
Aminobutyric 
acid),  
GABA 
receptor 
agonist 
Sigma 
Aldrich, UK 
10-500 μM for high 
concentration doses 
and 1.25-2.5 µM for 
low concentration 
doses 
Corns et al. 
(2013)  
Schmidt et al. 
(2001)  
TACA (trans-
4-
aminocrotonic 
acid) 
GABAρ 
agonist 
Sigma 
Aldrich, UK 
0.1 -15 μM Chebib et al. 
(1997) 
ODN Diazepam 
binding 
inhibitor 
(DBI)-
related 
peptide 
** 15 nM-20 nM  Gandolfo et 
al. (1997)  
**ODN peptide; ODN (H-Gln-Ala-Thr-Val-Gly-Asp-Val-Asn-Thr-Asp-Arg-Pro-Gly-
Leu-Leu-Asp-Leu-Lysup-OH), 65mg > 95% purity was prepared using the high-
performance liquid chromatography (HPLC) method specifically by Prof Andy Wilson 
from School of Chemistry, University of Leeds and also from Assoc. Prof Julien 
Chuquet and group from INSERM Lab, University of Rouen, France. 
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Figure 2-2 Configuration of electrodes for whole cell patch clamp 
electrophysiology on central canal area 
Image depicting of recording electrodes and pressure ejection electrode position 
during recording and puffing drugs in whole cell patch clamp electrophysiology in 
central canal area. 
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Table 2-4 Drugs applied in the bath solution 
DRUG NAME KNOWN FUNCTION SUPPLIER CONCENTRATION USED REFERENCE 
GABA γ-Aminobutyric acid GABA receptor agonist Sigma Aldrich, UK  400 µM Corns et al. (2013) 
Bicuculline GABAA antagonist Sigma Aldrich, UK 100 µM Park-Chung et al. 
(1999)  
Picrotoxin* GABAA receptor 
antagonist 
Tocris Bioscience, UK 1 μM Park-Chung et al. 
(1999) 
Midazolam Central benzodiazepine 
receptor & TSPO (agonist) 
Sigma Aldrich, UK 0.1 μM Tokuda et al. (2010)  
N,N-Dihexyl-2-(4-
fluorophenyl)indole-3-acetamide 
(FGIN-1-27)* 
TSPO (agonist) Bio-Techne, UK 1 μM Tokuda et al. (2010) 
Diazepam mixed CBR/TSPO agonist Sigma Aldrich, UK 1 μM Alfonso et al. (2012) 
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DRUG NAME KNOWN FUNCTION SUPPLIER CONCENTRATION USED REFERENCE 
8-OH-DPAT 5-HT1A agonist Tocris Bioscience 40 μM Middlemiss and 
Hutson (1990) 
Serotonin Hydrochloride Non-selective 5-HT agonist Sigma-Aldrich, UK 10 µM Wang, M. and Dun 
(1990) 
Cinanserin 5-HT2 antagonist Tocris Bioscience 20-30 µM Klempin et al., 
(2010) 
Cisapride 5-HT4 receptor agonist Tocris Bioscience 10 μM Bockaert et al., 
(2008) 
Niflumic acid Chloride channel 
antagonist 
Sigma-Aldrich, UK 250 μM Woodward et al., 
(1993) 
Nipecotic acid glial and neuronal GABA 
uptake 
Tocris Bioscience 300 μM  Barrett‐Jolley 
(2001)  
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DRUG NAME KNOWN FUNCTION SUPPLIER CONCENTRATION USED REFERENCE 
Baclofen GABAB receptor (agonist) Tocris Cookson, Bristol, 
UK 
1 μM and 5 μM Wang, L. et al. 
(2010)  
(2S)-3-[[(1S)-1-(3,4-
Dichlorophenyl)ethyl]amino-2-
hydroxypropyl] 
(phenylmethyl)phosphinic acid 
hydrochloride (CGP 55845) 
GABAB receptor 
(antagonist) 
Tocris Cookson, Bristol, 
UK 
200 nM Wang et al. (2011) 
1,2,5,6-Tetrahydropyridin-4-yl) 
methylphosphinic acid (TPMPA) 
GABAAρ antagonist Sigma-Aldrich, UK  80 μM Milligan et al. 
(2004)  
18β-glycyrrhetinic acid Gap junction inhibitor Sigma-Aldrich, UK 100 M dissolved in 50% 
ethanol 
Momose‐Sato et al. 
(2012)  
*drugs were diluted using DMSO and kept stored frozen in aliquots and then diluted at 1:1000 in the aCSF for applying to the bath 
**ODN peptide; ODN (H-Gln-Ala-Thr-Val-Gly-Asp-Val-Asn-Thr-Asp-Arg-Pro-Gly-Leu-Leu-Asp-Leu-Lysup-OH), 65mg > 95% purity was prepared 
using the high-performance liquid chromatography (HPLC) method specifically by Prof Andy Wilson from School of Chemistry, University of Leeds 
and also from Assoc. Prof Julien Chuquet and group from INSERM Lab, University of Rouen, France.  
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2.4 Cell identification 
 
Differential interference contrast imaging was used to identify healthy cells by their 
even grey tone and visible but not overly distinct outline. Prior to recording, 
ependymal cells were often distinguishable by their presence within the ependymal 
cell layer, their more cuboidal shape and their less distinct cell outline. CSFcCs 
differed from ependymal cells in that they tend to be larger and more likely to have a 
sub ependymal location. After recording, further morphological characteristics could 
be viewed due to the injection of 0.02% dextran tetramethyl rhodomine in the 
intracellular solution. Visualisation of recorded cell was used in conjunction with 
electrophysiological characterisation, to identify the cell type. Presence of a process 
into the central canal and/or spiking responses to depolarisation or repolarisation 
indicated that the cell being recorded was a CSFcC. Ependymal cells were identified 
by passive, no spiking profile and an absence of processes into the central canal. 
Neuronal cells could be identified by the production of action potentials and the 
presence of many axons and dendrites. Images were captured on the Q Capture Pro 
7 (Q Imaging Canada) as in Figure 3-1 (A). 
 
2.4.1 Electrophysiological cell characterisation 
For the characterisation of the electrophysiological behaviour of the recorded cell, 1 
second current pulses were applied to the cell with the resulting voltage responses 
measured and analysed. Positive current pulses (+10 to +80 pA) were used to 
determine if there were any spiking or action potentials produced in response to the 
depolarisation created by the current pulses. Negative current pulses (-10 to -50 pA) 
produced hyperpolarisations. These were then used to calculate the cell input 
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resistance (IR) by using Ohm’s Law (Input resistance=voltage response/current 
injected). 
 
2.4.2 Post fixative identification of cells using rhodamine and/or 
neurobiotin 
The recorded cells were identified using rhodamine and/or neurobiotin. Following 
recording, the recovered slices were fixed in 0.1 M phosphate buffer (PB) containing 
4% paraformaldehyde (PFA) and 0.25% glutaraldehyde and were stored at 4°C. For 
visualisation of the rhodamine, the slices were washed x3 using the 0.1 M phosphate 
buffer saline (PBS) for 2 times with 5 minutes gap. Then the slices were incubated in 
a fresh solution of 1% hydrogen peroxide (H2O2) using 10 ml methanol and 330 μl 
H2O2 stock solution. The slices were incubated in the solution for 30 minutes to 
prevent endogenous peroxidase staining of blood vessels and blood cells. Then the 
slices were wash well in PBS to remove all traces, 3 times, 5 minutes apart. The slices 
then were incubated in extraavidin peroxidase (EAP; 1:250) with PBSt (PBS+ 0.2% 
triton). The slices were left overnight or longer at 4°C on a shaker. The slices were 
washed 2 times, 5 minutes apart with PBS. Vector lab Peroxidases DAB kit (Vector 
Laboratories, UK; 5 ml distilled water, 2 drops buffer+ 4 drops DAB solution+ 2 drops 
H2O2 solution) were used to incubate slices for 2 minutes and the staining done with 
dark brown staining of filled cell. CUBIC 1 (25% urea, 25% NNN tetrakis 2 
hydroxypropyl ethylenediamine and 15% tritonx100) were used to clear the slices. 
The slices mounted on a glass coverslips. The slices then were visualised using 
microscope Eclipse E600 (Nikon, UK) and captured with Micropublishing 5.0 Camera 
(Q-Imaging, UK). Images were taken at 20x, 40x and 60x magnification. An Acquis 
imaging software (Synoptic, Cambridge, UK) was used to visualize the pictures taken 
from the microscope. 
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2.4.3 Post fixative identification of cells using streptavidin 
The recorded cells were identified using streptavidin 555 (1:500 in PBS, Life 
Technologies, UK). The recovered slices were fixed in 0.1 M phosphate buffer (PB) 
containing 4% paraformaldehyde (PFA) and were stored in 4°C. For visualisation, the 
slices were washed x3 using the 0.1 M PBS for 3 times with 5 minutes gap. The slices 
were incubated in PBSt 0.3% (PBS+ 0.3% triton) for 1 hour. The slices then were 
washed 2 times, 5 minutes apart with PBS. And lastly, the slices were mounted onto 
slides with vectashield with 4', 6-Diamidino-2-Phenylindole, Dihydrochloride DAPI 
(Corns et al., 2015) and viewed using Zeiss confocal microscope. 
 
2.5  Immunohistochemistry 
 
Animals used in this study were C57BL/6 mice as for the electrophysiology 
experiments, and also GAD67-GFP mice that express green fluorescent protein 
(GFP). The GAD67-GFP mice originally sourced from Yuchio Yanagawa (Tamamaki 
et al., 2003). The GAD-67 GFP mice were bred in-house in the University of Leeds. 
These animals have been used previously to identify CSFcCs since these cells will 
be visualised by the GFP (Gotts et al., 2016b; Corns et al., 2015) and have been 
validated by Tamamaki et al. (2003).  
The GAD67-GFP mice are a transgenic strain of mice that express GFP under the 
control of the endogenous GAD67 promotor due to the insertion of GFP cDNA into 
the GAD67 locus. The GFP is obtained from a bioluminescent jellyfish. The jellyfish 
produced a fluorescent product light when expressed in cells. This fluorescence does 
not require any exogenous substrates and cofactors, hence GFP expression can be 
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used to monitor gene expression and protein localisation (Chalfie et al., 1994). A 
cDNA-enhanced GFP was targeted to the locus encoding GAD67 using embryonic 
stem cells homologous recombination to generate chimeric male mice by 8 cell stage 
injection. GAD67-GFP knock in mice were obtained by breeding the male mice with 
C57BL/6 female mice. The expression of GFP in the GAD67-GFP can be evaluated 
by visualisation under an ultra violet light at 2-3 days of age and at this age, the 
fluorescent in the brain could be identified through the mice thin skull. For this 
experiment, only a few slices (1-3 slices) from a GAD67-GFP mouse aged 4-6 weeks 
old used to show the result. 
Nestin-GFP mice were also used to identify the ependymal cells since it is expressed 
by neural stem and progenitor cells. These transgenic mice are generated to express 
GFP under the control of regulatory elements of the nestin gene and have been 
previously validated (Mignone, J. et al., 2016).  
Nestin, an intermediate filament protein is expressed in majority of mitotically active 
CNS and peripheral nervous system progenitors that give rise to both neurons and 
glia. Nestin was found in the dorsal and ventral regions of the central canal but this 
was not found in all ependymal cells but a subset of ependymal cells with large basal 
bodies and typically two long cilia, referred to as central canal ependymal cells 
(Alfaro-Cervello et al, 2012). Presence of this proteins identified the neural stem and 
progenitor cells and the regulatory elements of the nestin gene were used to create 
a reporter line, thereby allowing the identification and isolation such cells in transgenic 
mouse (Michalczyk et al., 2005; Lendahl et al., 1990). 
Transgenic mouse lines in which the neural stem cells of the embryonic and adult 
central nervous system expressed GFP have been proven to be a useful study tool 
to show neurogenesis (Mignone, J. et al., 2016; Encinas et al., 2011).  
Nestin is downregulated in all cells upon differentiation (Zimmerman et al., 1994) but 
reappears transiently after injury to CNS where it has been found in reactive astroglia 
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of the brain and in ependymal cells of the rat after spinal cord injury (Namiki and Tator, 
1999; Holmin et al., 1997). 
The expression of GFP in the nestin-GFP can be evaluated by visualisation under an 
ultra violet light since postnatal day-1 of age and the fluorescent in the brain could be 
identified through the mice thin skull. Deuchars Lab had generated a nestin-GFP 
mouse transgenic line according to Mignone, J.L. et al. (2004). The male nestin-GFP 
were bred with 2 C57BL/6 female in the Central Biomedical Services Unit, University 
of Leeds and for this experiment, I only used 2-3 spinal cord slices from a 4 weeks 
old nestin-GFP mouse. 
 
2.5.1 Fixed spinal cord section preparation 
 
Animals were anaesthetized with Euthatal (sodium pentobarbitone, 60 mg/kg Merial 
Animal Health Ltd, UK) intraperitoneally. Using scissors, an incision was made 
through the skin from the caudal aspect of the sternum to the distal aspect of the 
clavicle on each side of the animal to allow access to the rib cage. The rib cage was 
removed to expose the heart. The animals were then perfused via the left ventricle 
with 20 ml of 0.1M phosphate buffer (PB) containing 4% paraformaldehyde (PFA). 
The whole vertebral column was dissected out and the spinal cord was carefully 
removed then the dura and pia mater. The spinal cord was post fixed in the same 
PFA solution overnight then a block of thoracolumbar spinal cord was sectioned at 50 
µM on a Leica VT100 S vibrotome (UK) and collected into 0.1 M PBS. After 3 x 10 
minute washes in PBS, slices were incubated in appropriate primary antibodies 
overnight in 0.1M PBS or 0.1% PBST (0.1M PBS containing 0.3% Triton X100, 3% 
donkey serum, 0.8% bovine serum albumin) at the concentrations given in Table 2.5. 
Triton X100 is a detergent that permeabilises the cell membranes allowing access to 
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intracellular antigens. Donkey serum and bovine serum albumin are used to reduce 
the amount of unspecific binding of the antibodies used to the tissue.as listed below 
(Table 2.5). CD24 biotin (Miltenyi Biotec) with concentration of 1:100 and diluted in 
Tween, were added to each of slices of C57BL/6 mice slices and were incubated 
overnight together with GABAB1A antibody and GABAρ1 antibody. 
The next day, the slices then were washed 3 times, 5 minutes apart with PBS. After 
repeated washing, the slices were incubated in secondary antibodies (refer Table 2-
5) conjugated to either Alexa Flour 488 or 555 (1:500; Invitrogen) for 1-2 hour and 
washed 3 times, 5 minutes apart. For GABAB1A and GABAρ C57BL/6 mice slices, 
streptavidin pacific blue (Invitrogen, S11222) was added to the slices to visualise the 
CD24 biotin and incubated for another 1-2 hour. Antibodies used in this thesis were 
for established markers with well-known patterns of expression. 
Lastly, the slices were mounted onto slides with vectashield with 4', 6-Diamidino-2-
Phenylindole, Dihydrochloride DAPI (Corns et al., 2015) and viewed using Zeiss 
confocal microscope, Zeiss LSM 700. The images were analysed using software Zen 
2.3, Carl Zeiss Microscopy, GmbH, 2011. The pictures from the Zen 2.3 were 
exported in jpeg/tiff format into CorelDRAW® software for additional input such as 
labelling. 
 
2.6 Acute slices for study of GABAB proliferation 
 
Spinal cord slices were prepared similar to previous method (in 2.2) except that the 
thickness of the transverse slices was increased to 500 μm, a thickness that has been 
used previously to look at spinal cord oscillations (Pierce et al., 2010). The spinal cord 
slices were divided into 3 groups which were the control group, the 1 µM baclofen 
group and the 5 µM baclofen group. The slices were incubated in vials filled with aCSF 
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(4 ml for each vial) for 30 minutes then 5-ethynyl-2’-deoxyuridine (EdU) (4 μl of 1 mM) 
was added to each vial to give a final concentration of 1 µM (Figure 2.3). Baclofen at 
the appropriate concentrations was added to their respective vials to achieve the final 
working concentrations of 1 and 5 µM. EdU is a nucleoside analogue of thymidine 
that is incorporated into deoxyribonucleic acid (DNA) during DNA synthesis and it 
labels proliferating cells (Chehrehasa et al., 2009). All vials were oxygenated with 
95% oxygen and 5% carbon dioxide and placed in a water bath at 37°. The agonist 
and EdU were changed every 2 hours and after 4 hours’ treatment with the drug, the 
spinal cord slices were fixed in 4% PFA 0.1 M PB for 1 hour (Stoppini et al., 1991). 
The 4% PFA was changed to 0.1 M PB solution. Then the 500 μm slices were 
embedded in 10% gelatine, which was further fixed for 4 hours and slices were 
resectioned at 50 μm before proceeding with EdU localization.  
 
 
 
 
 Figure 2-3 Experimental set up for acute slices with baclofen incubation 
 
aCSF containing EdU
and baclofen
slices
heated water bath 
at 37 ̊C
mesh membrane
95% O2 : 5% CO2
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2.6.1 EdU localization 
For EdU detection, sections were incubated in 320 μl of distilled water, 25 μl of 2 M 
Tris Buffer, 50 μl of 10 mM of copper sulphate, 5 μl of biotinylated azide 1 mM and 
100 μl of ascorbic acid for 30 minutes followed by washing with Tris (0.1 M). Then the 
sections were incubated in streptavidin 555 (1:1000 in PBS, Life Technologies, UK) 
before mounting onto slides with vectashield with 4', 6-Diamidino-2-Phenylindole, 
Dihydrochloride (DAPI) (Corns et al., 2015). DAPI binds to the DNA of cells and emits 
blue fluorescent colour so this is used to label the nucleus of cells. The proliferating 
cells were labelled using the streptavidin 555 and appeared red in colour and 
scattered throughout the whole area of spinal cord. The main area of interest was the 
central canal and the surrounding lamina X. 
 
2.6.2 EdU-positive cell counts 
EdU-positive cells were counted in central canal region. The central canal region and 
part of lamina X was identified as the area within 10 μm of the abluminal edge of the 
ependymal cells and could be visualized directly through the NIKON 600 microscope 
under 40x magnification (Corns et al. 2015). Cells were mapped and counted 
manually.  
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2.6.3 GABAB immunohistochemistry on ependymal cells and 
CSFcCs 
 
2.6.3.1 Fixed spinal cord section preparation 
As previously stated, all experiments were carried out in line with the animal ethics 
and regulations. Wild type mouse (C57BL/6) and GAD67-GFP mice (21 days old or 
adult) were anaesthetised by administration of pentabarbitone (60 mg/kg). The spinal 
cord was post fixed in the same PFA solution overnight then a block of thoracolumbar 
spinal cord was sectioned at 50 µm on a Leica VT100 S vibrotome (UK) and collected 
into 0.1 M PBS. After 3x 10 minute washes in PBS and prepared for incubation with 
primary antibody. The primary antibody GABAB1A was diluted 1 in 100 in PBST 0.1% 
and added with CD24-biotin REA743 (Miltenyi Biotec GmbH) diluted in 1 in 100 in 
Tween solution. Tween was used as the detergent here in preference to Triton since 
the antibody worked better. The slices were incubated with these antibodies 
overnight. For GAD-GFP mouse, the slices were incubated overnight with primary 
antibody GABAB1A, diluted in 1 in 100 in PBS. 
The next day, the C57BL/6 and GAD-GFP mouse slices then were washed 3 times, 
5 minutes apart with PBS. After repeated washing, C57BL/6 spinal cord slices were 
incubated in secondary antibodies. The C57BL/6 mouse slices were added with 
secondary antibody donkey anti-sheep conjugated with Alexa flour 555 (Invitrogen) 
for 1-2 hour and washed 3 times, 5 minutes apart. Then streptavidin (blue) was added 
to the plate and incubated for another 1-2 hour. CD24 is used as an ependymal stem 
cell marker. The GAD67-GFP mouse was used to show any co localisation of 
GABAB1A on CSFcC cells. 
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2.6.4 5-HTergic fibres and nestin positive cells in spinal cord of 
nestin-GFP mouse immunohistochemistry  
 
The immunofluorescence method was used to determine the location and apposition 
of 5-HTergic fibres with nestin positive cells in spinal cord. The animal was 
anaesthetised with sodium pentobarbitone (60 mg/kg) and then was intracardially 
perfused with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB). After the 
perfusion was completed, the spinal cord was removed and was kept in 0.1% PFA 
for 24 hours. After that, the solution was replaced with 0.1 M PB. 
Immunohistochemistry was performed. In order to detect 5-HTergic fibres, an 
antibody against 5-HT (1:1000; RA 2000; Neuromics) was used. Full details of the 
methods and antibodies used are in the table below:  
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Table 2-5 Primary and secondary antibodies used for pre-fixed spinal cord immunohistochemical 
1º ANTIBODY & 
SOURCES 
DILUTION 2º ANTIBODY DILUTION  REFERENCE 
GABAB1A antibody 1:100 in PBST 0.1% Donkey anti-sheep 1:1000 in PBS Charles et al. (2003) 
GABAρ1 antibody, Santa 
Cruz 
1:400 in PBST 0.1% Donkey anti-goat  1:1000 in PBS Milligan et al. (2004) 
ODN antibody, from 
(Tonon et al., 1990) 
1:500 in PBST 0.1% Donkey anti-rabbit 488 1:1000 in PBS Tonon et al. (1990) 
TSPO antibody, Abcam 
(ab 118913) 
1:100 in PBS Biotin donkey anti-goat 1:1000 for 2h 
and followed with SA 555 
1:250 in PBS and 
followed with SA 555 1: 
1000 
New et al. (Deuchars 
Lab) 
DBI antibody, Frontier 
Institute 
1:2000 in PBST 0.1% Donkey anti-rabbit 1:1000 1:1000 in PBS Christian et al. (2013) 
5-HT, Neuromics 1:500 in PBST 0.1% Donkey anti-rabbit 488 1:1000 in PBS Ghani et al. 
unpublished (Deuchars 
Lab) 
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2.7 Analysis of data 
 
2.7.1 Data collection 
Electrophysiological data were collected on the Spikes2 version 7.0 files data 
(Cambridge Electronic Design) and Clampex program (Molecular Devices, USA). 
Amplitudes for 2 bath or puff recordings were taken and mean for these 2 were used 
for amplitude for each results. Averages for according to pharmacological group were 
calculated and expressed as the mean ± standard error mean (S.E). For drugs in bath 
and puff solution, comparisons were made before during and after application of 
antagonist and modulators. The measurements of recordings were: amplitude of 
voltage response and input resistance (IR; as calculated from the current steps using 
Ohm’s Law). Other data of cell localisation, immunostaining were collected and 
analyse and recorded in Excel table sheet. 
 
2.7.2 Statistical analysis and statistical tests  
All data were entered and analysed using the IBM SPSS statistic 21 and Excel 
software. All the data were checked for normal distribution and tests chosen 
accordingly. To compare responses to drugs before and after application in the 
same cells, a paired t-test (parametric for normally distributed) or Wilcoxon ranked 
sum test (non-parametric) was used. To analyse and compare means between two 
groups and two-sample assuming unequal variances, the independent T-test was 
used. A Spearman’s Rank order of correlation for used to test correlation and One-
Way ANOVA was used to compare means between groups for the GABAB 
experiments. Data were expressed as mean ± s.e.m (standard error mean). P 
values less than 0.05 (*p<0.05) were indicated as the level of significance. Data that 
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produced significant results (*p<0.05) were further tested using post-hoc tests. The 
data are presented in the graphs and table forms.
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Chapter 3  
Effects of GABAergic modulation on ependymal cells 
 
3.1 Introduction 
 
There is little information regarding the neurotransmitters that may regulate 
proliferation in the spinal cord but some recent research has started to address this 
and we now know that neurotransmitters can influence proliferation and differentiation 
of spinal neural stem cells. Progenitors in stem cell niches in the brain have been 
shown to be regulated by GABA, glutamate, acetylcholine, dopamine and serotonin 
(Berg et al., 2013). In subventricular zone, GABA released from newborn neurons 
inhibits the proliferation of neighbouring progenitors to control the neurogenesis (Liu, 
X. et al., 2005; Haydar et al., 2000; LoTurco et al., 1995). Although less is known 
about the regulation of spinal stem cell niches by neurotransmitters, recent findings 
show influences of neurotransmitters on the stem cell niches especially the central 
canal contacting progenitors (Corns et al., 2015; Corns et al., 2013; Marichal et al., 
2012; Reali et al., 2011). Acetylcholine can induce cell proliferation in the spinal cord 
neurogenic niche which is mediated by α7*nAChRs (alpha-7 nicotinic receptor) and 
can be enhanced with a selective α7*nAChR positive allosteric modulator (PNU 
120596) (Corns et al., 2013). A neuropeptide; substance P (SP) can influence neural 
stem/progenitor cell proliferation and neurogenesis in spinal cord injury (Kim et al., 
2015). The researchers used a compression type spinal injury in adult Sprague 
Dawley rats. Through immunoblot analysis, they were able to show that SP also 
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increases the phosphorylated ERK and phosphorylated p38 kinases in neural 
stem/progenitor cell proliferation. 
Ependymal cells have been characterised as having a low input resistance (124 ± 24 
MΩ), a resting membrane potential of -84 ± 2 mV and passive response properties to 
current pulses in rat (Marichal et al., 2012). There is a presence of gap junction and 
dye coupling in the area of ependymal cells. However the significance of these have 
yet to be considered. 
In my work, I will be examining the characteristics of ependymal cells in the central 
canal of mice, determining how the cells communicate in the central canal of spinal 
cord and how they respond to GABA. 
 
3.2 Hypothesis and aims 
 
Here I first aimed to establish whether ependymal cells in spinal cords from mice aged 
P8-15 have similar properties to those observed in other species. It is hypothesised 
that ependymal cells from the spinal cords have passive electrophysiological 
properties with a high degree of gap junction coupling, thus differing from CSFcCs. 
The main hypothesis of this chapter proposes that ependymal cells are capable of 
responding to GABA and that these responses are mediated by specific receptor 
subtypes. The secondary hypothesis proposes that modulators at specific sites on 
the GABA receptors or ependymal cells can affect the responses of these cells to 
GABA.
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3.3 Results 
 
The results in this chapter are obtained from spinal cord slices prepared from postnatal 
8 to 15 day mice of either sex as described in general method. 
Basic electrophysiological characteristics of 118 ependymal cells in total, were 
recorded and used for different parts of this chapter. The ependymal cells recorded in 
this study had a mean resting membrane potential of -74.0 ± 0.57 mV, similar to the 
recorded resting membrane potential (-76 mV) observed by Corns et al. (2013). 
Whole cell patch clamp methods were used, which sets the reversal potential for 
chloride according to the chloride concentration in the aCSF (127 mM) and the 
intracellular solution (2.1 mM). The reversal potential is -103 mV. 
The majority of cells recorded in the central canal region were ependymal cells and 
were distinguished from the other major cell group in this region (the cerebrospinal fluid 
contacting cells (CSFcC)) by their electrophysiological properties. Using Q-capture 
software images (Figure 3-1 A), the cells were identified around the central canal with 
a faint outline of cuboidal shape cells, and were tightly bound together at the luminal 
surfaces (Figure 3-1 A, C, D). Electrophysiological characterisation showed that 
ependymal cells in this study had negative membrane potentials, and show passive 
electrophysiological properties, where the cells do not show any spiking activity (Figure 
3-1 B). There was a complete absence of spikes or action potentials in response to 
depolarising or hyperpolarising current pulses.  
There is a linear relationship between the size of the current pulse and the change in 
voltage (Figure 3-2 A). Input resistances for ependymal cells were small and ranged 
from 10 MΩ to 200 MΩ (Figure 3-2 B) compared to cells previously recorded by 
Corns et al. (2013). The ependymal cells in this study had an average input 
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resistance of 72.6 ± 3.9 MΩ (n=118). The highest numbers of cells have input 
resistances falling in the range of 30-40 MΩ (n=18).
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Figure 3-1 Basic electrophysiological characteristics of ependymal cells 
An example of DIC image of the spinal cord slice, showing the ependymal cell layer 
around the central canal and the pipettes used to obtain single cell patch clamp 
recordings or to enable puff application of drugs from ependymal cell with the i) 
recording electrode and ii) drug application pipette. Note the cell was filled with 
fluorescent dye and was seen post recording, imaged using Q-capture software (A). 
Example of whole cell patch clamp trace recorded in current clamp of an ependymal 
cell responding to the injection of positive and negative current pulses (B).  
During recording, the cell was filled with neurobiotin and for posthoc confirmation the 
cell was an ependymal cell. The arrow points to the patched and filled cell and there 
is clear dye spread to other ependymal cells around the central canal (C).  
A spinal cord slice section from a nestin-GFP mouse showing ependymal cells around 
the central canal (cc) (D).
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Figure 3-2 Current voltage relationship and histogram of input resistances  
Pooled data for 5 ependymal cells showing similar changes in voltage in response to 
positive and negative current pulses injected for ependymal cells (A). Frequency 
histogram for mean input resistances for ependymal cells (n = 118 cells) (B).
-120
-100
-80
-60
-40
-20
0
20
40
60
80
-100 -50 0 50 100
Δ
(m
V
)
I (pA)
cell 1 cell 2 cell 3 cell 4 cell 5
A
0
2
4
6
8
10
12
14
16
18
20
0-
10
10
--2
0
20
--3
0
30
--4
0
40
--5
0
50
--6
0
60
--7
0
70
--8
0
80
--9
0
90
--1
00
10
0-
11
0
11
0-
12
0
12
0-
-1
30
13
0-
-1
40
14
0-
-1
50
15
0-
-1
60
16
0-
-1
70
17
0-
-1
80
18
0-
-1
90
19
0-
-2
00
C
el
l n
um
be
r
Input resistance (MΩ) 
B
 
 
108 
 
3.3.1 Dye coupling reveals that ependymal cells are coupled to 
each other. 
 
Tracers were included in the intracellular solution such as neurobiotin, which is a gap 
junction permeable tracer (Kita and Armstrong, 1991; Vaney, 1991) and when the 
recorded ependymal cell is coupled to other ependymal cells through the gap 
junctions, the neurobiotin could diffuse through the gap junctions to fill some of the 
connected ependymal cells. In this study, the visualisation of neurobiotin with DAB 
revealed that the ependymal cells also showed gap junction coupling since there was 
dye in neighbouring cells to the neurobiotin-filled ependymal cell detected by post-
fixation DAB images. In those cells that were recovered (n = 27), the majority (n = 26) 
showed dye coupling. 
The extent of neurobiotin labelling demonstrated different levels of coupling between 
ependymal cells; sometimes this involved the whole ependymal layer surrounding the 
cc that was dye filled (Figure 3-3 A), while in others, not all of the ependymal cell layer 
(Figure 3-3B) was filled.  In other recordings, a smaller group of ependymal cells 
within one region of central canal (Figure 3-3 C and D) was observed. Visualisation 
of neurobiotin and/or rhodamine revealed that some of the ependymal cells had 
processes as seen in Figure 3-3 (C) and (D). Processes were found originating from 
the dorsal (D) and ventral (A) pole of central canal, from which they extended dorsally 
and ventrally along the midline. In the same group of cells, there was also a number 
of processes observed extending from the lateral aspects of central canal (C and D).  
Imaging of cells with rhodamine, which is not gap junction permeable, showed no 
coupling of cells indicating that there was no spillage of tracers. This is observed using 
the Q-capture software, when a single rhodamine-filled cell is observed (Figure 3-1 
A). 
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Figure 3-3 Intracellular dye-loading with neurobiotin revealed coupling between 
ependymal cells 
Visualisation of neurobiotin by DAB revealed ependymal cells that are dye coupled 
around the whole central canal of the (A and B), a multiple layer of ependymal cells 
that were dye-coupled around a region of the central canal (C), and dorsal 
processes extending from some of the cells within a group of dye-coupled 
ependymal cells located at the dorsal pole of the central canal (D). Images are all 
orientated with dorsal at the top, A, B and D using x20 magnification and C using 
x60 magnification, cc=central canal.
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3.3.2 Effects of 18β-Glycyrrhetinic acid on dye coupling of 
ependymal cell 
To determine the effect that gap junction coupling was having on the 
electrophysiological properties of ependymal cells, the non-selective gap junction 
blocker 18β-glycyrrhetinic acid (100 μM) (Davidson and Baumgarten, 1988) was bath 
applied. The input resistance was increased in five of the six cells tested following 
bath application of 18β-glycyrrhetinic acid (Figure 3-4 A). Four of the six cells showed 
changes of membrane potential even though overall, the change in these 4 cells did 
not reach significance (Figure 3-4 C). With 18β-glycyrrhetinic acid, the input 
resistance of ependymal cells tested significantly increased (n=6, Figure 3-4, A, D) 
from 42.45 ± 9.52. MΩ to 127.9 ± 32.70 MΩ. The wide range of changes in input 
resistance suggests that the ependymal cells are coupled to different degrees.  
18β-glycyrrhetinic acid also had an effect on membrane potential in 4 out of 6 
ependymal cells, causing depolarisation in these 4 cells (Figure 3-4 E). Interestingly, 
the change of input resistances was 124.27 ± 29.51 MΩ for the depolarising cells. 
The average change in input resistance for the cells that did not depolarise in 
response to 18β-glycyrrhetinic acid was much smaller (7.8 ± 7.8 MΩ). The changes 
of IR between depolarising and non-depolarising cells were not significantly different 
but only 2 cells were considered in the non-depolarising group.  
The correlation between the change in input resistance and change in membrane 
potential was examined. A Spearman’s Rank order of correlation showed a significant 
correlation between the change in input resistance and the change in membrane 
potential (r2=0.8, P<0.05, Figure 3-4 F). This suggests that the depolarisation that 
occurs in response to application of 18β-glycyrrhetinic acid is related to blockade of 
gap junctions. As the slices were not pre-incubated with 18β-glycyrrhetinic acid prior 
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to recording, the effect of 18β-glycyrrhetinic acid on dye coupling could not be 
investigated. 
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Figure 3-4 A gap junction blocker, 18β-glycyrrhetinic acid, increases input 
resistance of ependymal cells 
Example whole cell patch clamp traces showing effects of bath application of 18β-
glycyrrhetinic acid (A and B). The top trace shows an increase in input resistance is 
accompanied by a large depolarisation (A) while on the bottom trace, an increase in 
input resistance is observed with little change in membrane potential (B). Pooled 
data for 4 cells of the changes in membrane potential caused by 18β-glycyrrhetinic 
acid (C). Pooled data for 6 cells of the input resistance changes elicited by 18β-
glycyrrhetinic acid (D). Grouped data (mean ± SE) of the change in input resistance 
for the cells classed as non-depolarising cells compared to those classed as 
depolarising cells in response to bath application of 18β-glycyrrhetinic acid (E). 
Correlation between the change in input resistance and the change in membrane 
potential in response to bath application of 18β-glycyrrhetinic acid. Plots of changes 
in input resistance against changes in membrane potential showed significant 
correlation value *p<0.05 (F).
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3.3.3 The properties of cerebral spinal fluid contacting cells 
differed from those of ependymal cells 
To aid identification of CSFcCs, these cells were rounded and larger than the 
remaining ependymal cells and were usually seen as brighter cells located around 
the central canal using a contrast image camera software. A process with an end bulb 
often was observed extending into the central canal.  
Electrophysiology revealed that CSFcCs were different from ependymal cells and 
consisted of a varied population of cells. Their phenotype ranged from the one 
resembling ependymal cells to a phenotype resembling a repetitively firing neurone. 
Due to this varied phenotype, the criteria used to define as a CSFcC were the shape 
of the voltage responses to current pulses, visualisation of a CSF-contacting process 
post-recording using either rhodamine/neurobiotin or using a combination of 
rhodamine/neurobiotin with streptavidin alexafluor 555 to show that most cells were 
not coupled.   
Recordings were made from 13 CSFcCs that were identified microscopically and 
using Q capture software. The cells were found interspersed among the cuboidal cells 
around the CC. In contrast to ependymal cells, the majority of CSFcCs had spikelets 
or full action potentials, The mean IR of CSFcCs was significantly higher (703.6 ± 
86.1 MΩ, n=13) than that of ependymal cells while their resting membrane potential 
was more depolarised (-56.9 ± 4.4 mV, n=13). (Figure 3-5).  
Only 1 Subtype 1 CSFcC was identified that had a phenotype almost indistinguishable 
from ependymal cells (Figure 3-5 A, Ai). The cell had a resting membrane potential, 
in the range of the recorded resting membrane potential of ependymal cells; -73.5 
mV, a low input resistance (18.5 MΩ) and a lack of spontaneous or evoked activity. 
Within subtype 1 CSFcCs, previous research has further categorised the cells into 
subtype 1A and 1B by visualisation of neurobiotin post recording (Corns et al., 2015). 
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Subtype 1A were defined as cells which were coupled to neighbouring cells 
resembling ependymal cells. Neurobiotin can pass through gap junctions, therefore if 
cells are coupled to neighbouring cells, these cells may be visualised (Figure 3-5 Ai). 
Subtype 1B were defined as cells which were visualised alone and not coupled to 
neighbouring cells. In this study, no recordings were made of Subtype 1B CSFcCs. 
Subtype 2 CSFcCs were defined by the production of a single fast depolarisation in 
response to the injection of positive current (Figure 3-5 B). Subtype 2 had membrane 
potential oscillations that followed the single spike. These cells also had synaptic 
activity with negative current (Figure 3-5 B, black arrow). Rebound depolarisations 
were often observed following a negative current pulse (Figure 3-5. B; black 
arrowhead). Rebound depolarisations suggested the presence of T-type Ca2+ 
channels (Leresche and Lambert, 2018; Surges et al., 2006). Visualisation of subtype 
2 CSFcCs post-recording revealed a single cell with a single process (Figure 3-5 Bi). 
A single cell dye fill indicated that these types of cells were not coupled to 
neighbouring cells. 
Subtype 3 CSFcCs are defined by their ability to produce multiple spikes or action 
potentials in response to the injection of positive currents but only one of this subtype 
was recorded (Figure 3-5 C). This subtype 3 cell displayed spontaneous activity in 
form of EPSPs and sometimes spikes or action potentials and synaptic activity (Figure 
3-5 C, black arrow), followed by rebound depolarisations with negative current 
injections (Figure 3-5 C, arrowhead).  
The subtype recorded most frequently in this study was subtype 2 (n=11). A 
previous study of CSFcCs also showed a majority of Subtype 2 CSFcCs recorded in 
spinal cord of rodents (Corns et al., 2015). The visualisation of rhodamine post-
recording allowed the observation of CSF-contacting processes. These processes 
were better identified following the visualisation of neurobiotin. Not all cells were 
successfully visualised post recording and sometimes the processes were lost in the 
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resectioning procedure. Generally, the processes projected from the cells ventrally 
towards ventral area (Figure 3-5 Bi). 
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Figure 3-5 CSFcCs subtypes and their input resistance 
Example trace of whole cell patch clamp characterisation of Subtype 1 CSFcC (A). 
Subtype 1 had a phenotype that was almost indistinguishable from ependymal cells, 
a similar resting membrane potential, low input resistance, and a lack of spontaneous 
activity. This cell can be categorised further into 1A subtype by visualisation of 
neurobiotin, coupled to neighbouring cells, resembling ependymal cells (A). Example 
of whole cell patch clamp of subtype 2 CSFcC, producing a single spike and rebound 
depolarisation following injection of negative current was observed (B). The 
visualisation of neurobiotin by fluorescent microscopy image confirmed the cell as 
CSFcC (Bi). Example trace of a subtype 3 CSFcC producing multiple action potentials 
in response to the injection of positive current (C). All images are orientated, so dorsal 
at the top. Black arrows indicate spontaneous synaptic activity and black arrowheads 
indicate rebound depolarisations. Histogram showing CSFcCs with large input 
resistances, varying over a wide range (D).
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3.3.4 Ependymal cells respond to GABA  
Given the response to GABA in ependymal cells in rats as reported in previous work 
of Deuchars Lab (Corns et al., 2013), on CSFcCs (Corns et al., 2013; Marichal et al., 
2009) and on radial glia surrounding the central canal in the turtle (Reali et al., 2011), 
responses of GABA were further investigated on ependymal cells in mouse.  
GABA caused both depolarising and hyperpolarising responses and the type of 
response was dependent on the concentration of GABA applied. Of 26 ependymal 
cells tested, the higher concentration; 400 μM GABA bath, elicited a depolarisation 
with amplitude of 3.85 ± 0.29 mV compared to an amplitude of only 1.54 ± 0.13 mV 
with lower concentration 200 μM GABA bath (Figure 3-6 A, B). With high 
concentrations of bath applied GABA, depolarising responses were always observed. 
GABA at a concentration of 400 μM was therefore chosen to elicit the desirable 
amplitude response in ependymal cells. 
Second applications of GABA usually elicited a reduced amplitude response with bath 
(Figure 3-6 C) and puff application (not shown).  
Puff application of GABA with two different concentrations was also tested; high 
concentration 400 μM (Figure 3-7 A) and low concentration 1.25 μM (Figure 3-7 B) 
on ependymal cells, which elicited both depolarisations and hyperpolarisations. With 
puff application, as the concentration was increased, the responses were more likely 
to be depolarising (Figure 3-7A and C) and as the concentration was decreased, the 
responses were hyperpolarising (Figure 3-7 B and C).  
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Figure 3-6 Effects of GABA on ependymal cells were dependant on 
concentration. 
Bath application of GABA with two different concentration; 200 µM and 400 µM on 
same ependymal cell (A). There is an increase in amplitude for the dose of 400 µM 
compared to 200 µM (A) and (B). With high concentrations of bath applied GABA, 
depolarising responses were always observed. Second applications of GABA usually 
elicited a reduced amplitude response with bath application (C). Post-hoc 
confirmation with DAB; it was an ependymal cell (D) (cell rotated with dorsal at top, 
white arrow point to the patched cell, cc=central canal). 
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Figure 3-7 Ependymal cells respond to puff application of GABA both with 
depolarisation and hyperpolarisation.  
Puff application of GABA with two different concentration; high concentration 400 µM 
(A) and low concentration 1.25 µM (B) on ependymal cells. Ependymal cells respond 
to GABA both with depolarisation and hyperpolarisation. With puff application, as the 
concentration was increased, the responses were more likely to be depolarising (A 
and C) and as the concentration was decreased, the responses were hyperpolarising 
(B and C).  
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To establish whether the location of the cell affected the response observed, 
ependymal cells were recorded from around the central canal and the location and 
response were noted. It was clear that there was no location-specific response profile 
(Figure 3-8). 
 
 
 
 
 
 
Figure 3-8 Location of ependymal cells exhibiting the different responses to 
GABA. 
Whole cell patch clamp recordings were taken from regions throughout the area of 
central canal. There is no location specificity for the type of response observed. GABA 
was applied locally using a puff electrode or applied in the bath solution.
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3.3.4.1 The GABAergic response in ependymal cells is mediated in part 
by GABAA receptors.  
To determine which receptors are mediating the GABA response in ependymal cells, 
GABA was applied in the presence of the GABAA antagonists; bicuculline 50-100 μM 
(n=3). The depolarising GABA responses could not be antagonised by bicuculline 
(Figure 3-9 A). The amplitudes of control responses 3.02 ± 0.44 mV were slightly 
reduced to 2.59 ± 0.36 mV in the presence of bicuculline (n=3, n.s). The 
hyperpolarising responses to GABA using lower concentration (1.25 μM) responses 
could not be antagonised by bicuculline, amplitudes showed no significant change 
from -0.73 ± 0.30 to -0.80 ± 0.28 mV (n = 4, Figure 3-9 B).  
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Figure 3-9 Antagonism with GABAA antagonists was dependant on GABA 
concentration.  
Bicuculline (100 µM) slightly reduced the responses to high concentrations of GABA 
(400 µM). Examples of responses to high concentrations of GABA in the absence 
(black) and presence (red) of bicuculline are observed. Bicuculline (100 µM) could not 
antagonise the responses to low concentrations of GABA (1.25 µM). Examples of 
responses to low concentrations of GABA in the absence (black) and presence (red) 
of bicuculline are observed. 
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3.3.4.2 Effects of TPMPA on responses of ependymal cells to low 
concentrations of GABA 
 
Since low concentrations of GABA preferentially activate GABA receptors containing 
ρ subunits (Schmidt et al 2001), the effects of the GABAρ receptor antagonist TPMPA 
on responses to low concentrations of GABA were tested. TPMPA at a concentration 
of 80 μM significantly reduced the amplitude of the responses to low GABA from -
2.17 ± 0.83 mV to -1.21 ± 0.69 mV (*p≤0.05, n =5, Figure 3-10). 
Immunohistochemistry using an antibody against GABAρ1 on spinal cord sections 
revealed GABAρ1 immunopositive staining on CD24 immunopositive cells (Figure 3-
11 A) but levels of immunopositive structures were less numerous in the vicinity of 
GAD-GFP cells (Figure 3-11 B) which labelled the CSFcCs.   
To further characterise whether there was a contribution of ρ subunits, TACA as a 
GABAρ agonist was used. Puffing TACA at 0.1-0.8 µM always produced 
hyperpolarising responses (Figure 3.12 A) and these responses reduced in amplitude 
as the cell was hyperpolarised. Responses to TACA were reduced by TPMPA 80 μM, 
but this reduction did not quite reach significance for the five ependymal cells tested. 
The amplitude before TPMPA was -2.73 ± 0.71 mV and after TPMPA was -1.70 ± 
0.50 mV (*p = 0.07, n=5, Figure 3-12 B). 
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Figure 3-10 Ependymal cell responses to low GABA 1.25 μM 
Responses to low GABA concentrations were antagonised by the rho antagonist 
TPMPA. TPMPA antagonised the responses of low concentrations of GABA. An 
example of the response of a single ependymal cell to GABA in the absence (black) 
and presence (red) of TPMPA (*p≤0.05, n=7).  
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Figure 3-11 GABAρ1 immunofluorescence was observed around the central 
canal area of spinal cord 
Ependymal cells were immunopositive for CD24 (blue) (A) while GAD-GFP (green) 
tissue was used to label CSFcCs (B). Arrows point to GABAρ1 immunopositive 
punctate staining observed in close apposition to cells, cc=central canal.
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Figure 3-12 Ependymal cells were hyperpolarised by TACA  
This ependymal cell responded to TACA with hyperpolarisations (A). Responses to 
TACA were measured at 4 different holding potentials (-80 mV, -75 mV, -70 mV and 
-65 mV). The amplitude of hyperpolarisations decreased as the membrane holding 
potential was made more negative (Ai). Responses to TACA were reduced slightly 
by the rho antagonist, TPMPA but this did not reach significance (p = 0.07, n=5) 
(B). An example of the response of a single ependymal cell to TACA in the absence 
(black) and presence (red) of TPMPA (Bi).
 
 
129 
 
 
 
 
 
 
 
 
 
-75 mV
-70 mV
1 mV
5s
-65 mV 
-80 mV
TACA 0.1 µM
-10
-8
-6
-4
-2
0
-100 -50 0
am
pl
itu
de
 (m
V)
holding potential (mV)
A Ai
B
-4
-3.5
-3
-2.5
-2
-1.5
-1
-0.5
0
TACA with TPMPA
am
pl
itu
de
 (m
V)
n=5n=5
n.s
Bi
TACA
1 mV
1s
-72 mV
control
+ TPMPA  
 
 
130 
 
3.3.5 GABA actions may be modulated at different sites  
The GABA receptor has a number of modulatory sites located on specific subunits 
that form the overall receptor (Sigel et al., 2011). The presence of these sites enables 
selective and fine control of responses of cells to GABA. We focussed on one such 
site, the benzodiazepine site since it can be modulated by the endogenous peptide, 
diazepam binding inhibitor. DBI is broken down into two peptides, ODN that 
selectively activates the central benzodiazepine site in the GABA receptor, CBR and 
TTN which acts at another site that is located on the mitochondrial surface (Costa 
and Guidotti, 1991). DBI is strongly expressed in brain neurogenic niches (Alfonso et 
al., 2012). The function of DBI in neurogenesis of brain neurogenic niche raised the 
question whether the protein can have an effect on the ependymal cells in spinal cord 
neurogenic niche.  
Firstly, immunofluorescence labelling was carried out in tissue taken from nestin-GFP 
mice using antibodies specific for DBI and TSPO. In both cases, there was strong 
DBI and TSPO immunofluorescence located around the central canal area of spinal 
cord (Figure 3-13 A), extending into the fibres of these cells in particular for the case 
of the DBI-immunofluorescence. 
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Figure 3-13 DBI immunopositive structures around nestin-GFP ependymal cells 
in central canal area  
DBI immunopositive structures (A) in the central canal area of spinal cord and TSPO 
immunostaining (B) in the central canal area of spinal cord. White arrows indicate DBI 
and TSPO structures, cc=central canal.
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3.3.5.1 Is there a role for both central benzodiazepine receptor and 
translocator protein in modulating responses to GABA? 
 
To establish whether activation of these sites can affect the responses of ependymal 
cells to high concentrations of GABA, I first applied midazolam, which acts as non-
selective modulator at both CBR and TSPO. Application of midazolam (0.1 µM) 
significantly reduced the amplitude of responses to 400 µM GABA from 12.06 ± 2.26 
mV to 9.50 ± 2.25 mV (*p≤0.05, n = 14, Figure 3-14 A). 
Since midazolam has effects at both CBR and TSPO, I next tested the effects of 
activating TSPO alone since DBI peptides can modulate GABA through an alternative 
pathway distinct from binding to the DBI site on GABAA receptor. FGIN-1-27 is an 
anxiolytic drug which acts as a selective agonist at TSPO. FGIN-1-27 (1 μM) was able 
to increase the responses to GABA from baseline 5.53 ± 1.43 mV to 6.29 ± 1.57 mV 
(*p≤0.05, n = 12, Figure 3-14 B). The effects of FGIN-1-27 on GABA responses 
showed a latent plateau only in this single cell. 
PK-11195 is a selective antagonist for TSPO (Gandolfo et al., 1997). It is the most 
commonly used TSPO ligand due to its high affinity to TSPO determined in glial cells 
of ependymal walls, choroid plexus and olfactory bulb. Combining the application of 
FGIN-1-27 and PK-11195 before puffing GABA resulted in a blockade of the effects 
of FGIN-1-27 alone, such that GABA responses were no longer enhanced in 
ependymal cells (Figure 3-15, n=6). This indicates that the effects of FGIN-1-27 are 
mediated through the TSPO site. 
FGIN-1-27 is thought to have effects at TSPO by stimulating steroidogenesis of 
neuroactive steroids such as allopregnanolone, also known as 5-alpha-pregnane-
3alpha-ol-20-one. Allopregnanolone binds to an allosteric site on GABAA receptor 
distinct from the DBI site and potentiates GABA function. Allopregnanolone applied 
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at two different concentrations (1 μM, n=5 and 10 nM, n=4) slightly increased 
responses of ependymal cells to GABA (from 3.21 ± 1.23 mV to 5.9 ± 1.18 mV and 
from 1.62 ± 0.58 mV to 3.17 ± 1.14 mV respectively) but these did not reach 
significance (p= 0.10, Figure 3-16 A and p=0.09, Figure 3-16 B).  
The effects of these modulators were also tested on responses of ependymal cells 
to low concentrations (1.25 µM) of GABA. For FGIN-1-27 and allopregnanolone, 
neither modulator caused significant changes to the amplitude of the 
hyperpolarisations elicited by low GABA (Table 3.1). One further cell was tested 
with midazolam and this modulator also did not change the amplitude of the 
response to low GABA but this could not be tested for significance due to low 
numbers.
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Figure 3-14 Receptor modulators have differing effects on the responses of 
ependymal Cells to high [GABA] 
Midazolam (0.1 μM) decreases responses of ependymal cells to GABA (400 μM). An 
example of the response of a single ependymal cell to GABA in the absence (black) 
and presence (red) of midazolam (*p≤0.05, n=14) (A). Effects of FGIN1-27 (1 μM) on 
high concentration of GABA (400 μM). An example of the response of a single 
ependymal cell to GABA in the absence (black) and presence (red) of FGIN-1-27 
(*p≤0.05, n=12) (B).   
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Figure 3-15 Effects of combination of FGIN-1-27 and PK-11195 on the response 
to high concentration of GABA (400 μM).  
Pooled data showing the effects of a combination of FGIN-1-27 and PK-11195 on the 
response to high concentration of GABA (400 μM) (n=6) (A) and an example of the 
response of a single ependymal cell to GABA in the absence (black) and presence 
(red) of FGIN-1-27 and PK-11195 (B). 
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Figure 3-16 Allopregnanolone does not significantly change responses to high 
GABA concentration 
Allopregnanolone at both concentrations 1 μM (A) and 10 nM (B) does not 
significantly increase GABA responses on ependymal cell. Example of the response 
of a single ependymal cell to GABA in the absence (black) and presence (red) of 
allopregnanolone in 1 μM (n=5) (Ai) and 10 nM (n=4) (Bi).
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Table 3-1 Modulators have no effects on the responses of ependymal cells to low [GABA] 
Modulator Concentration Baseline depolarisation/ 
hyperpolarisation amplitude 
(mV) 
With modulator  
depolarisation/hyperpolarisation 
amplitude (mV) 
n N P value 
FGIN-1-27 1 μM -0.63 ± 0.22 -0.57 ± 0.20 5 4 0.29 
Bicuculline 100 μM -0.97 ± 0.25 -1.02 ± 0.25 4 4 0.16 
Allopregnanolone 1 μM -0.57 ± 0.13 -0.43 ± 0.08 6 5 0.38 
Allopregnanolone 10 nM -0.68 ± 0.25 -0.61 ± 0.23 3 3 0.10 
ODN 20 μM -0.87 ± 0.15 -0.74 ± 0.16 6 5 0.42 
Cyclo1-8[dleu5]OP 50-300 nM -0.59 ± 0.06 -0.63 ± 0.06 4 5 0.54 
Picrotoxin 1 µM -0.53 ± 0.15 -0.51 ± 0.14 3 2 0.65 
Modulators such as FGIN-1-27, ODN, allopregnanolone and picrotoxin had no effect on the responses to low [GABA], suggesting that the rho 
containing receptors are not modulated in the same way as the GABAA receptors. n values denote numbers of neurones, while N denotes 
numbers of mice.
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3.3.6 Can octadecaneuropeptide modulate responses of 
ependymal cells to GABA? 
Similar to DBI, ODN binds with high affinity to the CBR on the GABAA receptor; 
however, it binds only with low affinity to the TSPO.  
Firstly, the presence of ODN in the vicinity of ependymal cells was deduced using 
specific antibodies to ODN in spinal cord tissue taken from nestin-GFP mice. There 
was intense and localised ODN-immunofluorescence in the vicinity of nestin-GFP 
positive ependymal cells in the central canal region (Figure 3-17A), suggesting that 
ODN may be able to influence the activity of these ependymal cells.  
Indeed, when bath applied alone, ODN, the endogenous ligand of the central 
benzodiazepine receptor caused both depolarising (Figure 3-17 B) and 
hyperpolarising effects on ependymal cells (Figure 3-17 C). Regardless of whether 
responses to ODN were either depolarising or hyperpolarising, there were no 
significant differences in responses to GABA in the presence or absence of ODN. 
For each cell, the membrane potential was repolarised to test the effects of GABA. 
However, ODN did not significantly modulate the effects of either bath or puff applied 
GABA, regardless of the initial response to ODN, the direction of response to GABA 
and the concentration of GABA used (Figure 3-18 A and B). 
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Figure 3-17 ODN expression and effects on ependymal cells in central canal 
area of spinal cord 
ODN immunopositive staining using ODN antibodies showed ODN is widely 
expressed around the central canal area of spinal cord of nestin-GFP mouse (A, Ai). 
ODN at a concentration of 20 μM (bath application) caused both depolarising (B) and 
hyperpolarising (C) effects on ependymal cells. The responses to GABA on (B) are 
using puff application and responses to GABA on (C) are using bath application. Red 
arrow head showed the point at which the membrane potential was repolarised to 
retest GABA at the same membrane potential as prior to the ODN.
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Figure 3-18 ODN did not significantly change responses of ependymal cells to 
different concentrations of GABA 
ODN at a concentration of 20 μM did not significantly changed the GABA effects on 
ependymal cells; in higher concentration (A) and low concentration (B) of GABA. 
Example of the response of a single ependymal cell to GABA at high concentration 
(400 μM) and low concentration (1.25 μM) in the absence (black) and presence (red) 
of ODN 20 μM. Pooled data and an example of the response of a single ependymal 
cell to GABA in high concentration (400 μM, n=18, A) and low concentration (1.25 
μM, n=6, B) in the absence (black) and presence (red) of ODN 20 μM. Red arrow 
head indicate point of repolarisation.
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3.3.7 Octadecaneuropeptide alone hyperpolarised ependymal 
cells 
Since ODN had effects on the membrane potential of ependymal cells when bath 
applied alone, I tested responses of ependymal cells to puff applications of low 
concentrations of ODN (15-20 nM). ODN caused robust and repeatable 
hyperpolarising responses of 1.26 ± 0.25 mV (n = 45) in ependymal cells (Figure 3-
19 B). These hyperpolarising responses were observed in ependymal cells at all 
locations of the central canal (Figure 3-19 A). 
 
Figure 3-19 Ependymal cells responses to ODN.  
Location of ependymal cells exhibiting the different responses to ODN. Whole cell 
patch clamp recordings were taken from throughout the area of central canal. There 
is no location specificity for the type of response observed. ODN was applied locally 
using a puff electrode and also in the bath solution (A). ODN applied alone elicited 
hyperpolarising responses in ependymal cells. Clear effects of puffing ODN on 
ependymal cells (B).
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3.3.8 Effects of TPMPA on responses of ependymal cells to 
octadecaneuropeptide 
Since TPMPA blocked similar hyperpolarising responses to low concentrations of 
GABA, I applied this antagonist and observed significant reductions in the amplitude 
of responses to ODN, from -1.31 ± 0.26 mV to -0.91 ± 0.2 mV. (*p≤0.05, n=8, Figure 
3-20 A). However, there was no significant change in responses to ODN in the 
presence of the GABAA antagonist bicuculline (-1.95 ± 0.95 mV to -1.81 ± 0.84 mV, 
n=6). There were also no significant changes of responses to ODN with other 
antagonists, modulators or channel blockers as shown in Table 3.2.  
Interestingly however, the responses to ODN were antagonised by selective 
antagonist of metabotropic endozepine receptors, using cyclo (1-8) [dLeu (5)] OP. 
The responses were reduced from 0.59 ± 0.05 mV to 0.47 ± 0.05 mV (*p≤0.05, n=9, 
Figure 3-20 B). 
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Figure 3-20 ODN effects on ependymal cells.  
Antagonism of ODN (15 nM) responses on ependymal cells. ODN effects are 
antagonised by both TPMPA (A) and cyclo1-8[dleu5] OP (B) (*p≤0.05). On the right 
are examples of the response of a single ependymal cell to ODN (1.25 μM) in the 
absence (black) and presence (red) of TPMPA (*p≤0.05) and cyclo1-8[dleu5] OP.
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Table 3-2 ODN responses were not significantly reduced by other antagonists, modulators or channel blockers 
Antagonists Concentration Baseline 
hyperpolarisation 
amplitude (mV) 
Antagonists 
hyperpolarisation 
amplitude (mV) 
n N P value 
Nipecotic acid  300 μM -0.49 ± 0.11 -0.45 ± 0.12  5 4 0.070 
Niflumic acid  250 μM -0.47 ± 0.18 -0.81 ± 0.02 2 2 0.135 
Bicuculline  100 μM -1.95 ± 0.95 -1.81 ± 0.84 6 5 0.292 
FGIN-1-27      1 μM -0.58 ± 0.02 -0.71 ± 0.11 2 2 0.500 
Flumazenil   20 μM -2.41 ± 1.33 -2.22 ± 1.42  5 5 0.444 
PK-11195   10 μM -3.32 ± 1.76 -3.56 ± 1.75 3 3 0.398 
Midazolam   0.1 μM -0.58 ± 0.07 -0.63 ± 0.09 5 4 0.415 
Modulators had no effect on the responses to ODN, suggesting that ODN is not modulated in the same way as GABA. n values denote 
numbers of neurones, while N denotes numbers of mice.
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3.4 Discussion 
 
This chapter provides a characterisation of the pharmacological and 
electrophysiological characterisation of GABAA receptors in central canal area of 
spinal cord.  
Electrophysiological characteristics of ependymal cells surrounding the central canal 
displayed typical findings of glial cells: with negative resting membrane potentials of 
-74 mV, and no spontaneous or evoked activity, indicating a lack of voltage-gated 
channels. These properties differ from CSFcCs, which had more depolarised 
membrane potentials (-56.9 ± 4.4 mV), larger input resistance, varied phenotype of 
electrical activity and some also had passive responses. CsFcCs with active response 
properties have been previously reported under the name of CSF-contacting 
neurones (CSFcNs) (Marichal et al., 2009) and as CSFcC (Corns et al., 2015; 2013).  
The visualisation of neurobiotin following intracellular loading revealed not only that 
ependymal cells were coupled but that different degrees of coupling were present 
whereas in CSFcCs, only subtype 1 showed coupling indicative of the presence of 
some degree of gap junction. The coupling in ependymal cells can be reduced in the 
presence of gap junction blocker 18β-glycyrrhetinic acid as evidenced by the large 
increases in input resistance. Dye coupling with neurobiotin showed gap junctions 
present between these cells. Since these characteristics were similar to those 
observed previously in rats (Corns et al 2015), we are confident that the cells are the 
ependymal cells of the neurogenic niche.  
My study provides data on ependymal cells within the postnatal mammalian spinal 
cord which respond to GABA with 2 different characteristics. The higher concentration 
of GABA will produce mostly depolarising activity while the lower concentration will 
produce mostly hyperpolarising activity. There is no location specificity for the type of 
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response observed and the type of GABA application (puff or bath) did not contribute 
to the response.  
Our study further shows a complex role of GABA receptors in modulating the activity 
of ependymal cells since it is likely that GABAA receptors are present on ependymal 
cells and further modulation of these receptors through CBR and TSPO elicits a 
variety of effects. On further characterising the GABA receptors, it was observed that 
the GABAρ antagonist TPMPA reduced responses to low concentrations of GABA 
while TACA, a GABAρ agonist mimicked the responses to low GABA. This indicates 
the presence of atypical GABA receptors and/or mixed pharmacological properties of 
GABAA and GABAρ receptors. ODN effects on ependymal cells that may be mediated 
through sites other than at the CBR site suggest yet another mechanism by which the 
activity of ependymal cells may be modulated, through activation of a metabotropic 
ODN receptor.   
 
3.4.1 Basic electrophysiological characteristics are consistent 
with ependymal cells as previously observed  
The resting membrane potential of ependymal cells determined in this study in 
rodents, -74 mV is relatively similar to those determined previously , -84 mV for 
ependymal cells in rat spinal cord (Marichal et al., 2012), -80 mV for ependymal cells 
in the rat third ventricle (Jarvis and Andrew, 1988) and -76 mV (Corns et al., 2013). 
In other species, ependymal cells in turtle spinal cord had a resting membrane 
potential of -87 mV (Reali et al., 2011). The variations of membrane potential among 
studies may be due to variations in extracellular K+ concentration within aCSF or due 
to intracellular K+ concentration within intracellular patch pipette solution, differences 
in the region of the ventricle or central canal studied and differences of age of animals 
used. 
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The input resistance of ependymal cell determined in this study was 72.6 ± 3.9 MΩ. 
The input resistance is lower compared to that previously determined by Marichal et 
al. (2012); 124 MΩ, 167 MΩ in the turtle spinal cord (Reali et al., 2011) and 96 ± 13 
MΩ in ependymal cells of spinal cord (Corns et al., 2013). The lower input resistance 
suggests that the cells recorded in this study could be highly coupled since this would 
result in increased “leakiness” of the cells (Davidson and Baumgarten, 1988). The 
study from Marichal et al. (2012) recorded from cervical spinal cord, whereas in this 
study, most cells were recorded from thoracolumbar spinal slices. The other factor 
which can contribute to the differences are the age of animals, Marichal et al.(2012) 
used a younger animal i.e. P0-P5, while in this study, recorded ependymal cells were 
from taken from mice aged P8-P15. The expression of ion channels has been shown 
to change during postnatal development (Chvátal et al., 1995) and expression of 
connexins can vary during CNS development. Connexin 43 mRNA expression and 
protein expression increased from P0 to adulthood (Leung et al., 2002). If the same 
pattern of expression occurs in the ependymal cell, the more that cells are coupled 
towards P21, the greater the likelihood of lower input resistances, supporting the 
lower input resistance in this study compared to previous study.  
The lack of spontaneous activity and the linear voltage-current relationship showed 
similar findings with previous studies (Corns et al., 2013; Marichal et al., 2012; Reali 
et al., 2011). Ependymal cells showed lack of spontaneous activity because they do 
not express voltage-gated ion channels. Marichal et al. (2012) did not observe any 
outward current in their leak subtraction protocol in ependymal cells. This suggests 
that ependymal cells of postnatal mammalian central canal do not express voltage-
gated channels. For CSFcCs, the input resistance was 703.6 ± 86 MΩ, relatively low 
compared to the observation of Subtype 2 by Marichal et al. (2009) : 3950 ± 290 MΩ 
and also observation by Corns et al. (2015) : 2668 ± 130 MΩ; The difference may be 
due to different age and type of animals used.  
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Dye coupling occurs between ependymal cells. The different degree and variation of 
coupling has been shown to be similar to other studies (Corns et al., 2013; Russo et 
al., 2008). A degree of variation of coupling has been found in ependymal cell 
progenitor population in turtle where they referred to different sized clusters of cells; 
from quadrants of dye-coupled cells to small clusters containing a few cells only 
(Russo et al., 2008). The degree of coupling and the increase in input resistance 
observed in the presence of gap junction blocker, 18β-glycyrrhetinic acid is consistent 
with dye-coupling and the gap junctions present between ependymal cells. Connexin 
43 (Marichal et al., 2012) and connexin 45 (Chapman et al., 2013) were identified in 
previous studies of ependymal cells in rat and the connexin 43 subunit was revealed 
with immunohistochemistry in the ependymal cells of turtle (Russo et al., 2008). The 
correlation between the change in input resistance and the change in membrane 
potential in response to 18β-glycyrrhetinic acid indicates that the depolarisation is a 
direct effect of gap junction blockade.  
The ependymal region consists of cells arranged in lateral and dorsal-ventral domains 
(Marichal et al., 2012; Trujillo‐Cenóz et al., 2007). The majority of cells have two 
motile cilia but some have 1, 3 or 4 cilia (Alfaro‐Cervello et al., 2012). At least three 
different morphologically different cell types were described by these researchers in 
the central canal area: 1. ciliated ependymal cells with short basal processes, 2. 
ciliated ependymal cells with long processes reaching the pial surfaces (Radial glial 
like cells and 3. Typical CSFcC which is a single cell with a single long processes 
(Marichal et al., 2012; Meletis et al., 2008; Trujillo‐Cenóz et al., 2007). Most 
researchers seems to agree that on the lateral regions of the central canal, cells are 
either cuboidal ependymal cells or tanycytes and these can have short or long radial 
processes. However, many researchers fail to agree on how cells should be grouped 
or what characteristics are important to focus on when identifying these cells. Most 
researchers refer to the majority of lateral cells as cuboidal ependymal cells (Marichal 
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et al., 2012; Alfaro‐Cervello et al., 2012). However, according to Meletis et al. (2008), 
tanycytes and cuboidal types are the most abundant cell types among the ependymal 
cells and they are usually found at the lateral up to each pole while radial cells are 
usually situated at the dorsal and ventral poles. Only Meletis reports that tanycytes 
can be differentiated from cuboidal cells using electron microscopy because they 
have darker cytoplasm and can have two cilia or multiciliated (Meletis et al., 2008). 
We did not split the lateral cells into tanycytes or cuboidal ependymal cells in this 
study due to the problems in definitive identification. In our study, the first criterion to 
choose cells was based on the shape of faint but distinct outline of the cells – these 
were cuboidal in shape and were tightly bound together at the luminal surfaces. Our 
observation using DAB immunostaining with rhodamine showed ependymal cells had 
a multiple radial processes extending laterally from a single cell compared to CSFcCs 
which had a single long process arising from the main cell body which extended into 
the central canal. This suggests that like Alfaro-Cervello. (2012), we see longer 
processes in the lateral cells that may make them tanycytes. Factors to differentiate 
the ependymal cell from the subtype 1 CSFcC were the shape of the voltage 
responses to current pulses and visualisation of processes post-recording using 
either rhodamine or neurobiotin or using a combination of rhodamine/neurobiotin. 
Our acute slices were prepared from mice similar to Meletis et al. (2008). Tanycytes 
were only reported by Meletis et al. (2008), while other types of ependymal cell were 
described in rat (Marichal et al., 2012) and turtle (Trujillo‐Cenóz et al., 2007).  
In one of a study of ependymal cells in SVZ, ependymal cell possess a fractone bulbs 
that appeared at the apical membrane of ependymal cells at the end of first week 
after birth (Nascimento et al., 2018). If we consider that the ependymal cells of the 
spinal cord also have the same function in neurogenesis as the ependymal cell in 
SVZ area, their structures would be similar. In future plans, a study using electron 
microscopy could be done on neurobiotin filled cells recovered from patched acute 
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slices to observe the morphological characteristics of individual ependymal cells from 
the spinal cord. Future studies to consider the complex morphology of the different 
cell types may also be aided by using fate-labelling of cells (see general discussion). 
Since these characteristics were similar to those observed previously (Corns et al., 
2015; Marichal et al., 2012; Marichal et al., 2009), we are confident that the cells are 
the ependymal cells and CSFcCs of the neurogenic niche. In our study, tanycytes, 
cuboidal and radial ependymal cells were included in the observations as ependymal 
cells but the locations of the cells were taken into account. 
 
3.4.2 Ependymal cell responses to GABA 
Ependymal cells showed responses to GABA as in previous study (Corns et al., 2013). 
The effects of GABA on ependymal cells were dependant on concentration. With bath 
application of high concentration of GABA, the effects were mainly depolarisations. 
From my observation, only 1 cell showed hyperpolarisation using the higher 
concentration of GABA (400 µM). The cell was not included in the analysis of 
modulation of GABA since it alone exhibited hyperpolarisation. A few possibilities 
could explain the depolarisations seen in ependymal cells. Firstly this may arise 
because of intense activation of GABA receptors (Milligan et al., 2004; Staley and 
Proctor, 1999) which can lead to HCO3- efflux and Cl- influx. The imbalance can shift 
the excitatory value. The opposing HCO3- and Cl- fluxes through the GABAA 
ionophore diminishes the electrochemical gradient driving the hyperpolarising Cl- flux 
so that the depolarising HCO3- flux dominates.  
The depolarisations could also be due to contribution of GABA uptake transporters 
which transport GABA back into the cells with two Na+ ions and one Cl- ion, which 
caused a net positive charge into the cell. A study of GAT1, a family member of GABA 
transporter (Fattorini et al., 2017), revealed that GABA is transported back into the 
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cells with two Na+ ions and one Cl- ion. Thus, application of GABA can induce 
depolarisation in cells expressing GABA transporter. GAT3 has been observed to 
contribute to the mediation of GABA responses in progenitor cells surrounding the 
turtle central canal (Reali et al., 2011). The presence of GABA transporters in 
ependymal cells was not investigated in this study, however it is likely that expression 
of glial GABA transporter; GAT3 could contribute to the depolarisation in response to 
GABA. Finally, GAT1 was observed to be expressed in oligodendrocytes (Fattorini et 
al., 2017). To verify which GABA transporter is responsible in ependymal cells, a 
future experiment to apply GABA with GABA transporter antagonists could be done.    
The depolarisation induced by GABA using the perforated patch method is thought to 
be due to the presence of Na+-K+-2Cl- cotransporter (NKCC1) (Marichal et al., 2012). 
Immature neurones express high levels of NKCC1 (Clayton et al., 1998) which drive 
Cl- into the cell in exchange for the extrusion of Na+ and K+, maintaining the high 
intracellular Cl- concentration. On activation of GABA receptors, the Cl- ions exit the 
cell due to the concentration gradient, causing a depolarisation. This is less likely to 
be the case in our study though since the chloride equilibrium is set through the whole 
cell patch clamp method that fills the cell with a preset chloride concentration but it 
may be possible that at a local level, near the membrane and the chloride transporters, 
the concentration of chloride may differ from the rest of the cell.  Another point to 
make is that since these cells are coupled, it may be that in our recorded cell, where 
the equilibrium potential is set, a hyperpolarising response is observed. However in 
the gap junction coupled cells, where the equilibrium potential is set by chloride 
transporters, NKCC1 may be high thus causing depolarising responses to the bath 
application of GABA in these cells and this depolarisation is transmitted through the 
gap junctions to be recorded as an overall depolarisation in our cell.      
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It is most likely that the depolarisation of ependymal cells to higher concentration of 
GABA is not a result of one of the above causes but a combination of some of or all 
of the causes.  
On bath application, there is an increase in amplitude for the dose of 400 µM 
compared to 200 μM. Because of the low amplitude induced by 200 μM GABA, the 
dose of 400 μM was chosen to induce higher amplitude effects. Corns et al. (2013) 
used GABA dose of 200 µM to show amplitude of 3.85 ± 0.37 mV in ependymal cells 
similar to changes of amplitude in this study 3.85 ± 0.29 mV using 400 µM. The EC50 
GABA observed by Wang, D. et al. (2003) was 196 μM. The observation was done 
on postnatal neuronal progenitor cells of SVZ. Hence our GABA dose (200-400 µM) 
is optimal to induce GABAA receptor responses. The second bath and puff application 
usually showed a reduced amplitude of response because of receptor desensitisation. 
Receptors may change their sensitivity including becoming desensitized. Low doses 
may reduce desensitization. 
The whole cell patch clamp method was used which sets the reversal potential 
according to the chloride concentration in the aCSF (131 mM) and the intracellular 
solution (2.2 mM). Since the Cl- reversal potential is -103 mV and the cells are sitting 
at around -74 mV, it would be expected that the responses to GABA would be 
hyperpolarising. Puff application of GABA with concentration of 1.25 µM causes 
hyperpolarisations. With puff application, as the concentration was increased, the 
responses were more likely to be depolarising and as the concentration was 
decreased, the responses were hyperpolarising. A concentration of 50 µM was used 
during recording on ependymal glial cells (EGCs) of cerebellar slices from P13-P35 
mice and hyperpolarisations were observed (Reyes‐Haro et al., 2013). The 
differences of responses of GABA may involve factors such as different types of 
 
 
154 
 
animals, different location of the cells which could contribute to the receptor 
expression.  
The membrane potential of ependymal cells was repolarised to the resting membrane 
potential during the application of GABA to ensure that any opening and closing of 
voltage-gated channels in response to changes in the membrane potential did not 
affect the input resistance of ependymal cells. A change in input resistance would 
normally be expected to accompany a response to GABA, as opening of channels 
associated with GABAA receptors allows the movement of ions and thus input 
resistance would be decreased, but the input resistance for ependymal cells were 
already low due to extensive coupling, so the relative effect of ion channels opening 
on the size of the input resistance would quite low. If GABA had been given in the 
presence of gap junction blockers, which would increase input resistance, the 
responses observed would be expected to be bigger but this was not carried out in 
this study since the gap junction blockers often destabilised the cells, making it difficult 
to get consistent responses to drug applications.    
Since ependymal cells are found throughout the neural stem cell niche, but there is 
heterogeneity in the properties of these cells (which leads to the sub-classifications 
described above), ependymal cells were investigated based on location to identify 
any differences. No location specificity for the type of responses of GABA was 
observed in the central canal area of spinal cord, based on the widespread 
hyperpolarisations and depolarisations using whole cell patch clamp. GABA signalling 
reflects the different degrees of maturation, so no localisation of specificity should be 
observed in any of the region even though there are differences in origin of the cells. 
Reali et al. (2011) also had similar findings of varied responses of depolarisations and 
hyperpolarisations of the ependymal cells using GABA with concentration of 100-
1000 µM around the lateral aspects of central canal. These cells were electrically 
coupled as revealed by dye coupling of Alexa 488 and were in close proximity with 
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GAD+ terminals. The dorsal and ventral cells originate from different embryonic 
origins (Yu et al., 2013). Even though our observation did not characterise the neural 
stem cell marker individually, other studies showed all these type of ependymal cells 
expressed SOX2 (Alfaro‐Cervello et al., 2012; Barnabé-Heider et al., 2010; Sabourin 
et al., 2009). Using different neural stem markers, they also showed only dorsally 
situated ependymal cells express nestin/GFAP. This implies that ependymal cells are 
most likely heterogenous in their NSC potential and that all ependymal cell may 
possess different properties regardless of location.  
 
3.4.3 Atypical GABA receptor properties? 
GABA-gated ion channels may be comprised of different subunits and the exact 
composition defines the properties of the receptor. Subunits from the GABAA and 
GABAC receptor have multiple configurations and thus have different responses to 
agonists and antagonists.  
The depolarising GABA responses could be slightly reduced by GABAA receptor 
antagonists, bicuculline, quite similar to that observed by Corns et al. (2013). As 
GABAergic responses could be slightly reduced by the GABAA antagonist, 
bicuculline, it indicates that the response to GABA is in part being mediated by GABAA 
receptors. Bicuculline binds at the orthosteric site to stabilize the receptor in a closed 
state. Bicuculline acts as a competitive antagonist in which it competitively inhibits 
GABA binding to GABAA receptors, and GABA competitively inhibits bicuculline 
binding. Our ependymal cells may not show a maximum blockade with bicuculline for 
a number of reasons: 1. The concentrations of GABA used are too high for the 
bicuculline to overcome, 2. The residual GABA response could be a result of GABA 
transporter activity 3. There may be a presence of bicuculline resistant types of 
receptor subunit. 
 
 
156 
 
The presence of different GABAA receptor subunits may contribute to the different 
properties of the receptors which make them respond differently to lower or higher 
concentrations of GABA and also affects the degree of antagonism that is observed. 
Even though GABAA receptor expression subunit was not investigated for our 
ependymal cells of the spinal cord, a few immunohistochemical studies revealed high 
expression of α1, α3 , β2/β3 and γ2 subunits with lower expression of α2, α5, α6 and δ 
subunits in lamina X of spinal cord (Bohlhalter et al., 1996; Wisden et al., 1991). Due 
to these different subunits being present in the spinal cord, the degree of antagonism 
would be different even in similar animals. Another factor may be due to residual 
GABA action on the investigated cells. The residual GABA response could be a result 
of GABA transporter activity. To investigate this possibility, the GABA transporter 
blocker such as SNAP 5114 (GAT3 antagonist) could be co applied with bicuculline 
to see if they can antagonise the GABA response. We also need to consider the 
presence of GABAB receptors, which may also be present on the ependymal cells 
(see chapter 4) but this receptor solely causes hyperpolarisations so would not be 
expected to contribute to depolarising GABA responses.  
The hyperpolarising responses to GABA were not blocked by the GABAA receptor 
antagonist bicuculline at a very high dose of 100 µM. What was most interesting was 
that responses to low GABA concentrations were antagonised by the GABAρ 
receptor antagonist; TPMPA. Bicuculline is known to have little effect on GABAρ. The 
effects of GABA 50 µM were not fully antagonised (90.5 ± 3.7%) by 100 µM bicuculline 
in cerebellar astrocyte culture and were confirmed, by electron microscopy, the 
presence of GABAρ in the plasma membrane of GFAP+ cells (Pétriz et al., 2014). 
When TPMPA 10 µM was added to bicuculline, GABA responses were then 100% 
blocked in an observation by Pétriz et al. (2014). Therefore in cerebellar astrocytes, 
the GABAρ subunit underlies a bicuculline-resistant component of responses to 
GABA. In wild type mouse stratum griseum superficiale cells, muscimol at a low 
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concentration of 0.5 µM which selectively activates GABAρ receptors, also elicited 
responses that could not be blocked by a lower concentration of bicuculline, 10 µM 
(Schlicker et al., 2009). With both low and high concentrations of bicuculline, the 
receptors were insensitive, so regardless of concentration, the distinct ρ subunit 
confers a bicuculline-insensitive component.  
In all cases of effects of high doses GABA 400 µM (n=3) with bicuculline, bicuculline 
(100  µM) had no effect on the membrane potential (same as baseline reading; data 
not shown) of ependymal cells when applied alone similar with Corns et al. (2013) 
observation. Post washout GABA after bicuculline had a mean amplitude of 2.86 ± 
0.37 mV (n=3, data not shown), with 95 ± 1.8% changes towards the initial GABA 
responses (3.02 ± 0.44 mV, n=3).  The possibility of bicuculline is not working can be 
excluded as post washout GABA had reached to initial baseline changes from the co 
application of GABA and bicuculline responses. The stock and the drug safety 
checking were done during bicuculline stock preparation. The drug certificate of 
analysis had been reviewed before using the bicuculline.   
In a study using knockout rho1 (ρ-/-) mice, the effects of GABA on evoked potentials 
in spinal cord lumbar segment (L2-L6) recordings were no longer antagonised with 
TPMPA, but in the wild-type animals, the effects of GABA on these potentials had a 
significant TPMPA-sensitive component (Zheng et al., 2003). Without using knockout 
mice, previous studies in central nervous system observed a mixed response 
involving GABAA and GABAρ components (Reyes-Haro et al., 2017; Milligan et al., 
2004). Reyes-Haro et al. (2017) observed hyperpolarised evoked GABA currents 
induced by GABA 100 µM in GFAP-GFP astrocytes that were partially antagonised 
by bicuculline 100 µM but the remaining current persisted then the responses were 
fully abolished when TPMPA 100 µM was added to the bicuculline. An observation 
by Milligan et al. (2004) reported that the responses induced by CACA were reduced 
by preincubation with TPMPA 160 µM, but were then fully antagonised with further 
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addition of bicuculline 10 µM and had partial recovery from bicuculline. Application of 
picrotoxin, which is thought to act as a non-competitive inhibitor of chloride channels 
(Akaike et al., 1985), also abolished the responses to CACA. This showed evidence 
of a mixture of GABAA and GABAρ effects. Our responses of low concentration of 
GABA were not antagonised with picrotoxin, which was somewhat surprising but this 
was only tested on 3 cells so may need further investigation.  
Interestingly our data showed a significant reduction of amplitude of low GABA 
concentration responses with TPMPA 80 µM. On further confirmation to this, TACA, 
selective agonist of GABAρ1 elicited robust and reproducible hyperpolarising 
responses, similar to those observed with low concentrations of GABA. On application 
of TPMPA, the responses of TACA were reduced (n=5) but did not quite reach 
significance. Therefore, it may be worthwhile repeating in more cells to see if this 
reaches significance. TACA has greater potency than GABA at ρ receptors but also 
acts as an agonist at heteromeric GABAA receptors (Woodward et al., 1993), so the 
response effects may be divided in between GABAA and GABAρ receptor. Hence, 
there were a slight combination of action at both GABAA and GABAC in this study. 
GABAρ receptors are formed by functional homo- or heteropentamers composed of 
ρ1, ρ2 and ρ3 subunits (Enz and Cutting, 1999). The distribution of the three GABAρ 
subunits during postnatal development in the brain was described by Alakuijala et al. 
(2005). To date, there are still no characterisation or distribution studies of GABAρ 
subunits observed in the rodent postnatal development in spinal cord. 
Immunopositive staining on central canal area using GABAρ1 antibodies (Santa Cruz, 
sc-16879) was observed in the close vicinity of CD24 cells and also on GAD-GFP 
tissue. The immunopositive punctate staining observed in closed apposition to CD24 
and GAD-GFP cells. The appositions were seen in quite a number in CD24 cells while 
it was sparse at GAD-GFP cells, so this supports the observation of 
hyperpolarisations seen mainly from the ependymal cells. Rho1 subunits are 
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expressed abundantly at brainstem, while ρ2 and ρ3 are found at much lower level 
(Milligan et al., 2004). Rho1 subunits also found in the synaptic junctions in brainstem 
neurones in their observation. Milligan et al. (2004) used a pre embedding technique 
to detect ρ1 subunit immunoreactivity in synaptic junctions. Furthermore, from their 
observations, ρ1 and α1 subunits were co-localised at light and electron microscopy 
levels in brainstem neurons. In a study of rat cerebellum development, all subunits 
were expressed in the qRT-PCR of RNA isolated from postnatal developing 
cerebellum with relative comparative expression ratio ρ3>ρ1>ρ2 (Mejía et al., 2008). 
So there is a variant of expression of rho subunit in the central nervous system. We 
choose to focus on the ρ1 subunit because of the above immunopositive findings and 
previous results of immunoreactivity by Milligan et al. (2004). To confirm the 
expression of ρ1 subunits in the spinal cord, we could perform reverse transcription 
(RT)-PCR with primers specific cDNA to ρ1. If we used the same techniques to our 
spinal cord slices, so the expression of rho subunit/s can be identified.   
Our ependymal cells did not respond well with CACA and therefore this was not 
included in the results section. CACA is inactive at heteromeric GABAA receptors 
(Naffaa et al., 2017), but is a partial agonist (70% efficacy) at GABAρ1 recombinant 
homomeric receptors. So if ependymal cells showed a mixture of different receptor 
subtype, CACA would not be a suitable agonist to show responses. The restricted 
cyclic analogue, (+)-cis-2-(aminomethyl) cyclopropane carboxylic acid (CAMP) and 
trans-2-(aminomethyl) cyclopropane carboxylic acid (TAMP) have been shown to 
differentiate between subtypes of GABAρ receptor (Duke et al., 2000). The (+) CAMP 
has greater potency at GABAρ compared to CACA and TACA. The (+) CAMP is also 
a weak antagonist at GABAA and is able to inhibit GABA reuptake transporters, while 
TAMP is an antagonist for ρ3 subtypes (Vien et al., 2002). If we were able to proceed 
with further agonists and antagonists, CAMP and TAMP would be the choice to 
differentiate the effects on GABAA and among GABAρ subtypes. By using specific 
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agonists and antagonists, this would give us understanding of what type of channel 
was mediating the GABAergic effects with respect to rho subtypes and may also shed 
light on the structural organization of the pore of rho receptor, the permeability and 
ion selectivity of the channel.   
Indeed responses to lower concentrations of both GABA (1.25-2.5 μM) and ODN (15-
20 ηM) application were antagonised by TPMPA (80 μM) and not fully antagonised 
by GABAA receptor antagonist; bicuculline. So there is evidence of combination or 
coassembly of both receptors in the ependymal cells.  
 
3.4.4 Responses to GABA can be further modulated by 
endogenous peptides 
One potential site of modulation of GABA receptors is through the polypeptide 
discussed in the introduction, diazepam binding inhibitor (DBI). Two main breakdown 
products of DBI are triakontetraneuropeptide (TTN) and the octadecaneuropeptide 
(ODN). ODN is reported to have an action on central type benzodiazepine receptors 
(CBR) (Slobodyansky et al., 1989; Ferrero et al., 1986), while TTN activates 
peripheral type benzodiazepine receptors also known as translocator protein (TSPO).  
There was strong DBI and TSPO immunofluorescence located around the central 
canal area of spinal cord. DBI immunopositive staining extended into the fibres of 
these cells in particular for the case of the DBI-immunofluorescence, whereas TSPO 
immunofluorescence was markedly positive at most of the neural stem cells in nestin-
GFP mice. DBI immunopositive structures were found in embryonic slices of rodents 
and extended until postnatal age at the ventral and lateral white matter (Dickinson et 
al., 1996). Very sparse immunostaining was seen in the central canal area, compared 
to our study here. Extensive work by Dumitru et al. (2017) showed positive 
immunostaining in neural stem cells of SGZ and tanycytes in the third ventricle. Tonon 
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et al. (1990) used a different antibody complex that is rabbit antiserum to ODN, goat 
anti-rabbit gamma-globulins and the peroxidase-antiperoxidase (PAP) complex. 
ODN-immunoreactive structures were detected in glial and ependymal cells of the 
brain. Our finding showed extensive expression of DBI and TSPO in the region of the 
central canal neural stem cells possibly at the ependymal cell membrane.  
An important initial finding has been made to demonstrate the reduction of GABA 
induced Cl- currents by DBI in a study by Bormann et al. (1985), using cultured 
mammalian unidentified spinal cord neurons. Bormann et al. (1985) reported that 
reduction of GABA responses by DBI did not occur in the presence of DBI antagonist, 
flumazenil. DBI is indeed mediated by benzodiazepine receptors, rather than due to 
direct blockade of the Cl- channel by the DBI peptide itself (Bormann, 1991).  
Using the non-selective modulator, midazolam which acts on both CBR and TSPO 
(Tokuda et al., 2010), the responses to GABA were reduced. In characterising which 
subunits in the GABA receptor formed the binding site for midazolam using 
expression studies comprised of different subunits, it was found that in cells 
expressing the γ2 subunit with α1 and β1 subunits, midazolam produced high-affinity 
binding for CBR ligands (Pritchett et al., 1989). The fact that the responses to high 
concentration of GABA were modulated by midazolam suggests a potential 
involvement of central benzodiazepine receptors as shown by decreases in GABA 
responses with midazolam activity but does not rule out a role for TSPO as well. To 
test whether some of the response was due to activation of TSPO, FGIN-1-27, a 
selective TSPO agonist was applied. In our experiments, FGIN-1-27 (1 μM) also 
increased the GABA mediated response in ependymal cells to the higher 
concentration (400 μM) of GABA.  
The fact that the responses to GABA are inhibited by midazolam while the response 
to GABA is augmented by FGIN-1-27 suggests that the effect at the CBR 
predominates with midazolam, causing an overall inhibition. However, the responses 
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of GABA in the presence of ODN did not show significant changes regardless of the 
GABA concentration used. Even though our results with benzodiazepine receptor 
ligand ODN did not show any significant results, it was interesting that in cells 
responding to GABA by depolarising, the effects were reduced with ODN without quite 
reaching significance. This lack of effect of ODN is in sharp contrast to GABA 
responses in the sub ventricular zone where GABA responses in neural stem cells 
were significantly reduced by the same concentration of ODN that we applied (Alfonso 
et al., 2012). The reduction in GABA currents induced by ODN was strongly 
diminished in gamma2 F77I mice which represent a mutation in the gamma2 subunit 
of GABAA receptor that decreases binding to the benzodiazepine binding site. Their 
mouse line constitutes an optimal system to test whether DBI modulates 
neurogenesis via the GABAA receptor. In our observations, using C57BL/6 mice, 
ODN with the dose of 20 μM causes both depolarisation and slow hyperpolarisation 
effects on ependymal cells. The spill over of ODN into both synaptic and peri-synaptic 
effects on the cell may affect CBR and TSPO simultaneously. It may be therefore that 
the GABAA receptors are not in the appropriate configuration to enable binding of 
ODN to the CBR alone. One cannot exclude the possibility of ODN acting via TSPO 
or via its function as acyl-CoA esters reservoir even though ODN only binds with low 
affinity to TSPO. Another option to directly test the effects of activation of the CBR on 
responses to GABA, rather than inhibiting binding at this site, which is how ODN 
exerts its effects would be to use diazepam, which produces a biphasic potentiation 
of GABA receptor especially at receptors containing α1β2γ2 subunits (Walters et al., 
2000). The experiments by Walters et al. (2000) were done on Xenopus Laevis 
oocytes and parameters were obtained from fitting the incorporation of different 
subunits. The nanomolar component of diazepam action depends on the presence of 
the γ subunit and their ρ1 receptor channels are insensitive to diazepam. This 
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experiment would at least elucidate whether it is possible to enhance GABA 
responses through an action at the CBR. 
To test the effects of activating TSPO alone, FGIN-1-27 was used. With FGIN-1-27, 
GABA responses increased significantly. So there is a positive modulation likely 
mediated through TSPO. We also tested using a combination of FGIN-1-27 and PK-
11195; and this combination of TSPO agonist and antagonist, had no overall effect 
on amplitude of GABA responses, thus positive modulation of GABA was reduced as 
TSPO were blocked by PK-11195. An action of GABA on TSPO can promote the 
synthesis of GABA-enhancing neurosteroids. In a study by Tokuda et al. (2010) using 
hippocampal slices, activation of TSPO by the selective agonist FGIN-1-27 caused 
neurosteroidogenesis, observed as an increase in the intensity of allopregnanolone 
immunofluorescence, within just 30 minutes of application. Next, Tokuda et al. (2010) 
used finasteride to function as a neurosteroidogenesis inhibitor and showed that this 
blocked the increased levels of neurosteroidogenesis in response to midazolam so 
they suggested that a component of the effect of midazolam is to stimulate 
neurosteroidogenesis, presumably via the TSPO. Therefore a further experiment 
here would be to test this directly, using FGIN-1-27 in the presence of finasteride to 
investigate whether in the spinal cord, activation of TSPO may stimulate 
neurosteroidogenesis. I also studied the effects of application of a neurosteroid, 
allopregnanolone on responses of cells to GABA. The potency of allopregnanolone 
is dependent on the subunit composition of the GABA receptors (Belelli et al., 2002) 
and so two concentrations were tested here. The lower concentration is more likely 
to act at receptors that include α1 and α3 subunits plus β1 and γ2 while the higher 
concentration is likely to also target those receptors containing α2, α4 and α5. We did 
show, that the responses of GABA were increased in ependymal cells in the presence 
of both high and low concentration of allopregnanolone (1 µM and 10 nM) but this did 
not reach significance for either situation. This was surprising since many studies 
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have showed that allopregnanolone has a permissive effect on modulating responses 
of GABA receptor activation (Puia et al., 2003; Pinna et al., 2000). The lack of 
response may be due to a high degree of variation in the amplitude of the responses 
of ependymal cells to GABA, both before and after allopregnanolone, especially since 
the n numbers are low (n = 5 and 4 for the high and low concentrations respectively). 
The allopregnanolone mechanism of action on GABAA is concentration dependant. 
In lower nanomolar concentrations it acts allosterically while at higher concentration 
(micromolar range) it directly gates the GABAA receptor complex (Puia et al., 2003; 
Callachan et al., 1987). Furthermore neurosteroids may directly gate GABAA receptor 
also at lower concentration at around 100 nM (Shu, H.-J. et al., 2004). My doses of 
allopregnanolone: 1 µM and 10 nM may act both as allosteric modulators and directly 
at the GABAA receptor but neither of these mechanisms would explain our lack of 
significance. 
The positive modulation of allopregnanolone on GABA receptor is thought to be due 
to allosteric modulation and also in hybrid system, increasing both frequency and 
duration of the chloride channel opening (Lambert et al., 2009). However it is possible 
that allopregnanolone may become sulphated since the enzyme 3α-hydroxysteroid 
sulfotransferase is present in tissue (Driscoll et al., 1993) and thus some of the effects 
of the this drug are due to its sulphated metabolite. This is relevant since sulphated 
neurosteroids have been shown to antagonize GABAA receptors in a non-competitive 
manner where allopregnanolone inhibits channel activity in either a closed state prior 
to GABA agonist activation or in an open state, such as blocking activity in instances 
where GABA is bound (Akk et al., 2001). With high concentration of GABA, the effects 
of sulphated neurosteroids is thought to be due to the different binding site and 
mechanism (synaptic) and due to this (which depends on the subunit type of 
receptor), this group of neurosteroids can serve as a homeostatic balance to the 
positive modulator (Reddy and Kulkarni, 1998). More recently, the sulphated 
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neurosteroids may display biselectivity of modulation on GABAA as well due to the 
presence of δ and γ subunit (Shu, H.J. et al., 2012). So the effects of neurosteroids 
are primarily affected by GABA subunit rather than the binding site of GABA receptor.  
Our observations on low GABA concentrations showed no significant effect with 
modulators such as FGIN-1-27, ODN and allopregnanolone (1 µM and 10 nM). Most 
of GABAρ receptor studies did not use FGIN-1-27 and ODN as modulators, while a 
study with low GABA concentration action with neurosteroids found out that there is 
differential modulations of ρ1 receptor channel (Morris et al., 1999). However, 
neuroactive steroids can modulate the ρ1 subunit in xenopus laevis oocytes (Morris 
et al., 1999). The modulation of ρ1 receptors by neurosteroid compounds was 
dependant on GABA concentration. These effects were prominent in the presence of 
low concentrations of GABA (0.2-0.4 μM). The differential modulation by 
neurosteroids depends on the type of derivatives. The 5α derivatives 
(allopregnanolone, alphaloxone and 5α-tetrahydro- deoxycorticosterone (5α-
THDOC)) were potentiators of GABAρ while the 5β compounds (5β-tetrahydrodeoxy- 
corticosterone (5β-THDOC), 5β-Dihydroprogesterone; 5β-DHP) were the inhibitors to 
GABAρ. Morris et al. (1999) showed the 5α derivatives potentiate and prolong decay 
time whereas 5β compounds were inhibitors of GABA currents. Morris et al. (1999) 
hypothesised that this was because of the difference in the structure component of 
hydrogen atom in the neurosteroid itself. The structural differences of the 
neurosteroids can influence the relative position within their effector site which can 
influence ρ1 ion channel in an opposing way (Morris et al., 1999). Finally the effects 
of the neuroactive steroids on ρ1 receptor were shown to be long lasting because the 
application of GABA did not return to the control level for few minutes after 
neuroactive steroid treatments. In contrast, these effects of neurosteroid modulation 
did not occur in an earlier study by Woodward et al. (1992) using GABA (1-2 μM) on 
retina RNA of Xenopus oocytes. Our allopregnanolone doses may have similar 
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structure components but maybe due to different doses used, the degree of 
modulation may be different.  
These suggests that the rho containing receptors are not modulated in the same way 
as the GABAA receptor. 
 
3.4.5 How can ODN be exerting direct effects on ependymal 
cells? 
ODN immunopositive staining using ODN antibodies supplied by Tonon et al. (1990), 
(1:500) on Nestin-GFP mouse showed ODN is expressed in the central canal area of 
spinal cord. No previous immunofluorescence study using ODN antibodies has been 
done in spinal cord. ODN can be detected in non-neuronal cells throughout the rat 
brain and it was restricted to glial ependymal cells (Tonon et al., 1990). Different 
results have been obtained by Alho, H et al. (1989) who, using antibodies against 
DBI, found that immunostaining was associated with neurons in several brain regions 
that are hypothalamus, amygdala, hippocampus and cerebellum. Furthermore in later 
studies, cultured astrocytes are strongly labelled with specific ODN antibodies 
(Lamacz et al., 1996). 
On further characterising the modulation of GABA responses through an effect on 
CBR, direct responses of the cell to ODN were observed.  This was of interest since 
ODN, which exert anxiogenic activity, has been previously shown to increase 
intracellular calcium concentration in cultured rat astrocytes through activation of a 
metabotropic receptor, not the CBR (Leprince et al., 1998; Gandolfo et al., 1997). The 
nanomolar concentration was found to induce marked increases in Ca2+ in cultured 
rat astrocytes (Lamacz et al., 1996). Cultured astrocytes were also found in their 
experiments to release substantial amounts of ODN, which showed evidence of an 
ability of astrocytes to synthesize DBI in vitro. They were able to block the effect of 
 
 
167 
 
ODN on Ca2+ with pertussis toxin. However, the surprising finding using ODN from 
our study was that, when puffed alone at nanomolar concentration, ODN caused 
fast hyperpolarising responses in ependymal cells that were strikingly similar to those 
elicited by the lower concentrations of GABA and TACA responses.  
In our study, the effects of ODN puff showed no location specificity in the central canal 
area. Our responses to nanomolar ODN were significantly but not fully blocked by 
cyclo1-8[dleu5]OP. Cyclo1-8[dleu5]OP is an ODN metabotropic receptor antagonist, 
so a component of the responses may be due to an action at this receptor, which in 
turn may elicit calcium influx but it is still surprising that the effect is hyperpolarising, 
rather than depolarising, as would be expected with calcium influx. One possible 
explanation may be that ODN is somehow directly activating the GABA receptors that 
contain rho subunits since the hyperpolarising effects of ODN were significantly 
blocked by TPMPA. Our ODN did not show any significant blockade with other 
antagonists, modulators or channel blockers. So there is an evidence there are 
atypical GABA receptors responsible for this action with ODN. 
One study of interest to us, showed that ODN protects astrocytes against hydrogen 
peroxide induced apoptosis (Hamdi et al., 2012). Their ODN seemed to reside on the 
cell membrane of astrocytes and keep the cell membrane integrity. It would be 
interesting to see if application of ODN on spinal cord slices could act to protect 
ependymal cells against hydrogen peroxide induced apoptosis.  
 
3.4.6 How does GABA affect proliferation in the spinal cord? 
A study by Reali et al. (2011) showed the effects of GABA on BLBP immunoreactive 
progenitor cells that are found in central canal of turtle spinal cord. These cells appear 
to be similar to the ependymal cells observed surrounding the mammalian central 
canal (Corns et al., 2013; Marichal et al., 2012; Meletis et al., 2008). Many studies 
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carried out in brain showed that GABA was able to control proliferation of cells in 
subventricular ventricular zones (SVZ) and dentate gyrus (DG) (Wang, D. et al., 2003; 
Haydar et al., 2000). It is reported that GABA reduced the number of BrdU labelled 
cells in the SVZ. Similar outcomes were reported by Nguyen et al. (2003) where 
GABA reduced the number of BrdU- incorporated neural progenitor cells compared 
to control and by (Tozuka et al., 2005); GABAA receptor agonists decreased while the 
antagonist increased the BrdU labelled progenitor cells. Even though those studies 
conclude that GABAergic inputs had blocked the cell cycle progression and further 
neurogenesis, GABA is indeed an important regulator of neurogenesis in 
subventricular zone and dentate gyrus. Moreover, with the findings in Corns et al. 
(2013), GABA acts significantly on spinal ependymal cells and GABA in this study 
showed significant increase in amplitude with modulation of FGIN-1-27; the selective 
agonist at TSPO, which is thought to induce neurosteroidogenesis (Tokuda et al., 
2010). In SVZ, DBI negatively modulates the activity of the GABAA receptor in transit 
amplifying cells and enhances their proliferation through this mechanism and not 
through its binding to TSPO. Similar action is seen in SGZ NSCs and transit 
amplifying cells through binding to the GABAA receptor and enhances the proliferation 
of NSCs (Dumitru et al., 2017). In other unpublished experiments in our research 
group (New, Deuchars and Deuchars), we have shown that midazolam can modulate 
the levels of cell proliferation in the spinal cord. So GABA through GABAA receptor 
can enhance proliferation of NSCs. 
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3.5 Conclusion 
 
This study concludes that the ependymal cells surrounding the central canal of 
postnatal mammalian spinal cord showed the characteristics of neural stem cells as 
previously described with extensive gap junctions. The presence of gap junctions 
showed that this cell functioning unit was through a group of cells and not as a single 
unit. The ependymal cells responded to the neurotransmitter GABA possibly through 
expression of multiple combination of subunits and multiple receptors. Ependymal 
cells in our study showed atypical GABA receptors since it was not blocked by GABAA 
receptor antagonist; bicuculline while hyperpolarising responses to low GABA were 
antagonised by the GABAρ receptor antagonist, TPMPA. With TACA, a selective 
agonist of GABAρ1, GABA responses may partially being blocked and this provides 
evidence of a combination or coassembly of GABAA and ρ receptors in the 
ependymal cells or the presence of two different receptors.  
The modulation of GABA receptors is through multiple sites on the subunit and 
membrane of the cell including both CBR and TSPO. DBI, TSPO and GABA regulate 
spinal cord neurogenesis in a close partnership. The balance between DBI 
polypeptide action, and actions through other GABA receptors then may be able to 
balance the modulation of the GABA in neurogenesis.
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Chapter 4  
Activation of GABAB receptors in ependymal cells  
 
4.1 GABAB receptors 
 
GABAB receptors belong to the G-protein coupled receptors (GPCR) family that act 
slowly and maintain the inhibitory tone (Bettler et al., 2004). The GABAB complex were 
composed of GABAB1 and GABAB2 subunit with a 1:1 stoichiometry and both are 
required in forming functional receptors (McCarson and Enna, 1999). Results from 
recombinant studies suggest that the GABAB1 subunit provides the G-protein coupling 
site whilst the GABAB2 subunit is necessary for both cell surface expression and agonist 
activation (Margeta‐Mitrovic et al., 1999; Jones et al., 1998).  
The GABAB1 subunit exists in two isoforms (GABAB1A and GABAB1B) which are 
generated from GABAB1 gene by differential promoter usage. GABAB receptors can 
modulate activity of voltage gated calcium channels thereby regulating neuronal 
excitability (Ulrich and Bettler, 2007). 
Within SGZ of adult mouse hippocampus, GABAB receptors are expressed by multiple 
cell types including neural stem cells, neuroblasts and newborn neurons and GABAB 
receptor activation is able to inhibit dentate gyrus neural stem cell proliferation (Giachino 
et al., 2014), while chronic antagonism of this receptor increased cell proliferation in the 
ventral but not dorsal hippocampus (Felice et al., 2012). Expression of GABAB in the 
SVZ area has not been well addressed but GABAB receptor blockade has been 
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observed in SVZ to influence which the migration of tangential interneurons (López-
Bendito et al., 2003).  
Little is known about the role of GABAB receptors in spinal cord proliferation but they 
are widely expressed in the spinal cord (Wang, L. et al., 2008) and may have effects on 
the neurogenic niche of the spinal cord. Several studies provide evidence for the 
influence of GABAB receptors on neurogenic niches in the brain (Jurčić et al., 2018; 
Giachino et al., 2014; Felice et al., 2012) and a study on brainstem CSFcCs showed 
GABAB receptor mediated effects on these cells (Jurčić et al., 2018). However no-one 
has looked at the contribution of these receptors in the neurogenic niche of the spinal 
cord.  
 
4.2 Hypothesis and aims 
 
As ependymal cells have been shown to respond to GABA in the previous chapter, the 
aim of this chapter is to establish whether ependymal cells in spinal cords from mice 
aged P8-P15 also express GABAB receptors. This was determined using both 
electrophysiology and immunofluorescent methods. The main hypothesis of this chapter 
is that ependymal cells are capable of responding to baclofen, an agonist of GABAB 
receptors and that antagonism of this receptor can affect the responses of these cells 
to baclofen. Furthermore, since previous reports have shown that activation of GABAB 
receptors can inhibit neurogenesis in other neurogenic niches, I hypothesise that 
application of baclofen will reduce ependymal cell proliferation in spinal cord slices
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4.3 Results 
 
4.3.1 GABAB1A subunits were expressed in central canal of spinal 
cord 
GABAB1 immunopositive punctate staining was observed throughout the region of the 
central canal and especially observed in close apposition to cells expressing the 
ependymal cell marker (CD24) (Figure 4-2 A), or near GFP positive cells in GAD-GFP 
mouse (Figure 4-2 B). At high magnification (x40), it is not known whether the 
immunofluorescent structures close to the cells are either in the membrane or in close 
appositions onto the membrane, which would signify post and pre-synaptic labelling 
respectively. 
The GABAB1 staining was found throughout the central canal region and did not show 
any regional localisation. This is relevant when considering the locations of the cells 
that were tested for responses to baclofen.  
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Figure 4-1 GABAB1A immunopositive staining at the central canal of spinal cord 
Fluorescence immunohistochemistry using GABAB1A antibody together with 
antibodies for ependymal cell marker (CD24) (A), or on GAD-GFP mouse (B) in the 
central canal area. There are close appositions of the GABAB1A immunopositive 
punctate structures with both ependymal cells and CSFcCs in central canal (cc).
10 µm 10 µm
GABAB1a GABAB1a
CD24 GADGFP
A B
CC 
CC 
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4.3.2 Hyperpolarising effects of baclofen on ependymal cells in 
the spinal cord 
To determine the effects of activation of GABAB receptors, baclofen was applied in 
the bath solution. The effects of bath application of baclofen were tested on 15 
ependymal cells located at different sites around the central canal (Figure 4-3). 
Regardless of their position, 15 cells responded to baclofen with a hyperpolarisation. 
No ependymal cells were depolarised by baclofen. In response to 1 µM baclofen, the 
hyperpolarisations were on average -0.91 ± 0.11 mV in amplitude (Figure 4-3 A) while 
the higher dose 5 µM were on average of -0.73 ± 0.15 mV in amplitude (Figure 4-3 
B). No significant differences were observed between the amplitudes in response to 
the 2 concentrations (p=0.37).  
The hyperpolarising effect could be antagonised by the selective GABAB antagonist 
CGP 55845 (200 nM) since the hyperpolarising response to baclofen was reduced 
from -0.91 ± 0.11 mV to -0.27 ± 0.07 mV (*p≤0.05, n=11, Figure 4-3 A & Ai) for 
baclofen (1 μM) and from -0.73 mV ± 0.15 to -0.11 ± 0.07 mV (*p≤0.05, n=4, Figure 
4-3 B & Bi) for baclofen (5 μM).
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Figure 4-2 Effects of baclofen on ependymal cells 
Effects of baclofen (1 μM) (A) and (5 μM) (B) with CGP 55845 (200 nM) on ependymal 
cells. Both baclofen (1 μM) and (5 μM) caused hyperpolarising responses in 
ependymal cells and these were antagonised with the selective GABAB antagonist 
CGP 55845 (200 nM) (Ai & Bi). Two concentrations are used to confirm if there is any 
difference. (*p≤0.05, n = 11 for baclofen (1 μM) and *p≤0.05, n=4 for baclofen (5 μM)). 
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To establish whether the location of the cell affected the response observed, 
ependymal cells were recorded from around the central canal and the location and 
response were noted. It was clear that there was no location-specific response profile 
(Figure 4-4). This fits well with the immunofluorescent data showing that GABAB1A  
immunopositive staining was located around the whole of the central canal. 
 
 
 
 
 
Figure 4-3 Location of ependymal cells exhibiting the responses to baclofen.  
Whole cell patch clamp recordings were taken from throughout the area of the central 
canal. There is no location specificity for the responses observed. Baclofen 5 µM and 
1 µM were applied in the bath solution.
baclofen 5 µM hyperpolarisation
baclofen 1 µM hyperpolarisation
D
V
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4.3.3 Activation of GABAB receptors decrease levels of 
proliferating cells in the central canal area 
Since the responses to baclofen were always hyperpolarising, we were interested to 
know whether activation of the GABAB receptor with baclofen could affect the level of 
proliferating cells in the neurogenic niche. Using EdU as a marker of cell proliferation 
and applying baclofen at two different concentrations (1 and 5 µM) to spinal cord 
slices incubated for 4 hours, there was a significant reduction in the numbers of newly 
proliferating cells in those sections treated with baclofen compared to control slices 
((control=2.81 ± 0.21 cells/50 µm section, 5 µM=1.91 ± 0.15 cells/50 µm section and 
1 µM=1.79 ± 0.17 cells/50 µm section), N=4 mice, n = 237 sections) (Figure 4.5). The 
slices were viewed using a fluorescent microscope and images were noted to show 
reduced numbers of fluorescently labelled cells in the area of central canal for both 
concentrations of baclofen (1 μM) and (5 μM) (Figure 4.6).  
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Figure 4-4 Effects of baclofen on EdU-labelled cells in the central canal area 
Bar chart showing the numbers of EdU-labelled cells in the central canal area for each 
group; control, baclofen (5 μM) and baclofen (1 μM). The numbers of EdU-labelled 
cells in baclofen (1 μM) and baclofen (5 μM) treated slices were reduced significantly 
when compared to control. There is no difference between baclofen (1 μM) and 
baclofen (5 μM). (*p≤0.05, N=4 mice, control; n=74 slices, baclofen (1 μM); n= 84 
slices and baclofen (5 μM); n= 79 slices.)  
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Figure 4-5 Fluorescent images of central canal of spinal cord show reduced 
numbers of EdU labelled cells after baclofen treatment 
EdU-labelled cells were labelled using the streptavidin 555 and appeared red in colour 
and scattered throughout the whole area of spinal cord (A) but especially high in the 
central canal region. Sections treated with baclofen showed sparse to no EdU 
labelling in the central canal region (B). Images orientated with dorsal pole of the 
central canal (cc) at the top.    
CC 
50 µm 
CC 
50 µm 
A 
B Baclofen 1 µM 
control 
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4.4 Discussion 
 
4.4.1 GABAB receptors are expressed in neurogenic niche of 
spinal cord 
In-situ hybridisation and immunohistochemistry in the rat revealed that GABAB1 
receptors were differentially distributed throughout spinal cord predominantly in 
laminae II and IX while GABAB2 receptors were evenly distributed throughout the 
spinal cord including lamina X (Towers et al., 2000). In this chapter, we have shown 
that GABAB1A immunopositive structures form close appositions with ependymal 
cells, which are the putative neural stem cells in the central canal area. CD24, the 
marker used in this study is an ependymal cell surface marker (Pfenninger et al., 
2011; Calaora et al., 1996). The GABAB1A immunopositive structures also seem to 
form close appositions near the stained GAD-GFP cells suggesting that GABAB 
receptors may influence CSFcCs, although this was not studied here. It would be 
possible to further confirm inputs onto ependymal cells using the nestin-GFP mouse 
described in chapter 5 to see if the GABAB receptors form close appositions with the 
nestin positive cells. Nestin is a marker of undifferentiated neural cells in both the 
developing and adult nervous systems but mostly indicate more immature ependymal 
cell phenotype (Hamilton et al., 2009). All the immunostaining results are not 
conclusive to show whether the immunofluorescent structures close to the cells are 
either in the membrane or in close appositions onto the membrane. So in future plans, 
a study using electron microscopy could be carried out, either using fixed sections as 
described here or even using cells filled with neurobiotin and then fixed to see whether 
those cells that respond to baclofen express the GABAB subunits at the electron 
microscopic level.   
 
 
181 
 
In this study, whole cell patch clamp recordings were made from ependymal cells in 
the central canal area in order to investigate GABAergic inhibition through GABAB 
receptor. The use of 1 and 5 µM doses of baclofen is to determine any discriminative 
responses to these concentrations of the agonist baclofen based on previous studies.  
In spinal cord slices, sympathetic preganglionic neurones showed 2 different 
responses to low concentrations (1 µM) of baclofen, with small amplitude 
hyperpolarisations being reduced in low Ca2+ solutions or cadmium, suggesting that 
the response was due to closure of calcium channels. Larger amplitude 
hyperpolarisations were observed in other cells that were mediated by opening of 
potassium channels (Wang, L. et al., 2010). They considered that these responses 
may be due to differences in the subunits of the receptors underlying these 
responses. This idea was feasible since baclofen at low concentrations (1 µM) is often 
used to stimulate receptors with high affinity such as presynaptic receptors (Brooks 
and Glaum, 1995) that act to close calcium channels and reduce the neurotransmitter 
release and these are most likely to express GABAB1A (Vigot et al., 2006). However 
baclofen at high concentration (5 µM) can alter postsynaptic membrane excitability in 
dorsolateral septal nucleus (Yamada et al., 1999) and these express GABAB1A (Vigot 
et al, 2006) and often involve opening of potassium channels. Ependymal cells 
however, did not respond differently to either concentration of baclofen unlike that 
observed in sympathetic preganglionic neurones (Wang, L. et al., 2010). In our 
observation, so far there are no cells that fail to respond to baclofen. The mean 
amplitude of baclofen effects in our study using 2 different concentrations showed no 
significant difference. In fact, both concentrations resulted in small hyperpolarisations, 
reminiscent of the responses of sympathetic preganglionic neurones that were 
mediated through closure of calcium channels and thus likely to involve GABAB1A 
receptors expressed in the postsynaptic membrane. This suggests that in ependymal 
cells, only GABAB1A containing receptors are present and this fits with our 
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immunofluorescence experiments showing GABAB1A immunopositive structures in 
the central canal area, although the presence of GABAB1B subunits was not tested 
due to a paucity of good antibodies. It is possible that the age of the mice used in 
these experiments affected these responses, since GABAB1B expression increases 
during the first postnatal month in the brain (Fritschy et al., 1999) while GABAB1A is 
predominant during embryonic period and at birth during first two postnatal weeks 
(Khoshdel-Sarkarizi et al., 2019). The immunofluorescence studies were done in 
adult mice, suggesting that the GABAB1A is still present into adulthood. However an 
explanation for only observing small responses in our electrophysiology experiments 
may be that the levels of GABAB1B subunits are very low compared to GABAB1A at the 
age of animals used and so only small responses were observed. It is also possible 
that the small response observed in the ependymal cells was due to 
hyperpolarisations of the coupled cells which were then conducted through gap 
junctions to hyperpolarise the recorded cell.  
 
4.4.2 Responses to baclofen were antagonised by CGP 55845, a 
selective GABAB antagonist 
As described in Chapter 3, bicuculline could not completely antagonise the 
GABAergic response, even at high concentration of 100 µM. This suggested that 
there was another receptor or transporter contributing to the mediation of GABAergic 
responses. Baclofen was applied in the bath solution and always caused a 
hyperpolarising response in ependymal cells tested. A small yet robust and 
reproducible hyperpolarising response to baclofen suggests that ependymal cells do 
express GABAB receptors.  
CGP 55845 is a selective GABAB receptor antagonist. CGP 55845 was found to be 
the most potent GABAB receptor antagonist tested in a study using hemisected spinal 
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cord (Brugger et al., 1993) so this is convincing evidence that the GABAB receptor is 
present. 
 
4.4.3 Activation of GABAB receptors affect levels of proliferation 
in central canal area 
Since baclofen had effects on ependymal cells, we tested whether activation of 
GABAB receptors could affect proliferation. In the presence of baclofen, the numbers 
of proliferating cells in the area of central canal, identified using the EdU click 
chemistry method, were significantly lower than numbers in control slices. Once 
again, there was no significant difference between the two concentrations. Such a 
role for GABAB receptors has been suggested in other brain regions and cells 
(Giachino et al., 2014; Felice et al., 2012; Luyt et al., 2007; Magnaghi et al., 2004) 
and deserves further investigation.  
 
4.4.4 GABAB receptor modulation of neurogenesis in other 
neurogenic niches  
Felice et al. (2012) showed the evidence of modulation of GABAB receptors may 
affect adult neurogenesis in hippocampal dentate gyrus. Their work showed that 
chronic treatment of the GABAB antagonist CGP 52342 causes an increase in cell 
proliferation in the SGZ area without affecting cell survival. The neurogenic effects of 
GABAB receptor inhibition affect the ventral hippocampus which is responsible for 
stress and emotion regulation. This showed a link between antidepressant and 
neurogenic GABAB receptor blockade. A recent study was carried out by Giachino et 
al. (2014) where they used GABAB genetic deleted mice GABAB1-/- or GABAB2-/-. 
Impairing GABAB signalling pharmacologically or in mice deficient for GABAB1 
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receptor gene, increases the cell proliferation in dentate gyrus while activating GABAB 
receptors has the opposite effect (Giachino et al., 2014). Similar to Felice et al. (2012), 
cell survival was unaltered in GABAB1 knockout mice. In GABAB1 deficient mice, the 
ability to modulate GABA release may be altered. This suggests that activation of 
GABAB may synergistically work with GABAA receptor to mediate the antimitotic 
effects of GABA. The modulation of proliferation and differentiation by GABAB 
receptor may be an interesting future therapeutic target for conditions where there is 
over proliferation such as in spinal cord ependymomas or in conditions such as in 
multiple sclerosis where replacement cells may be useful to aid recovery. 
 
4.4.5 GABAB receptor in neurotransmitter signalling. 
GABAB couples to G proteins as evidenced in several studies. GABAB receptors 
predominately couple to G1α and Goα-type G proteins. GABAB receptors were able 
to modulate opening of calcium channels at the cell membrane as well as intracellular 
calcium mobilisation in pyramidal neurons of postnatal rats (Gaiarsa et al., 1995). 
Other than coupling to Ca2+ channels, GABAB receptors also couple to K+ channels 
and induce slow inhibitory postsynaptic currents through opening of GIRK channels. 
The physiological effect of GIRK is normally a K+ efflux resulting in a 
hyperpolarisation. Presynaptic GABAB receptors seem to be coupled to GIRK 
channels in immature granule neurons of hippocampus and activation of GIRKs can 
induce changes in membrane excitability and affects cellular processes (Cabezas et 
al., 2012). G1α and Goα-type G proteins inhibit adenylyl cyclase types I, III, V and VI 
(Simonds, 1999) while Gβγ stimulates adenylyl cyclase types II, IV and VII (Tang and 
Gilman, 1991) and the stimulations depend on the presence of Gsα. Through cAMP 
signalling and adenylate-cyclase activity, GABAB receptors regulate neural 
development in perinatal period of pyramidal neuron progenitors (Bony et al., 2013). 
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Using ELISA immunoassay, and measurement of cAMP levels after bath application 
of GABAB receptor agonist or antagonist similar to that by Bony et al. (2013) would 
be beneficial to add on to our experiments to see any involvement of cAMP mediated 
signalling. The cAMP pathway also can be potentiated by GABAA receptors as in 
activation of GABAA receptor in SGZ neurogenic niche. Thus the adenylate-cyclase-
cAMP pathway is a point where there is a crosstalk of GABAA and GABAB receptor 
in neurotransmitter signalling. 
 
4.5 Conclusion 
 
This study concludes that the ependymal cells surrounding the central canal of 
postnatal mammalian spinal cord express GABAB receptors and the pharmacological 
activation of GABAB receptors decreased neural stem cell proliferation. Our data 
indicate that signalling through GABAB receptors is an inhibitor of postnatal 
neurogenesis.
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Chapter 5  
Effects of serotonin on ependymal cells 
 
5.1 Introduction 
 
5-hydroxytryptamine, (5-HT) is a phylogenetically ancient neurotransmitter that 
appears early in development and extends widely throughout the brain. The 
distribution of 5-HT receptor subtypes in the spinal cord is heterogeneous. There is 
evidence for postnatal neurogenesis in the brainstem and central canal area of the 
spinal cord but whether 5HT influences this is not known. 
5-HT has been reported to regulate adult neurogenesis (Banasr et al., 2004). The 
depletion of serotonin in the brain of adult rodents decreases neurogenesis in the 
hippocampal dentate gyrus (Brezun and Daszuta, 1999). 
Previous research has highlighted 2 specific 5-HT receptors in the modulation of adult 
neurogenesis in the hippocampus; 5-HT1A and 5-HT2 and this research is discussed 
in detail in section 1.9.2 of the Introduction. Research was carried out on the role of 
different receptors by using agonists, antagonists and partial agonists. Knockout mice 
were also used to investigate the involvement of 5-HT1A receptors. 
A previous report has shown that there is no effect of 5-HT on CSFcCs of spinal cords 
(Laura Corns, unpublished data), and in fact these cells were found not to express 5-
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HT in the rat and mouse spinal cord, unlike the situation in lower vertebrates (Nagatsu 
et al., 1988).  
Unpublished data from our lab has also shown that cisapride (5-HT4 agonist) 
application in acute spinal cord slices resulted in higher numbers of proliferating cells 
in central canal of spinal cord compared to control. 
Since 5-HT1A, 5-HT2 and 5-HT4 receptors have been shown to have established 
effects on neurogenesis, this section will elaborate on the effects of activating or 
antagonising these receptors on ependymal cells since they are considered the 
neural stem cells of central canal neurogenic niche. 
 
5.2 Hypothesis and aims 
 
This chapter aims to determine whether activation of 5-HT receptors can depolarise 
or hyperpolarise ependymal cells of spinal cord. If the activation of these receptors 
does, they may have the potential to influence neurogenesis in spinal cord. The direct 
or indirect action of 5-HT on postnatal neurogenesis and the cascade involved to 
promote neurogenesis is still unclear. Since 5-HT expressing axons are known to 
project onto the supra-ependymal surface of lateral ventricles (Tong et al., 2014; 
Aghajanian, G.K. et al., 1975), we tested whether similar projections onto ependymal 
cells occur in the area of central canal of spinal cord. My first hypothesis was that 5-
HT fibres would be located in close proximity to the ependymal cells. The second 
hypothesis was that activation of specific 5-HT receptors may influence the activity of 
these cells. The 5-HT1A and 5-HT2 receptors were chosen because the 5-HT1A 
receptor agonist 8-OH-DPAT produces an increase in cell proliferation in the dentate 
gyrus (Arnold and Hagg, 2012; Klempin et al., 2010) and 5-HT2 receptor antagonist 
cinanserin induces an increase in cell proliferation (Klempin et al., 2010). Cisapride, 
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a 5-HT4 receptor agonist was also tested in the light of the changes in cell proliferation 
observed when this agonist was applied in acute slices.  
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5.3 Results  
 
5.3.1 Close relationship between 5-HTergic fibres and nestin 
positive cells in spinal cord in nestin-GFP mouse 
The relationship between neurogenic niches and 5-HTergic fibres is one of the factors 
that determine the likelihood of 5-HT modulating cell proliferation. To investigate this 
factor, 5-HT immunofluorescent staining was done on nestin-GFP (green fluorescent) 
spinal cord sections and the areas of close apposition noted. Nestin was used as a 
potential neural stem cell marker (Hendrickson et al., 2018; Wiese et al., 2004).  
Immunohistochemistry using a specific antibody against 5-HT (1:1000; RA 2000; 
Neuromics) revealed 5-HT immunofluorescent terminals observed in close apposition 
to ependymal cells (Figure 5.1). The numbers of ependymal cells with close 
appositions from 5-HT immunoreactive terminals were not quantified but it was clear 
that not every ependymal cell had labelled close apposition. To investigate whether 
ependymal cell could respond to 5-HT, it was bath applied to spinal cord slices.  
 
 
 
 
 
190 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1 Relationship between 5-HTergic fibres and nestin-GFP cells in 
nestin-GFP mouse.  
High power of fluorescent images of spinal cord showing 5-HT fibers in a spinal cord 
area in nestin-GFP mouse. 5-HTergic fibres (white arrows) are located near the 
central canal area (A). Nestin-positive neural stem cells (green) (B) 5-HTergic fibres 
closely apposed nestin-positive neural stem cells (red-squared boxes). Enlarged 
view of 5-HTergic fibres closely apposing nestin-positive neural stem cells (C), 
cc=central canal.  
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5.3.2 Ependymal responses to 5-HT 
As ependymal cells responded to GABA, their ability to respond to other 
neurotransmitters was investigated. In particular, an interaction between ependymal 
cells and 5-HT was examined due to previous reports of 5-HT containing terminals in 
the area surrounding the central canal (Rajaofetra et al., 1989). 
 
5.3.2.1 Responses to 5-HT are both depolarising and hyperpolarising 
Whole cell patch clamp recordings on ependymal cells revealed that 5-HT at a 
concentration of 10 µM caused either depolarisation or hyperpolarisation (Figure 5-
2). 18 of 27 cells tested responded to the application of 5-HT, the other 9 cells were 
not affected by this drug. The majority of responding cells (n = 13/18) were 
depolarised by 5-HT. The mean depolarisation was 1.71± 0.21 mV (n = 13) while the 
mean hyperpolarisation was -2.11 ± 0.56 mV (n = 5). 
The locations of cells responding to 5-HT with either depolarisations or 
hyperpolarisations were plotted (see Figure 5-3) and it was clear that there was no 
correlation between location and response type (Figure 5-3) in the medial and ventral 
regions, however only depolarising responses were observed in the dorsal 
ependymal cell region. 
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Figure 5-2 Responses of ependymal cells to 5-HT were either depolarisations 
or hyperpolarisations 
Examples of whole cell patch clamp recording of ependymal cells which were (A) 
depolarised and (B) hyperpolarised by 10 μM 5-HT. From 27 cells, 13 cells were 
depolarised by 10 µM 5-HT, 5 cells were hyperpolarised and 9 cells showed no 
response to 10 µM 5-HT. Pooled data are shown in C showed the depolarisations 
and hyperpolarisations cell number with mean amplitude.
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Figure 5-3 Location of ependymal cells exhibiting responses to 5-HT in central 
canal area 
Location of ependymal cells exhibiting the different responses to 10 μM 5-HT. 
Whole cell patch clamp recordings were taken from throughout the area of central 
canal. 5-HT was applied using the bath solution.
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5.3.3 Which 5-HT receptors were involved in responses observed 
in ependymal cells?  
A number of agonists and antagonists were used to establish which receptors may 
be underlying the responses to 5-HT. Since 5-HT2 receptors are known to be present 
in the spinal cord (Doly et al., 2004; Marlier et al., 1991), the effects of the 5-HT2 
antagonist; cinanserin on 5-HT induced depolarisations were determined on 8 cells 
that were depolarised by 5-HT. In seven of these cells, the 5-HT mediated 
depolarisations were significantly antagonised by 20 µM cinanserin, (1.63 ± 0.3 mV 
to 0.62 ± 0.2 mV, Figure 5-4).   
 
Figure 5-4 Depolarisations in response to 5-HT and were antagonised by 
cinanserin 
An example of recording from whole cell patch clamp traces demonstrating that the 
depolarisations in response to 5-HT (10 μM) were antagonised by cinanserin (10-20 
µM) (p≤0.05, n=7).
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Since unpublished results of in vitro experiments from Deuchars Lab revealed that 
sections of spinal cord treated with a full agonist at 5-HTR4 had higher numbers of 
proliferating cells, the effects of this drug on ependymal cell responses were 
determined. In slices treated with 5-HTR4 agonist (cisapride), two different 
experiments were conducted with different concentrations. Only when using 10 µM of 
5-HTR4 agonist (cisapride) were there significantly more EdU positive cells in central 
canal area compared to control (3.6 ± 0.3 vs 2.59 ± 0.2; p ≤ 0.05) (Ghani and 
Deuchars, unpublished observations). Therefore this concentration was used. 
When proceeded with the whole cell patch clamp recordings on ependymal cells with 
cisapride 10 µM and of 5 cells tested, only 1 cell responded with a very small 
amplitude hyperpolarisation (0.8 mV, Figure 5-5 A).   
The other receptor probed was 5-HT1A since Marlier et al. (1991) also reported that 
this receptor was expressed in the central region of the spinal cord. Of 6 cells tested 
with applications of the 5-HT 1A receptor agonist 8-OH-DPAT, only 2 responded with 
hyperpolarisations (Figure 5-5 B).The other traces showed no responses to 8-OH-
DPAT. 
This suggests that the major receptor mediating depolarisations is the 5-HT2 receptor 
while small hyperpolarisations are mediated through either 5-HT4 or 5-HT1A 
receptors. The locations of all cells tested and their responses showed little 
correlation between types of response elicited and the location of the cell recorded 
(Figure 5-6). 
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Figure 5-5 Responses of ependymal cells to cisapride and 8-OHDPAT 
Whole cell patch clamp trace demonstrates hyperpolarisation in response to 
cisapride (10 µM) (A). Whole cell patch clamp trace demonstrates the 
hyperpolarisation in response to 8-OH-DPAT (40 μM) (B). 
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Figure 5-6 Location of ependymal cells exhibiting the different responses to 5-
HT, agonist and antagonist.  
Whole cell patch clamp recordings were taken from throughout the area of central 
canal. There is little correlation between specificity for the type of response observed 
and location of the cell.Dorsal pole cells showed depolarisation whereas ventral and 
midline cells showed hyperpolarisations. 5-HT were applied locally in the bath 
solution. 
No effect of 5-HT
5-HT depolarisation
5-HT hyperpolarisation
8-OH-DPAT hyperpolarisation
No effect of 8-OH-DPAT
Cisapride hyperpolarisation
No effect of cisapride
5-HT depolarisation antagonised by cinanserin
D
V
 
 
198 
 
For summary, according to localisation of cell and the corresponding type of 
responses, hyperpolarisations occurred in the cells located mainly ventrally to the 
central canal and any effects of cisapride and 8-OH-DPAT were mainly in cells 
located around the midline of the central canal area (Figure 5-6). 
 
5.4 Discussion 
 
In this chapter, I have shown that 5-HT immunoreactive fibres form close appositions 
with the cells in the ependymal cell layer and furthermore that application of 5-HT can 
cause both depolarisations and hyperpolarisations of ependymal stem cells, which 
are mediated through activation of different 5-HT receptors.  
 
5.4.1 The presence of 5-HT fibres close to ependymal cells 
suggest a possible neuromodulatory role  
There is a close apposition of 5-HTergic fibres with Nestin-expressing neural stem 
cells localized at the central canal of spinal cord. Using nestin as neural stem cell 
marker that showed consistent results in a previous study (Hendrickson et al., 2018), 
nestin-GFP mice were used to identify the location of neural stem cells in the central 
canal of spinal cord. We observed that the nestin-GFP cells with high fluorescent 
intensity were confined to the central canal area. My findings suggest that 5-HT can 
influence the activity of nestin-positive neural stem cell as the position of these fibres 
is very close to the cell surface and by modulating 5-HT levels, we may be able to 
modify the degree of cell proliferation and cell differentiation at that area.  
Serotonergic fibres, whose cell bodies reside in the raphe nuclei, travel down to all 
levels of spinal cord. The tracts are located at the dorsolateral funiculus then ramify 
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into the grey matter and establish the synaptic contacts with neurons that are involved 
in somatic outflow (Perrier and Cotel 2015). In addition, there are serotonergic inputs 
onto autonomic preganglionic neurones and interneurones (Deuchars, S. and Lall, 
2015). 5HT fibres are also located in the dorsal horn of spinal cord (Croul et al., 1998; 
Thor et al., 1993). At the thoracolumbar level, the serotonergic fibres are concentrated 
in the intermediolateral part of spinal cord and then course medially to surround the 
central canal area. Detection of 5-HTergic distribution in nestin-GFP mice showed 
close apposition of 5-HTergic fibres with nestin-positive neural stem cell in central 
canal of spinal cord. This the first time that such innervation of potential stem cells 
has been observed in rodents but previous studies in turtle have shown a dense 5-
HTergic plexus of fibres innervating central region and forming close appositions with 
radial glia and immature neurones, most probably the CSFcCs (Trujillo‐Cenóz et al., 
2007). They suggested that 5-HT may play a role in proliferation, migration or 
differentiation in turtle and this may also be the case in rodents.   
 
5.4.2 Responses of ependymal cells to 5-HT 
 
It is clear from the data that not all ependymal cells responded to either 5-HT or the 
specific agonists that were applied and this may be due to heterogeneity in this cell 
population with respect to the 5-HT receptor expression. The locations of cells that 
did respond to 5-HT indicated that there was a degree of region specific effect of 5-
HT with cells at the dorsal pole only depolarised in response to 5-HT while those 
located at or ventral to the midline regions were more likely to be hyperpolarised. 
Furthermore, depolarisations were antagonised by the 5-HT2 antagonist cinanserin. 
The majority of cells at the dorsal and ventral poles of the central canal are considered 
to be radial glia while the cells at the lateral regions are more likely to be cuboidal 
ependymal cells (see introduction). In response to injury, the majority of newly 
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proliferated cells are located at the dorsal and dorsolateral regions (Alfaro‐Cervello et 
al., 2012). This suggests that these cells may be more responsive to perturbations 
and perhaps 5-HT acting at 5-HT2 receptors on these dorsal cells may contribute to 
mediating this response. However,  the 5-HT2 receptor agonist α-methyl-5-HT (1 and 
10 μM) (1.39 ± 0.3 vs 2.4 ± 0.3; 3.23 ± 0.3 vs 2.59 ± 0.2) did not affect levels of 
proliferating cells per 50 µm section in vitro when applied for 4 hours (Ghani et al 
unpublished observations). This is interesting since it suggests that activation of 5-
HT2 receptors does not initiate short-term proliferative responses. This is similar to 
that observed by Banasr et al. (2004), who reported little effect of 5-HT2A/C agonists 
on hippocampal cell proliferation with short term treatment (one injection, 
administered 2 hours before BrdU and then the animals were sacrificed 2 hours after 
that). In contrast, longer term administration of the 5-HT2 receptor agonist methyl-5-
HT (for 1 or 7 days following BrdU injections) decreases hippocampal cell proliferation 
(Klempin et al., 2010). This therefore suggests that 5-HT may activate 5-HT2 
receptors on some classes of spinal cord ependymal cells and that long-term 
activation of these receptors may start to contribute to the proliferative responses. It 
would therefore be worthwhile testing the effects of 5-HT2 receptor activation on 
numbers of proliferating cells in spinal cord slices maintaining in culture for up to 7 
days. By monitoring the cells using time lapse microscopy, it may be possible to 
observe which cells in the different regions are most affected.  
I also observed that there are no ependymal cells responsed to 5-HT1A agonists at 
the dorsal and ventral poles of the central canal, although the numbers of cells tested 
in these regions was relatively small. Given the small responses of 8-OH-DPAT to the 
ependymal cells, maybe there are only low numbers of 5-HT1A receptors located at 
the postsynaptic cell membrane. Further experiments could increase n numbers to 
establish whether this was indeed the case. In unpublished data from our laboratory, 
various antibodies to 5-HT1A receptors were tested to look at expression patterns of 
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this receptor but the staining was not good and it seems that the established 
antibodies do not work well in the spinal cord. However, unpublished data from 
Deuchars Lab showed that 8-OH-DPAT applied to acute spinal cord slices (4 hours 
treatment, 30 μM concentration) did not significantly affect the numbers of 
proliferating cells in the central canal region (6.07 ± 0.5 vs 6.83 ± 0.5 cells per 50 µm 
section) so potentially, this receptor does not play a prominent role in modulation of 
proliferation in the spinal cord. This contrasts with other neurogenic niches (Klempin 
et al., 2010; Banasr et al., 2004).  
Only one cell of the 5 tested, responded to cisapride with a small hyperpolarisation, 
the cell was located on the lateral point of the central canal.  This is somewhat 
surprising since cisapride (at the same concentration used here, 10 µM) applied to 
spinal cord slices in vitro for 4 hours, caused significantly more EdU positive cells per 
50 µm section  in the central canal area compared to control (3.6 ± 0.3 vs 2.59 ± 0.2 
cells ; p ≤ 0.05).  It is possible that responses to 8-OH-DPAT and cisapride were being 
missed in ependymal cells because the examined cells did not express the 5-HT1A 
and 5-HT4 receptors or potentially the G proteins necessary to mediate the response 
are being washed out by the intracellular solution from the patch pipette, although this 
does not occur with 5-HT alone.  
There are a few other drug choices such as tegaserod that can be used in the 
experiments. Tegaserod maleate is a partial agonist for 5-HT4 receptors. In vivo 
experiments showed that activation of 5-HTR4 receptors using tegaserod maleate 
resulted in greater numbers of proliferating cells in mice gut of enteric system (Liu, 
M.-T. et al., 2009).
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5.4.3 What could be the functional effects of 5-HT receptor 
activation on spinal cord plasticity and proliferation? 
Altman (1969) suggested that cells proliferate and migrate from subependymal layer 
of lateral ventricle to olfactory bulb in normal conditions. This same process that 
occurs in brain areas might also apply to the spinal cord area. In an interesting study 
on proliferative responses to injury, Rusanescu and Mao (2015) suggested the 
migration of proliferating cells could occur from lamina X to the dorsal horn of spinal 
cord area after constriction injury of sciatic nerve in rats. Since neuropathic pain can 
stimulate an increase in the level of 5-HT (Rusanescu and Mao, 2015), it may be that 
this 5-HT then activates the ependymal cells to proliferate and migrate to the dorsal 
horn. To explore this further, the use of mice where ependymal cells are labelled with 
fluorescent markers for fate mapping (using a FoxJ1 promoter) would enable cells 
originating from the central canal to be visualised as they proliferate and migrate 
(Barnabé-Heider et al., 2010). 
In many studies, acute application of serotonergic drugs showed lack of effects on 
neurogenesis. Malberg et al. (2000) found that ranylcypromine, reboxetine, fluoxetine 
and haloperidol only increased BrdU labeling after chronic (14 to 28 days), but not 
short-term (1 to 5 days) administration. This may be due to the fact that most of the 
drugs have long time courses for their therapeutic action. However, there is also 
evidence of acute effects on serotonin receptor activation observed in studies on 
selective serotonin reuptake inhibitors (SSRIs) (Klempin et al., 2010; Santarelli et al., 
2003). Furthermore, in vivo, acute treatment with 8-OH-DPAT (2 h pre BrdU 
treatment) significantly increased precursor cell proliferation whereas 1 week of 
treatment had no significant effect (Klempin et al., 2010). Therefore it is clear that 
both the receptors are being activated and the timing of the drugs will influence 
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potential neurogenic effects and this must be carefully considered when carrying out 
experiments on spinal cord.
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5.5 Conclusion 
 
Despite uncertainty regarding the receptors responsible, the important observation 
of this study is it demonstrate that the ependymal cells are capable of responding to 
5-HT. Molecular mechanisms of the 5-HT receptor mediated effects on spinal cord 
neurogenesis are yet to be determined.
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Chapter 6  
General discussion 
 
6.1 Impact of this study 
 
The region surrounding the central canal is proposed as a latent neural stem cell 
niche. This study observed the characteristics of ependymal cells, which are 
considered as a source of neural stem cells in the spinal cord, with an emphasis on 
a potential role of GABAergic signalling in controlling activity in these cells. This study 
has demonstrated the complexity of GABA mediated control of spinal cord ependymal 
cell activity, showing a potential role for multiple receptors and modulation sites on 
these cells. This study also included elaboration on the 5-HT receptor effects on 
ependymal cells as 5-HT receptors also have been shown to have influence on 
neurogenesis. 
 
 
 
 
 
 
 
 
206 
 
6.2 Applicability of these findings to neurogenesis 
 
6.2.1 Ependymal cells may function as the neural stem cells of 
spinal cord 
 
The identity of stem cells in the postnatal spinal cord has been difficult to establish 
and remains controversial. Although there are some studies which described the grey 
and white matter of the rat spinal cord as containing proliferating cells (Horner, P.J. 
et al., 2000), yet other studies showed the majority of stem cells reside within the 
central canal of spinal cord (Corns et al., 2015; Marichal et al., 2012; Trujillo‐Cenóz 
et al., 2007) which is comprised of both ependymal cells and CSFcCs. The 
ependymal region is a complex structure consisting of cells arranged in lateral and 
dorsal-ventral domains (Marichal et al., 2012; Trujillo‐Cenóz et al., 2007). Ciliated 
ependymal cells with basal processes mainly predominate in lateral domains of 
central canal while radial glial like cells are mainly concentrated in both polar region. 
In contrast, CSFcCs do not have specific locations and are not considered to be 
neural stem cells, at least in mammals. The concept of the ependymal cells being 
neural stem cells is therefore considered throughout this general discussion. 
 
6.2.2 Relevance of gap junction coupling of ependymal cells 
within the spinal cord neurogenic niche 
 
We used patch-clamp electrophysiology to assess passive and active electrical 
properties of spinal cord cells that are in the neurogenic niche region, namely 
ependymal cells and CSFcCs. Evidence from my experiments, it was clear that the 
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majority of ependymal cells exhibited extensive gap junction coupling but the role of 
this coupling is unclear, since it cannot fulfil the same role as that observed in 
neurones; i.e. to enable synchronised neuronal firing. It has been proposed that 
coupled ependymal cells can act as regulators of extracellular K+ in the grey matter 
by taking up K+ into their basal membranes, in regions where K+ levels are high and 
then shunting K+ through the gap junctions to the apical surface and from there into 
the CSF (Jarvis and Andrew, 1988). This has been suggested for ependymal cells in 
other regions, such as hypothalamus (Jarvis and Andrew 1988). Another suggestion 
is that the gap junctions enable synchronisation of the movements of the cilia, which 
also helps with movement of the CSF (Jiménez et al., 2014).  
Another possible reason for ependymal cells to form gap junctions is to allow the 
control of cellular proliferation (Bittman et al., 1997). During development, the 
coupling occurs only between radial glia and neural precursor cells, and is cell cycle 
phase dependent; uncoupling the cells decreases the number of cells that enter the 
S (DNA replication phase) of the cell cycle (Bittman et al., 1997). It appears that it is 
the propagation of Ca2+ waves through gap junctions that influences this proliferation. 
This was demonstrated in the embryonic ventricular zone, as reducing the Ca2+ waves 
between neighbouring radial glia reduces the ventricular zone proliferation 
(Weissman et al., 2004). 
This suggests that the propagation of Ca2+ waves through gap junctions is a common 
mechanism that influences proliferation in both the embryonic and postnatal brain. It 
is possible to suggest that this common mechanism could be extended to the 
postnatal spinal cord, with the propagation of Ca2+ waves between ependymal cells 
and other coupled cells (CSFcC Type 1), controlling the constant proliferation of 
ependymal cells that occurs to maintain the ependymal cell population. 
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6.2.3 GABAergic responses in ependymal cells may indicate that 
they are part of the spinal cord circuitry - implications for 
the neurogenic niche. 
 
GABA is the key regulatory neurotransmitter in the developing brain as well as the 
main inhibitory neurotransmitter in the adult central nervous system. Extracellular 
GABA levels are regulated by high affinity sodium and chloride dependant GABA 
transporters (BORDEN, 1996) which efficiently removes GABA from synaptic clefts. 
There are possible endogenous sources of GABA which could influence ependymal 
cells and neighbouring cells.  
The first source is from GABAergic terminals that are known to be present in the area 
surrounding the central canal. A comprehensive study of the GABAergic cells in the 
vicinity of the central canal suggested that at least a proportion of these may also co-
release acetylcholine (Gotts et al., 2016), which is of interest since ependymal cells 
also respond to this neurotransmitter (Corns et al 2015). GABA may also be released 
from terminals associated with cells that are distant from the spinal cord, such 
bulbospinal cells originating in the rostral ventrolateral medulla identified by 
Deuchars, S.A. et al. (1997). Since in these experiments, I have always exogenously 
applied GABA, the possibility that GABA being released from distant terminal cannot 
be ruled out. The second source is from the CSFcCs. Many studies have shown that 
CSFcCs express GABA in rat and mouse (Corns et al., 2013; Marichal et al., 2009; 
Stoeckel et al., 2003; Barber et al., 1982) and also in other species such as turtle 
(Russo et al., 2004). These cells may therefore release GABA into the CSF region 
where it can activate receptors on the ependymal cells.  Alternatively, the CSFcCs 
may release the GABA at different sites, potentially through GABA transporters on 
their membrane surface or from non-synaptic sites yet to be identified.  
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GABA binds to ionotropic receptors GABAA and GABAρ which are ligand gated 
chloride channels, and metabotropic receptor GABAB to trigger downstream 
signalling events. So the presence of these receptors in the neural stem cells of spinal 
cord and the effects of their activation supports the idea that they modulate 
ependymal cell activity.  
The effect of GABA depends on the type of receptor it binds to and on the intracellular 
Cl- concentration. The subunit composition of the receptor determines the subcellular 
localisation, conduction, kinetics and pharmacology (Sibbe and Kulik, 2017). GABAA 
receptors are localized both synaptically and extrasynaptically. The former are 
activated by high GABA concentrations released into the synaptic cleft and generate 
fast inhibitory postsynaptic currents. Extrasynaptic GABAA receptors are present peri- 
and extrasynaptically. These receptors are activated by lower concentrations of 
GABA arising spilled over from nearby synapses.  
GABA receptors containing α1, α2 and γ2 subunits are often present at the synapse 
and mediate phasic inhibition, while receptors containing α5 and δ are often 
extrasynaptically localized and mediate tonic inhibition (Farrant and Nusser, 2005). 
Metabotropic GABAB receptors are coupled to guanosine triphosphate (GTP)-binding 
proteins (G proteins) and are responsible for mediating slow effects. GABA binding 
leads to a conformational change of the receptor, which is transmitted to the Gα 
subunit of the G protein, leading to the exchange of GDP for GTP (Ulrich and Bettler, 
2007; Bettler et al., 2004). The GTP bound Gα subunit then dissociates from the other 
two subunits of the G protein, the β and γ subunit. Gα subunit can activate 
phospholipase C or inhibit the enzyme adenylyl cyclase, which reduces the levels of 
secondary messenger cyclic adenosine monophosphate (cAMP), this in turn leads to 
the inactivation of the cAMP dependent protein kinase A (PKA). The two pathways 
activated by Gα are some of the most important cellular signalling and can regulate 
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different processes, modulation of the activity of different ion channels (Terunuma, 
2018).  
The subunit composition of receptors on ependymal cells and the sensitivity of these 
to GABA may influence which of the receptors are activated by GABA from different 
sources. 
 
6.2.4 DBI is expressed in ependymal cells and is responsible for 
modulation of GABAA receptors. 
 
Previous work has shown that ependymal cells of spinal cord respond to GABA 
(Corns et al., 2013; Reali et al., 2011). There are important sites in the GABAA 
receptor that are responsible for modulating the effects of GABA. DBI is strongly and 
specifically expressed in all NSCs in the SVZ and in a population of transient 
amplifying cells (Alfonso et al., 2012). Since ependymal cells are considered as the 
spinal cord neural stem cell, I investigated modulation of these GABA receptor sites. 
The presence of DBI in stem cells from SVZ and SGZ suggests that the function of 
this protein might be related to the early process of neurogenesis (Dumitru et al., 
2017; Alfonso et al., 2012) in adult brain, so maybe there would be a similar function 
of this protein in the spinal cord NSCs.  
Modulation of GABA receptors by midazolam is likely to occur at dual sites, which are 
CBR and TSPO. The finding of this study showed that the response to GABA was 
inhibited by midazolam while the response to GABA was augmented by FGIN-1-27, 
an agonist at TSPO suggests that the effect at the CBR predominates with 
midazolam, causing an overall inhibition. Since my data indicate that DBI acts by 
modulating GABA signalling partly through the CBR, there is a potential of DBI to 
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have influences on regulating neurogenesis in the spinal cord. Future experiments 
could determine this and are described below in the section of future work.  
The lack of effect of ODN on responses to GABA in my studies is in sharp contrast to 
the reduction in GABA responses induced by ODN in the subventricular zone (Alfonso 
et al., 2012). The reduction in GABA currents induced by ODN in their study was 
strongly diminished in gamma2 F77I mice which is an optimal mouse line to test 
whether DBI modulates neurogenesis via the GABAA receptor. I saw significant 
decreases in responses to GABA with midazolam. Therefore, using gamma2 F77I 
mice, would be useful to test if midazolam modulation of GABA on ependymal cells 
still occurs in the ependymal cells. The effects of ODN were intriguing, since overall 
no significant effect of ODN on GABA responses was observed, yet there was the 
strong immunopositive DBI and ODN staining around the whole of the central canal 
region.  This suggests that there is further complexity to the role of ODN at the GABA 
receptors and potentially, we need to carry out correlated electrophysiology and 
immunohistochemical or mRNA-seq analysis of single cells to understand what 
GABA receptor subtypes are expressed in each cell and how they are affected by 
ODN. This idea is further developed in the section on future experiments.   
Activation of TSPO may stimulate neurosteroidogenesis (Tokuda et al., 2010). The 
effects of application of a neurosteroid, allopregnanolone on responses of cells to 
GABA in our observations did not reach significance for both concentrations of 
allopregnanolone. The lack of response may be due to a high degree of variation in 
the amplitude of the responses of ependymal cells to GABA, both before and after 
allopregnanolone. Another possibility is that the types of receptor present on the 
ependymal cells vary and some are modulated differently by allopregnanolone.  
Increasing numbers of recorded cells may establish whether there are clear 
subclasses of cells with responses to GABA that are differentially modulated by this 
neurosteroid. Furthermore, further experiments using FGIN-1-27 in the presence of 
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finasteride, a blocker of neurosteroidogenesis could investigate whether in the spinal 
cord, the effects on GABA responses of activation of TSPO by FGIN-1-27 are indeed 
through stimulation of neurosteroidogenesis. 
The potential sites of action of these modulators are summarised in Figure 6-1. DBI 
with/or ODN acts as positive and negative modulator at CBR. Other than CBR, there 
is also involvement of TSPO evidenced by modulation by midazolam and FGIN-1-27. 
The modulation of GABA receptor causes increases in neurosteroids production 
through neurosterodogenesis via TSPO. The neurosteroids; allopregnanolone: 1 µM 
and 10 nM may act both as allosteric modulators and directly at the GABAA receptor.  
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Figure 6-1 Potential mechanisms of action of DBI through CBR and TSPO in 
ependymal cell.  
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6.2.5 A reduction in proliferation of ependymal cells was 
observed, mediated by activation of GABAB receptors 
 
My results on the role of GABAB receptors showed a direct activation of receptor with 
agonist baclofen, resulted in a hyperpolarising response. The hyperpolarisations were 
antagonised but not fully blocked with CGP 55845, a GABAB receptor antagonist. On 
using acute slices to see the effects of activating the GABAB receptor on ependymal 
cell proliferation, there was a clear and significant decrease in the numbers of 
proliferating cells in the central canal region. To further prove that this effect is through 
an action at GABAB receptors, CGP 55845 could be applied alongside baclofen to 
determine if the decreased proliferation was no longer observed.  
My work suggests that ependymal cells have a diverse range of GABA receptors 
modulating their overall activity, with both hyperpolarising and depolarising responses 
observed.  To dissect out the contribution of these different responses to the 
proliferative capabilities of the ependymal cells, it is important to consider further 
experiments using EdU labelling of dividing cells in combination with selective drugs 
used in this study that caused depolarising and hyperpolarising responses. If these 
experiments were carried out in vivo, then it would be possible to also investigate the 
fate of these newly proliferated cells. This would give a comprehensive picture of how 
GABA can modulate proliferation and differentiation of the neural stem cells in the 
spinal cord.  
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6.2.6 Can activation of the 5-HT receptor also contribute to the 
proliferative capabilities of the ependymal cells?  
 
Results from this study also show that a population of ependymal cells can respond 
to 5-HT with both depolarisations and hyperpolarisations. Blockade of 5-HT receptor 
mediated depolarisations with cinanserin indicate the possible presence of 5-HT2 
receptors in the spinal cord. Furthermore, hyperpolarisations with 8-OH-DPAT 
indicate that 5-HT1A receptors are also present. Since raphe nuclei neurones are the 
sole source of 5-HT terminals in the spinal cord (Deuchars, S. and Lall, 2015), it is 
likely that under normal circumstances, these receptors would be activated by release 
of 5-HT from these terminals. Given that antidepressant drugs can promote adult 
neurogenesis and new hippocampal neurons have been implicated in mediating 
some effects of antidepressants (Petrik et al., 2012), our findings are relevant to 
human disease. A role of both 5HT2 and 5HT1A receptors in other neurogenic niches 
has been reported (Klempin et al., 2010). Therefore manipulating the receptors to 
induce proliferation and differentiation using specific drugs would be a valid next step 
to determine a potential role in spinal cord neurogenesis.  
 
6.2.7 Ependymal cells contribute to increased cell division 
following spinal cord injury 
 
How tissue injury can activate ependymal cells to trigger endogenous repair needs 
further clarification. It is not possible to infer that only ependymal cells are responsible 
for the proliferation of cells during spinal cord injury even though both mouse and rat 
with and without endogenous repair capabilities, respectively showed an increase in 
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the proliferation of ependymal cells (Meletis et al., 2008; Mothe and Tator, 2005). 
Some cells in the central canal still react to injury by proliferating and migrating toward 
the lesion (Mothe and Tator, 2005; Johansson et al., 1999) and some cells show 
proliferation and become astrocytes within the circle area of the scar (Meletis et al., 
2008). Ependyma-derived cells seem to play a central role in the formation of the scar 
thereby limiting the extension of damage (Sabelström et al., 2013). Astrocyte-like and 
oligodendrocyte-like cells derived from the ependymal cells concentrate in the core 
of the scar and release growth factors that improve the survival of neurons around 
the lesion (Sabelström et al., 2013). However, Ren et al. (2017) questioned the actual 
contribution of ependymal cells to scar formation suggesting that more research is 
needed to understand the potential of the central canal area as a source for repair. 
Using FoxJ1 genetic knock-in cell fate mapping of ependymal cells, together with 
immunohistochemical labelling of astrocytes, they showed ependymal cell progeny 
contribute less than 2% of the total newly proliferated astrocytes. Furthermore they 
showed that ependymal cell contribution to other cell types after spinal cord injury is 
also minimal, ependymal progeny fail to migrate substantially into spinal cord injury 
lesions and remain primarily in the area of the damaged ependymal layer around the 
central canal.  Finally, they indicate that ependymal progeny do not contribute any 
cells to nearby spinal cord injury lesions that do not directly damage the ependymal 
layer. 
Two transgenically-targeted fate mapping strategies with a Nestin-CreERT line and a 
human FOXJ1-CreERT line used by previous studies (Sabelström et al., 2013; 
Barnabé-Heider et al., 2010; Meletis et al., 2008) differ in their findings from the study 
done by Ren et al. (2017). The difference may be due to recombination patterns or 
pattern of spinal cord injury used among them. After all the pattern of spinal injury 
may be the prominent cause of these differences because the extent of the injury 
would signify the involvement of ependymal layer or not.  
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6.3 Applicability of the findings regarding the neurogenic 
potential of ependymal cells to human 
 
Cells in the adult human spinal cord ependymal region do not proliferate after injury 
at any time or distance from the lesion (Paniagua‐Torija et al., 2018). Their findings 
seriously challenge the view of spinal cord ependymal region as a neurogenic niche 
in adult humans. However other studies show increases in nestin positive cells in the 
spinal cord region in post-mortem tissue from humans (Cawsey et al., 2015), so there 
are discrepancies in the literature and few studies have been possible of this nature.  
What is clear is that in humans, we have no knowledge of whether manipulating or 
modifying the activity of the ependymal cells with neurotransmitters can affect levels 
of proliferation.   
 
 
218 
 
6.3.1 Can ependymal cells and GABA levels contribute to 
increased cell division in ependymoma?  
Ependymal tumours are a group of central nervous system tumours, where the 
tumour contains some cells that resemble ependymal cells. Ependymomas express 
cell surface markers CD133, Nestin, brain lipid-binding protein (BLBP) which are also 
expressed by neural stem cells (Hadjipanayis and Van Meir, 2009). Ependymomas 
also show most of the unique features of ependymal cells including lumen formation 
with junctional complexes, microvilli and cilia and molecular and genetic evidence 
shows that ependymomas arise from radial glia (Taylor et al., 2005). Indeed in a 
review on the cells that may contribute to the ependymoma, radial glial cells were 
considered as the candidate stem cells (Poppleton and Gilbertson, 2007) but it is still 
not clear whether this is also the case for spinal cord ependymomas. Ependymomas 
are different from other glial tumours, such as astroblastoma or chordoid glioma which 
focally displayed aspects of ependymal differentiation since in ependymomas, the 
cells remain in an undifferentiated state (Lehman, 2008). 
In humans, laser microdissection of the ependymal layer and extraction of the mRNA 
enabled the gene expression profiles of this region to be studied (Garcia-Ovejero et 
al., 2015). They showed that the region had high levels of some genes associated 
with low grade or quiescent ependymomas and suggested that in humans, the 
potential for production of ependymomas was present but normally the cells were 
kept in a non-reactive state whereas in some cases ependymomas may arise 
(Paniagua‐Torija et al., 2018; Garcia-Ovejero et al., 2015).  
The main treatment for ependymomas has not changed for many years and involves 
resection of the tumour (Lehman 2008) but the ependymoma often recurs after 
surgery so a different approach is necessary to control recurrence.  The discovery of 
ependymal like cancer stem cells has therefore provided researchers with a practical 
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point of focus for studying the postnatal cellular and molecular events of 
tumorigenesis. This is where my findings may be relevant as a potential avenue for 
exploration of modulating the activity of these ependymal stem cells.  
Many central nervous system tumours show increased levels of DBI and TSPO (Alho, 
Hannu et al., 1995; Miettinen et al., 1995) and higher levels of TSPO are associated 
with a greater likelihood of malignancy and reduced survival (Janczar et al., 2015; 
Vlodavsky and Soustiel, 2007). Therefore my findings could suggest that modulating 
levels of the DBI or the GABA receptor itself may be a possible therapeutic avenue 
for exploration in reducing recurrence of ependymomas after surgery or reducing 
malignancy.  
Considering their key roles in homeostatic control, it is not surprising that connexins 
and their channels are frequently targeted upon treatment due to impairment of this 
critical balance. Tumour cells generally display reduced gap junctional intercellular 
communication or coupling and numerous mechanisms underlie the loss of 
intercellular communication in carcinogenesis (Trosko, 2003). We do not know if the 
cells in ependymomas still express gap junctions, although it may be expected due 
to the high incidence of these in normal ependymal cells. However, epigenetic 
modifications, such as DNA hypermethylation could trigger silencing of connexin 
gene expression to see if this affects the extent of the ependymoma.   
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6.4 Technical consideration and limitations 
 
Using selective agonists and antagonists to identify receptor or receptor subtype(s) 
on a specific cell is a popular method. By combining the effects of these drugs with 
patch clamp electrophysiology and immunohistochemistry the receptor types found 
in ependymal cell can be elucidated to a degree. 
However, these methods can only provide incomplete evidence and therefore always 
need to be supported by other techniques which would provide more comprehensive 
confirmation e.g. integration of electrophysiological recordings with single cell RNA-
seq that is Patch–seq, a method based on sequencing RNA aspirated from the soma 
of single patch-clamp-recorded neurons (Fuzik et al., 2016). In these experiments, it 
was possible to record from single cells then aspirate the complete contents of each 
cell into the recording electrode to then carry out full analysis of the transcriptome. 
This would be a very powerful way of exploring if responses that are observed 
electrophysiologically are directly correlated with what is expressed in that cell.  
Whole cell patch clamp recordings are well suited to do recordings from small cells 
but perturbs intracellular ionic concentrations by dialysing cytoplasmic contents, so 
perforated patch recording is another option and can circumvent these limitations. We 
could perform patch recordings using the cation selective ionophore gramicidin which 
does not interfere with Cl- concentrations. This would enable a better picture of how 
chloride channel opening and movement of chloride ions contribute to the responses 
observed. If we were to combine this with harvesting the recorded cells and then 
perform mRNA-seq (Fuzik et al 2016), this would provide information on the chloride 
transporters present in the potential subgroups of ependymal cells showing different 
responses to GABA.   
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The excitatory action of GABA may arise from the cellular injury due to slicing 
procedure, which leads to accumulation of intracellular Cl- in injured cells and 
contributes to the depolarising responses observed. This problem is potentially 
reduced by taking recordings from the centre of the slice, which was 300 µm thick.  
The fact that ependymal cells are compact, with few processes is an advantage here 
but this issue of injury cannot be completely excluded. The use of 300 µm slices would 
also remove potential synaptic inputs onto these cells that may affect the activity in 
these cells. While there is little evidence in other studies of synaptic activity (Corns et 
al., 2015; Corns et al., 2013; Marichal et al., 2012), these studies also use slices. The 
extent of gap junction coupling may also be affected by removal of coupled cells in 
the slicing. However, recording from these cells in vivo would be an extremely 
technically demanding experiment and use of calcium or voltage indicators would also 
be prohibited due to the depth of the cells from the surface of the spinal cord. 
Therefore, the use of spinal cord slices at least maintains a degree of circuitry whilst 
enabling stable and prolonged recordings from the cells.  
Due to the fact that there are unspecified subunits contributing to the receptors found 
in the central canal, there may be confounding effects at these uncharacterised 
receptors using agonists and antagonists even though some of the modulators are 
considered selective drugs. Even with the use of combining mRNA seq analysis of 
recorded cells, it is still not possible to elucidate the actual subunit composition of the 
different receptors so it is hard to know how this issue can be avoided at this stage of 
investigation.  
The used of wild type/C57BL/6 in the study of patch clamp is the best animal for 
maintaining consistent normal activity compared to transgenic or knockout mouse 
because the animal represent the best normal environment. Using wild type mice 
allowed me to test the patch clamp methods in a C57BL/6 background without any 
genetic modifications that could influence the results. Used of acute slices possibly 
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not representing normal or in vivo physiology but this is the best way to do patch 
clamp as it will reach the cell specifically. The current result possibly showed the 
contribution from all cell type and factors that control GABAergic manipulations on 
cells proliferation in the spinal cord central canal niche and may not specifically 
represent the ependymal cell even though the recording were confirmed from the 
ependymal cell because of the remaining minimally disturbed environment of a cell 
and niche. The best animal with a genetically expressed FoxJ1 are the best animal 
model for ependymal cell investigation (see 6.5.3). 
 
6.5 Future work 
 
6.5.1 Extension of the existing experiments 
 
The possibility that ODN activation in ependymal cells can result in an increase in 
intracellular Ca2+ was not investigated in this study, but it is undoubtedly an important 
future experiment, especially in the light that bath applications of ODN sometimes 
depolarised the cells. It is possible that activation of ODN receptors on the ependymal 
cell could induce increases in intracellular Ca2+ which could stimulate many of the 
neurogenesis processes. Propagation of Ca2+ waves through gap junctions as seen 
in radial glial cells during embryonic neurogenesis and neural progenitor cells in the 
postnatal SVZ (Weissman et al., 2004) may also contribute to a potential proliferative 
response in the spinal cord. 
The relationships between the cells in the area surrounding the central canal would 
be very interesting to examine. A dual patch clamp electrophysiology could be used 
to investigate the relationship between ependymal cells and CSFcCs or between 
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ependymal cells and type 1 CSFcC. If a response is seen in one of the cells, different 
GABA receptor antagonists or modulators could be applied to see whether the 
response could be antagonised or enhanced. Another method would be to use breed 
mice in which a genetically encoded voltage indicator or a genetically encoded 
calcium indicator such as GCaMP is expressed solely in cells that express FoxJ1 so 
changes in fluorescence are only observed in the ependymal cells. Then changes in 
voltage or calcium influx to a specific activation of a receptor or application of a 
specific modulator can be monitored in all ependymal cells simultaneously.  
 
6.5.2 Optogenetic activation of GABAergic CSFcCs or 
neighbouring neurones to investigate effects on ependymal 
cells 
The identification and manipulation of different GABAergic inputs are important to 
understand the source of GABA that may be influencing neural stem cells in spinal 
cord circuits. Using an optogenetic approach based on expressing light-sensitive 
opsins in a given cell population would enable us to selectively activate these cells 
and investigate how this activation affects the responses of ependymal cells. CSFcCs 
express the ion channel PKD2L1 and this is not observed in other cell types in the 
spinal cord (Corns et al., 2015; Huang et al., 2006). If channel rhodopsin was 
expressed exclusively in PKD2L1 positive cells, light activation of these cells 
combined with patch clamp recordings from ependymal cells would allow 
investigation into whether this produced changes in membrane potential in the 
ependymal cells. Further pharmacological analysis with selective GABAergic 
antagonists or modulators would elucidate whether the effects were due to release of 
GABA from these CSFcCs.  Similarly, channel rhodopsin could be expressed in 
parvalbumin expressing GABAergic interneurones in the spinal cord to see if 
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activation of these cells had any effect on ependymal cells. This may give further 
information about the source of the GABA.  
 
6.5.3 Use of genetically modified animals to study the role of 
ependymal cells and their responses to GABA 
The use of point mutation and gene knock-out techniques on animals will allow the 
contribution of receptor subunits to be studied separately, both on the responses of 
the cells to GABA and on potential proliferative responses. Receptor subunit 
differences may contribute to the wide array of observations on GABA receptor 
modulation. Specific GABA subunit null mutant mice have been developed and used 
for testing the contributions of these subunits e.g. for GABA α1 and β2 (Blednov, Y. 
et al., 2003) and ρ1 (Blednov, Y.A. et al., 2014) but issues may arise when considering 
how much compensation occurs with such null mutants and what happens to the 
subunits composition of the remaining GABA receptors. Potentially use of conditional 
inactivation of a specific subunit gene in adults, such as that used by Earnheart et al. 
(2007) in their investigation into the role of γ2 subunits in hippocampal neurogenesis 
would be the best way to examine each subunit.  
Development of the spinal cord requires dynamic and tightly controlled expression of 
numerous transcription factors. Forkhead Box protein (Fox J1) is a transcription factor 
involved in the generation of cilia and is expressed in ependymal cells of adult central 
nervous system. In a study using Fox J1 fate mapping, Li, X. et al. (2018) observed 
that Fox J1 is also expressed by the progenitors of other neural subtypes during the 
developmental process but in adult, it is solely expressed by the ependymal cells in 
the spinal cord. Fox J1 deletion unsettled embryonic progenitor proliferation and cell 
fate determination and resulted in formation of adult ependymal cells having impaired 
stem cell potential and inability to respond to spinal cord injury. So by using these 
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transgenic mice with a specific Fox J1 cell deletion, we could investigate whether Fox 
J1 is critical in GABA/DBI mediated changes in ependymal cell proliferation.  
Another approach is to study the role of the gap junctions in ependymal cells in the 
proliferative responses of spinal cord ependymal cells. In the third ventricle around 
the hypothalamus, tanycytes are considered the neuronal precursor cells and here, 
when coupling of tanycytes is genetically absent or pharmacologically inhibited, there 
are decreases in neural stem and neural precursors (Recabal et al., 2018). They 
demonstrated that Cx43 is the most abundant connexin expressed in rat tanycytes. 
Using wild-type, Cx30-/- and Cx30-/-, Cx43fl/fl : glial fibrillary acidic protein (GFAP)-Cre 
(double knockout, dKO) mouse lines, (Recabal et al., 2018) demonstrated that 
tanycytes are highly coupled to each other. In the dKO mouse line, there is absence 
of Cx43 expression, and they detected a significant decrease in the number of 
hypothalamic proliferative parenchymal cells. So it is relevant to suggest that the use 
of specific connexin knockout mice will determine the direct role of gap junctions in 
ependymal cells in the proliferative responses, either just in the intact spinal cord or 
in response to specific receptor activation or modulation. 
Knock-out mice have been used to study the role of particular gene products in 
biochemical processes, in mediating the effects of neuropharmacological substances, 
and in complex behaviours. The advantage of using the knockout mouse line, is that 
there will be no interference of other recessive genetic variants, so the result will a 
specific and precise target. The disadvantages of using knock-out mice to study 
neurobiological problems is that often it is important to target the deletion or mutation 
to specific cell types and this requires complex cross-breeding of the different mouse 
lines to enable this. Injections of viruses that overexpress or knockdown proteins, 
such as those used by Dumitru et al. (2017); Alfonso et al. (2012) to specifically 
knockdown DBI and ODN in their transient amplifying cells would be a better 
approach.  
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6.5.4 Cultured slices and in vivo experiments to test the outcome 
of manipulation of GABA receptors on ependymal cell 
proliferation 
 
Organotypic spinal cord slice cultures can provide many slices at one time to test for 
multiple conditions, so these experiments can help in identifying GABAA receptor 
compounds that modulate ependymal cell proliferation. EdU can be added to the 
culture medium along with the compounds to enable counting of proliferating cells.  
Furthermore, combining with immunofluorescence for specific markers of different 
cell types, such as neurones, oligodendrocytes and astrocytes, the fate of the 
proliferating cells can be established. Since agonists and antagonists can be co-
applied, this experiments will enable to give pharmacological characterisation and 
subtypes of receptor involved which contribute to the cell proliferation. By using 
agonists and antagonist, an in vivo experiments also can be done by injecting the 
drugs for few days and after that the animal will be perfused and spinal cord will be 
processed for EdU immunohistochemistry to see the effects of proliferation.  
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6.6 Conclusions 
 
This study has provided pharmacological characterisation of the responses to GABA 
and 5-HT of ependymal cells surrounding the central canal of spinal cord and how 
the GABA responses may be further modulated. The extent and diversity of 
modulation using the different modulator sites on ependymal cell demonstrate the 
complexity of the ependymal cell and highlights the need for further investigation. The 
pharmacological profile of responses to GABA in ependymal cells of spinal cord 
suggests atypical GABA receptors since it was not fully blocked by GABAA receptor 
antagonist; bicuculline, and showed evidence of a combination or coassembly of 
GABAA and ρ receptors due to low GABA responses were antagonised by TPMPA 
and further confirmation with an agonist of GABAρ (TACA) also showed changes with 
TPMPA and may be further significant with an additional increase in sample size. 
Potential site of modulation of GABA receptors is through DBI breakdown product; 
ODN which acts as positive and negative modulator at CBR and TSPO. ODN is 
somehow directly activating the GABA receptors that contain ρ subunits since the 
hyperpolarising effects of ODN were significantly blocked by TPMPA. So there is an 
evidence there are atypical GABA receptors responsible for this action with ODN. 
From immunohistochemistry finding, there are evidences of DBI and ODN 
immunopositive staining and most likely they are in the cell membrane.   
Baclofen (a selective GABAB receptor agonist) also hyperpolarised ependymal cells, 
an effect antagonised by GABAB antagonist; CGP 55845, indicating a further role for 
GABAB receptors on ependymal cells. The numbers of proliferative cells in the central 
canal region were significantly lower in baclofen treated slices compared with control. 
Further confirmation of the atypical or multiple receptors involvement can be further 
confirmed by Western blot study to detect and characterise the receptor proteins in 
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the ependymal cell using patch clamp cell isolation technique. Given that the 
ependymal cells are capable of responding to 5-HT, a further study of the synaptic 
contacts of 5-HT fibres onto GABAergic neurones can be done.  
The balance of these GABAA, GABAρ and GABAB receptor modulation and 5-HT 
receptor may regulates the activity of ependymal cells as component of neural stem 
cells.  
It is possible that the manipulation of one or all receptor types in spinal cord area 
could allow a greater control over the proliferation and differentiation of cells within 
this cell, with beneficial implications for the treatment of spinal cord injury or spinal 
cord pathologies such as ependymomas.   
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